

ONTARIO HEALTH TECHNOLOGY ASSESSMENT SERIES

Fibreglass Total Contact Casting, Removable Cast Walkers, and Irremovable Cast Walkers to Treat Diabetic Neuropathic Foot Ulcers: A Health Technology Assessment

KEY MESSAGES

What Is This Health Technology Assessment About?

About 1 in 10 people in Ontario have diabetes. Each year, about 2% to 3% of them develop a foot ulcer. Diabetic foot ulcers put people at risk for foot and lower leg amputation. Pressure offloading devices, which include fibreglass total contact casting, removable cast walkers, and irremovable cast walkers, are used to treat foot ulcers, but they are not routinely publicly funded in Ontario.

The objective of this report was to assess the clinical benefits and harms of fibreglass total contact casting, removable cast walkers, and irremovable cast walkers in people with diabetic foot ulcers. We compared these devices with each other and with therapeutic shoes. We looked at the cost-effectiveness of these devices and calculated the budget impact of publicly funding them. We also interviewed people who have used these devices to learn more about their experiences.

What Did the Health Technology Assessment Find?

Total contact casting and irremovable cast walkers showed better ulcer healing than removable cast walkers, and they were also more cost-effective. If more people used these devices, the health system would likely save money because fewer people would need amputations. Patients with diabetic foot ulcers preferred total contact casting over removable cast walkers, largely because they perceived that total contact casting led to better healing.

HEALTH TECHNOLOGY ASSESSMENT AT HEALTH QUALITY ONTARIO

This report was developed by a multidisciplinary team from Health Quality Ontario. The lead clinical epidemiologist was Vania Costa, the lead health economist was Hong Anh Tu, the public engagement senior program analysts were David Wells and Mark Weir, and the medical librarians were Corinne Holubowich and Melissa Walters.

The medical editor was Jeanne McKane. Others involved in the development and production of this report were Arshia Ali, Harrison Heft, Claude Soulodre, Ana Laing, Kellee Kaulback, Vivian Ng, Anil Thota, Andrée Mitchell, Nancy Sikich, and Irfan Dhalla.

We are grateful to the following individuals for their expertise: Mariam Botros, Executive Director, Wounds Canada; Director, Diabetic Foot Canada. John M. Embil, Consultant, Infectious Diseases; Director, BSc(Med) Program, University of Manitoba; Director, Infection Prevention and Control Unit, Health Sciences Centre; Director, Infection Prevention and Control Program, Winnipeg Regional Health Authority; Professor, Department of Internal Medicine and Medical Microbiology, University of Manitoba. Devon Jahnke, Chiropodist, Diabetes Educator, Centre for Complex Diabetes Care, Diabetes Care Service, Sudbury Outpatient Centre, Health Sciences North. John D Lanthier, Assistant Professor, Northern Ontario School of Medicine, Clinical Sciences Division. Ann-Marie McLaren; Chiropodist/Wound Team, St. Michael's Hospital. Deirdre O'Sullivan-Drombolis, Physical Therapist, Wound Resource, Riverside Health Care, University of Western Ontario. Laura Teague, Ontario Woundcare Interest Group Executive, Health Policy; Adjunct Lecturer, Faculty of Nursing, University of Toronto; Adjunct Lecturer, Faculty of Rehabilitation, Western University. Ruth Thompson, Chiropodist, Ottawa Hospital Rehabilitation Centre. Kevin Woo, Assistant Professor, School of Nursing, Faculty of Health Sciences, Queen's University.

The statements, conclusions, and views expressed in this report do not necessarily represent the views of the consulted experts.

Citation

TBA

ABSTRACT

Background

Diabetic neuropathic foot ulcers are a risk factor for lower leg amputation. Many experts recommend offloading with fibreglass total contact casting, removable cast walkers, and irremovable cast walkers as a way to treat these ulcers.

Methods

We completed a health technology assessment, which included an evaluation of clinical benefits and harms, value for money, and patient preferences for offloading devices. We performed a systematic literature search on August 17, 2016, to identify randomized controlled trials that compared fibreglass total contact casting, removable cast walkers, and irremovable cast walkers with other treatments (offloading or non-offloading) in patients with diabetic neuropathic foot ulcers. We developed a decision-analytic model to assess the cost-effectiveness of fibreglass total contact casting, removable cast walkers, and irremovable cast walkers, and we conducted a 5-year budget impact analysis. Finally, we interviewed people with diabetes who had lived experience with foot ulcers, asking them about the different offloading devices and the factors that influenced their treatment choices.

Results

We identified 13 randomized controlled trials. The evidence suggests that total contact casting, removable cast walkers, and irremovable cast walkers are beneficial in the treatment of neuropathic, noninfected foot ulcers in patients with diabetes but without severe peripheral arterial disease. Compared to removable cast walkers, ulcer healing was improved with total contact casting (moderate quality evidence; risk difference 0.17 [95% confidence interval 0.00–0.33]) and irremovable cast walkers (low quality evidence; risk difference 0.21 [95% confidence interval 0.01–0.40]). We found no difference in ulcer healing between total contact casting and irremovable cast walkers (low quality evidence; risk difference 0.02 [95% confidence interval –0.11–0.14]). The economic analysis showed that total contact casting and irremovable cast walkers were less expensive and led to more health outcome gains (e.g., ulcers healed and quality-adjusted life-years) than removable cast walkers. Irremovable cast walkers were as effective as total contact casting and were associated with lower costs. The 5-year budget impact of funding total contact casting, removable cast walkers, and irremovable cast walkers (device costs only at 100% access) would be \$17 to \$20 million per year. The patients we interviewed felt that wound healing was improved with total contact casting than with removable cast walkers, but that removable cast walkers were more convenient and came with a lower cost burden. They reported no experience or familiarity with irremovable cast walkers.

Conclusions

Ulcer healing improved with total contact casting, irremovable cast walkers, and removable cast walkers, but total contact casting and irremovable cast walkers had higher rates of ulcer healing than removable cast walkers. Increased access to offloading devices could result in cost savings for the health system because of fewer amputations. Patients with diabetic foot ulcers reported a preference for total contact casting over removable cast walkers, largely because they perceived wound healing to be improved with total contact casting. However, cost, comfort, and convenience are concerns for patients.

TABLE OF CONTENTS

LIST OF TABLES	7
LIST OF FIGURES	8
OBJECTIVE	9
BACKGROUND.....	9
Health Condition.....	9
Clinical Need and Target Population	9
Current Treatment Options	9
Health Technology Under Review	9
<i>Total Contact Casting.....</i>	<i>9</i>
<i>Removable and Irremovable Cast Walkers</i>	<i>10</i>
Regulatory Information.....	10
Ontario Context	10
CLINICAL EVIDENCE	11
Research Question	11
Methods.....	11
<i>Literature Search.....</i>	<i>11</i>
<i>Literature Screening.....</i>	<i>11</i>
<i>Types of Participants.....</i>	<i>11</i>
<i>Types of Interventions.....</i>	<i>12</i>
<i>Types of Outcomes Measures</i>	<i>12</i>
<i>Inclusion Criteria</i>	<i>12</i>
<i>Exclusion Criteria</i>	<i>12</i>
<i>Data Extraction.....</i>	<i>13</i>
<i>Statistical Analysis</i>	<i>13</i>
<i>Quality of Evidence</i>	<i>13</i>
<i>Expert Consultation.....</i>	<i>14</i>
Results	14
<i>Literature Search.....</i>	<i>14</i>
<i>Design and Characteristics of the Included Studies</i>	<i>15</i>
<i>Definitions and Patient Characteristics in the Included Studies.....</i>	<i>16</i>
<i>Methodological Quality of the Included Studies</i>	<i>17</i>
<i>Results for Total Contact Casting Versus Irremovable Cast Walkers</i>	<i>18</i>
<i>Results for Total Contact Casting Versus Removable Cast Walkers</i>	<i>22</i>
<i>Results for Total Contact Casting Versus Therapeutic Shoes.....</i>	<i>27</i>
<i>Results for Irremovable Cast Walkers Versus Removable Cast Walkers</i>	<i>33</i>
<i>Results for Removable Cast Walkers Versus Therapeutic Shoes.....</i>	<i>38</i>
Discussion	42
<i>Strengths and Limitations.....</i>	<i>42</i>
Conclusions.....	43
ECONOMIC EVIDENCE	44
Research Question	44
Methods.....	44
<i>Literature Search.....</i>	<i>44</i>

<i>Literature Screening</i>	44
<i>Types of Studies</i>	44
<i>Types of Participants</i>	44
<i>Types of Interventions</i>	44
<i>Types of Outcomes Measures</i>	44
<i>Data Extraction</i>	45
<i>Study Applicability</i>	45
Results	45
<i>Literature Search</i>	45
<i>Review of Included Economic Studies</i>	46
<i>Applicability of Included Studies</i>	49
Conclusions.....	49
PRIMARY ECONOMIC EVALUATION	50
Research Questions.....	50
Methods.....	50
<i>Type of Analysis</i>	50
<i>Target Population</i>	50
<i>Perspective</i>	50
<i>Interventions</i>	50
<i>Discounting and Time Horizon</i>	50
<i>Model Structure</i>	51
<i>Clinical Outcome and Utility Parameters</i>	53
<i>Cost Parameters</i>	55
<i>Analysis</i>	56
<i>Main Assumptions</i>	57
<i>Generalizability</i>	57
<i>Expert Consultation</i>	57
Results	58
<i>Cost-Effectiveness Analysis</i>	58
<i>Cost-Utility Analysis</i>	59
Discussion	63
Conclusions.....	64
BUDGET IMPACT ANALYSIS	65
Research Question	65
Methods.....	65
<i>Target Population</i>	65
<i>Resource</i>	66
<i>Canadian Costs</i>	68
<i>Analysis</i>	68
Results	69
<i>Base Case Analysis</i>	69
<i>Scenario Analysis</i>	71
Discussion	73
Conclusions.....	73

PUBLIC AND PATIENT ENGAGEMENT	74
Objective	74
Background	74
Methods.....	74
<i>Engagement Plan</i>	74
<i>Recruitment of Participants</i>	75
<i>Approach</i>	75
<i>Data Extraction and Analysis</i>	76
Results	76
<i>Physical and Emotional Experience of Living With Diabetic Foot Ulcers</i>	76
<i>Treatments for Diabetic Foot Ulcers</i>	77
Discussion	83
Conclusions.....	84
CONCLUSIONS	85
ABBREVIATIONS	86
GLOSSARY	86
APPENDICES.....	87
Appendix 1: Literature Search Strategies	87
<i>Clinical Evidence Search</i>	87
<i>Economic Evidence Search</i>	91
Appendix 2: Clinical Evidence Quality Assessment.....	96
Appendix 3: Design and Characteristics of the Studies Identified	97
Appendix 4: Outcome Definitions and Wound Classification System.....	104
Appendix 5: Baseline Characteristics of Patients Included in the Studies Identified	106
Appendix 6: Results of Applicability Checklist for Studies Included in the Economic Literature Review ..	110
Appendix 7: Budget Impact Analysis—Scenario Analysis	111
Appendix 8: Public and Patient Engagement—Interview Materials.....	115
REFERENCES	119

LIST OF TABLES

Table 1: Total Contact Casting Versus Irremovable Cast Walkers	18
Table 2: Total Contact Casting Versus Irremovable Cast Walkers, Complications	20
Table 3: GRADE Evidence Profile for Total Contact Casting Versus Irremovable Cast Walkers	21
Table 4: Total Contact Casting Versus Removable Cast Walkers	22
Table 5: Total Contact Casting Versus Removable Cast Walkers, Complications	25
Table 6: GRADE Evidence Profile for Total Contact Casting Versus Removable Cast Walkers	26
Table 7: Total Contact Casting Versus Therapeutic Shoes	27
Table 8: Total Contact Casting Versus Therapeutic Shoes, Complications	31
Table 9: GRADE Evidence Profile for Total Contact Casting Versus Therapeutic Shoes	32
Table 10: Irremovable Cast Walkers Versus Removable Cast Walkers	33
Table 11: Irremovable Cast Walkers Versus Removable Cast Walkers, Complications	36
Table 12: GRADE Evidence Profile for Irremovable Cast Walkers Versus Removable Cast Walkers	37
Table 13: Removable Cast Walkers Versus Therapeutic Shoes	38
Table 14: Removable Cast Walkers Versus Therapeutic Shoes, Complications	40
Table 15: GRADE Evidence Profile for Removable Cast Walkers Versus Therapeutic Shoes	41
Table 16: Treatment Comparisons—Summary	43
Table 17: Results of Economic Literature Review—Summary.....	48
Table 18: Clinical Outcome Parameters Used in the Economic Model	53
Table 19: Utility Parameters Used in the Economic Model	54
Table 20: Costs Used in the Economic Model	55
Table 21: Resource Utilization Used in the Economic Model.....	56
Table 22: Base Case Cost-Effectiveness Analysis	58
Table 23: Sensitivity Analysis—Change of Irremovable Cast Walker Weekly Visits	59
Table 24: Base Case Cost-Utility Analysis	59
Table 25: Scenario Analysis.....	60
Table 26: Estimated Diabetes Prevalence in Ontario, 2016–2020.....	65
Table 27: Estimated Annual Number of Patients With Diabetic Foot Ulcers and Access to an Offloading Device in Ontario, 2016–2020	66
Table 28: Estimated Amputations Among Patients With Diabetic Foot Ulcers by Access to an Offloading Device in Ontario, 2016–2020	67
Table 29: One-Year Costs Per Patient to Adopt Offloading Devices ^{a,b}	68
Table 30: Budget Impact of Adopting Offloading Devices at 50% Access in Ontario, 2016–2020	69
Table 31: Budget Impact of Adopting Offloading Devices at 75% Access in Ontario, 2016–2020	70
Table 32: Budget Impact of Adopting Offloading Devices at 100% Access in Ontario, 2016–2020	70
Table 33: Net Budget Impact of Adopting Offloading Devices When Access Increased by 25% and 100% in Ontario, 2016–2020, Base Case Analysis.....	71
Table 34: Net Budget Impact of Adopting Offloading Devices When Access to Offloading Devices Increased by 25% and 100% in Ontario, 2016–2020, Scenario Analysis	72
Table A1: Risk of Bias Among Randomized Controlled Trials for the Comparison of Offloading Devices	96
Table A2: Design and Characteristics of the Randomized Controlled Trials	97
Table A3: Definitions Used in the Studies Identified	104
Table A4: Ulcer Classification Systems.....	105
Table A5: Baseline Characteristics of Patients Included in the Randomized Controlled Trials.....	106

Table A6: Cost-Consequence Analysis (Cost Per Patient)	110
Table A7: Budget Impact of Adopting Offloading Devices at 50% Access and 100% Proportion of Use for Each Device in Ontario, 2016–2020	111
Table A8: Budget Impact of Adopting Offloading Devices at 75% Access and 100% Proportion of Use for Each Device in Ontario, 2016–2020	112
Table A9: Budget Impact of Adopting Offloading Devices at 100% Access and 100% Proportion of Use for Each Device in Ontario, 2016–2020	113
Table A10: Proportion of Use of Offloading Devices in Ontario, 2016–2020 ^a	113
Table A11: Net Budget Impact of Adopting Offloading Devices at Varying in Proportions of Use for Irremovable Cast Walkers in Ontario, 2016–2020	114

LIST OF FIGURES

Figure 1: PRISMA Flow Diagram	15
Figure 2: Total Contact Casting Versus Irremovable Cast Walkers, Treatment Discontinuations	18
Figure 3: Total Contact Casting Versus Irremovable Cast Walkers, Percentage of Healed Ulcers ^a	19
Figure 4: Total Contact Casting Versus Removable Cast Walkers, Treatment Discontinuations	23
Figure 5: Total Contact Casting Versus Removable Cast Walkers, Percentage of Healed Ulcers	23
Figure 6: Total Contact Casting Versus Therapeutic Shoes, Treatment Discontinuations	28
Figure 7: Total Contact Casting Versus Therapeutic Shoes, Percentage of Healed Ulcers	29
Figure 8: Irremovable Cast Walkers Versus Removable Cast Walkers, Treatment Discontinuations	34
Figure 9: Irremovable Cast Walkers Versus Removable Cast Walkers, Percentage of Healed Ulcers	34
Figure 10: Removable Cast Walkers Versus Therapeutic Shoes, Treatment Discontinuations	39
Figure 11: Removable Cast Walkers Versus Therapeutic Shoes, Percentage of Healed Ulcers	39
Figure 12: PRISMA Flow Diagram	46
Figure 13a: Decision-Analytic Model	51
Figure 13b: Scenario Model	52
Figure 14: One-Way Sensitivity Analysis, Base Case, Total Contact Casting Versus Irremovable Cast Walkers ^a	61
Figure 15: One-Way Sensitivity Analysis, Scenario 1, Total Contact Casting Versus Irremovable Cast Walkers ^a	62
Figure 16: One-Way Sensitivity Analysis, Scenario 2, Total Contact Casting Versus Irremovable Cast Walkers ^a	63
Figure A1: Letter of Information	115
Figure A2: Consent and Release Form	117
Figure A3: Interview Guide	118

OBJECTIVE

This health technology assessment looked at the clinical benefits and harms, cost-effectiveness, cost utility, and patient experiences of fibreglass total contact casting, removable cast walkers, and irremovable cast walkers in patients with diabetic neuropathic foot ulcers to determine whether they should be publicly funded.

BACKGROUND

Health Condition

Diabetes can lead to nerve damage (diabetic neuropathy), causing muscle weakness or wasting and loss of pain and protective sensation.¹ Loss of pain and feeling in the foot, combined with increased pressure from shoes, trauma, or foot deformity,¹ all contribute to the development of foot ulcers.^{1,2}

Foot ulcers can cause substantial morbidity (disease) and put people at risk for amputation of the foot or leg.³ Foot ulcers can also become infected, which impairs healing^{1,4} and further increases the risk of amputation.¹

Clinical Need and Target Population

In Ontario in 2015, the estimated prevalence of diabetes was 1.5 million (10.2%).⁵ People with diabetes have a 15% to 25% lifetime risk of developing a foot ulcer,^{3,6,7} and estimates indicate that 2% to 3% of people with diabetes experience a foot ulcer in a given year.⁷

Compared with the general population, rates of diabetes are higher among people with First Nations,⁸ South Asian, Asian, African, or Hispanic heritage.⁵ Because of this, the prevalence of diabetes-related ulcers in these populations is also higher.⁹

Current Treatment Options

Treatment of diabetic neuropathic foot ulcers involves debridement (removing dead or diseased tissue), pressure offloading,^{10,11} infection control, and maintaining adequate circulation.⁴

Health Technology Under Review

Offloading (redistributing) pressure from high-pressure areas on the foot is a basic aspect of neuropathic foot ulcer care.¹² Offloading interventions include wheelchairs or crutches and bed rest, but these options limit a person's mobility.¹³ Therapeutic shoes, felted foam, removable cast walkers, and total contact casting allow people to get around more easily.^{10,13} Many types of therapeutic shoes are available, including half-shoes, healing sandals, custom-made shoes, and depth-inlay shoes.¹⁴ However, these shoes have different characteristics and may differ in their ability to offload pressure.¹⁴

Total Contact Casting

Total contact casting uses plaster or fibreglass casting tape that is moulded to maintain contact with the sole of the foot and lower leg.¹⁴ The cast supports the foot and lower leg and redistributes pressure over the entire plantar surface (sole of the foot) to reduce pressure over the ulcer area.^{11,15,16} Casts may also help reduce or control swelling^{15,17} and protect the foot from

infection.¹⁰ Because the cast is moulded to the patient's lower leg and foot, it may also be useful when premade cast walkers do not fit properly.¹⁶

Total contact casts cannot be removed by the patient, so they do not allow for daily inspection of the ulcer.¹⁸ For this reason, they are not recommended for patients with severe peripheral arterial disease¹⁵; untreated osteomyelitis or soft-tissue infections¹¹; ulcers on the opposite foot; or poor balance (because of a risk of falls).^{2,12} Total contact casts may affect daily activities, interfering with sleeping, bathing, and driving.¹⁴ Casts must be applied by a qualified health care professional²; they can irritate the skin and lead to more ulcers if they are not applied appropriately.^{12,14} They should be changed weekly,³ and they are time-consuming to apply and remove.⁴ The fact that total contact casts cannot be removed by the patient enforces treatment adherence, which may lead to improved outcomes.¹⁴

Note: Throughout the report, whenever we mention total contact casting, we are referring to fibreglass total contact casting unless specified otherwise.

Removable and Irremovable Cast Walkers

Removable cast walkers keep the ankle at a 90-degree angle, reducing pressure on the forefoot.⁴ They can be removed by the patient, allowing for frequent ulcer inspection and dressing changes.¹⁴ For this reason, they can be used for infected ulcers.¹⁴ Removable cast walkers also allow the patient to bathe and sleep more comfortably.¹⁰ However, the fact that they can be easily removed affects patient adherence and may have a negative effect on ulcer healing.¹⁴

Removable cast walkers can be made irremovable by securing them in place with a cohesive bandage, plaster, or fibreglass.¹⁴ Irremovable cast walkers enforce treatment adherence, because patients cannot take them off.¹⁴ However, because health care professionals can remove them easily, irremovable cast walkers (like removable cast walkers) are suitable for ulcers that require frequent inspection and treatment, such as infected ulcers.¹⁵

Removable and irremovable cast walkers are contraindicated in patients with poor balance or severe peripheral arterial disease.¹⁹ They are not custom-made, so they may not fit all patients, including those with very short legs, wide feet, or severe deformities.¹⁶

Regulatory Information

Cast walkers and the fibreglass tape used to prepare total contact casting and irremovable cast walkers are considered class I devices and do not require medical device licensing from Health Canada.

Ontario Context

In Ontario, patients pay for cast walkers. Patients pay out of pocket for the materials used to prepare the total contact cast, but application of the cast is publicly funded. Access to total contact casting may be limited by the need for qualified personnel to apply the cast. Geographic isolation may also be a concern, because patients need to make frequent clinic visits to have total contact casts or irremovable cast walkers replaced or reapplied.

CLINICAL EVIDENCE

Research Question

What are the clinical benefits and harms of total contact casting, removable cast walkers, and irremovable cast walkers compared with other offloading devices (including each other) and non-offloading treatments in patients with diabetic neuropathic foot ulcers?

Methods

Research questions were developed by Health Quality Ontario in consultation with patients, health care providers, clinical experts, and other health system stakeholders.

Literature Search

We performed a literature search on August 17, 2016, to retrieve studies published from inception to the search date. We used the Ovid interface to search the following databases: MEDLINE, Embase, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Health Technology Assessment, National Health Service Economic Evaluation Database (NHSEED), and Database of Abstracts of Reviews of Effects (DARE); we also used the EBSCOhost interface to search the Cumulative Index to Nursing & Allied Health Literature (CINAHL).

Search strategies were developed by medical librarians using controlled vocabulary (i.e., Medical Subject Headings) and relevant keywords. Search filters for randomized controlled trials, systematic reviews, meta-analyses, and health technology assessments were applied to the search strategies. The final search strategy was peer-reviewed using the PRESS Checklist.²⁰ Database auto-alerts were created in MEDLINE, Embase, and CINAHL and monitored for the duration of the health technology assessment (HTA) review.

We performed targeted grey literature searching of HTA agency sites and clinical trial registries. We also reviewed reference lists of included studies for any additional studies not identified through the systematic search. See Appendix 1 for literature search strategies, including all search terms.

Literature Screening

A single reviewer reviewed the abstracts and, for those studies meeting the eligibility criteria, we obtained full-text articles. We also examined reference lists for any additional relevant studies not identified through the search.

Types of Participants

The population of interest included patients with type 1 or 2 diabetes who had neuropathic infected or noninfected foot ulcers.

Types of Interventions

The interventions evaluated were:

- Fibreglass total contact casting
- Removable cast walkers
- Irremovable cast walkers

We included the following comparators:

- The interventions listed above, compared to each other
- Other offloading devices, such as therapeutic shoes, custom braces, or ankle and foot orthoses
- Non-offloading ulcer treatments (e.g., ulcer dressings)

Types of Outcomes Measures

- Treatment discontinuations and reasons for discontinuation
- Ulcer healing
- Time to ulcer healing
- Patient adherence to treatment, as measured by level of activity
- Quality of life and patient satisfaction
- Complications

Inclusion Criteria

- English-language full-text publications in patients with diabetic, neuropathic, plantar ulcers (infected or noninfected)
- Randomized controlled trials (RCTs) evaluating at least one of the interventions of interest
- Studies with a mixed population, if at least 90% of the patients matched the population of interest
- Studies in which less than 90% of the patients matched the population of interest but reported results separately for the population of interest

Exclusion Criteria

- Nonrandomized controlled trials and noncomparative studies
- Studies evaluating total contact casting prepared with materials other than fibreglass, unless fibreglass total contact casting was used as a comparator
- Editorials, case reports, and commentaries

Data Extraction

We extracted relevant data on study characteristics and risk-of-bias items, and PICOT (population, intervention, comparison, outcome, time). We used a data form to collect information about:

- Source (i.e., citation information, contact details, study type)
- Methods (i.e., study design, study duration and years, participant allocation, allocation sequence concealment, blinding, reporting of missing data, reporting of outcomes, and whether or not the study compared two or more groups)
- Outcomes (i.e., outcomes measured, number of participants for each outcome, number of participants missing for each outcome, outcome definition and source of information, unit of measurement, standard deviations or 95% confidence intervals [CIs], and time points at which outcome was assessed)
- Baseline characteristics of the patients included in the studies, including those based on the PROGRESS-Plus categories (place of residence, race/ethnicity, occupation, gender, religion, education, socioeconomic status, social capital)²¹

We contacted authors of the studies to provide clarification when needed.

Statistical Analysis

For dichotomous variables, we presented the number and percentage of participants who experienced the outcome, the risk ratio, the risk difference, and 95% CIs. We reported the results of intention-to-treat analyses. We expressed results for continuous outcomes as mean difference and standard deviation (SD). For time to ulcer healing, we reported the results of Kaplan-Meier analyses.²²

Quantitative syntheses of the individual studies were performed when appropriate and in the absence of substantial heterogeneity using Review Manager v. 5.3 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014).²³ Statistical heterogeneity was assessed using the I^2 statistic.²⁴ Graphical display of the forest plots was also examined. A P -value <0.05 was considered significant for the overall effect estimate.

Subgroup analyses were undertaken according to population subgroups such as ethnicity, comorbidities (diabetes control), adherence, ulcer characteristics, and any PROGRESS-Plus categories²¹ if the information was available.

Quality of Evidence

The level of quality of the body of evidence for each outcome was evaluated according to the Grading of Recommendations Assessment Development and Evaluation (GRADE) Handbook.²⁵ We started with the assumption that randomized controlled trials are high quality, whereas observational studies are low quality. We then rated the studies based on the following considerations: risk of bias, inconsistency, indirectness, imprecision, publication bias, magnitude of effect, dose-response gradient, and any residual confounding factors. The overall quality was determined to be high, moderate, low, or very low using a step-wise, structural methodology. The quality level determination reflects our certainty about the evidence.

The quality of the randomized controlled trials was assessed according to the Cochrane Collaboration criteria for evaluating risk of bias (Appendix 2).²⁶

Expert Consultation

Between August 2016 and January 2017, we sought expert consultation on the use of total contact casting, removable cast walkers, and irremovable cast walkers to treat diabetic neuropathic foot ulcers. Members of the consultation included physicians, nurses, and chiropodists who manage diabetic foot ulcers. The role of the expert advisors was to contextualize the evidence and provide advice on the use of the interventions being evaluated.

Results

Literature Search

The search yielded 329 citations published before August 17, 2016. After removing duplicates, we reviewed titles and abstracts to identify potentially relevant articles. We obtained the full texts of these articles for further assessment. Thirteen RCTs met the inclusion criteria.^{16,27-38} The results of one study were reported in two separate publications.^{37,39} We hand-searched the reference lists of the included studies, along with health technology websites and other sources, to identify additional relevant studies, but none were identified.

Figure 1 presents the flow diagram for the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA).




Figure 1: PRISMA Flow Diagram

Abbreviation: PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-analyses.
 Source: Adapted from Moher et al.⁴⁰

Design and Characteristics of the Included Studies

The 13 RCTs yielded a total of 19 treatment comparisons.^{16,27-38} Total contact casting was compared with irremovable cast walkers in three studies,^{27,28,35} with removable cast walkers in six studies,^{16,27,31-33,37} and with therapeutic shoes in five studies.^{16,30,34,37,38} Irremovable cast walkers were compared with removable cast walkers in three studies.^{27,29,36} Removable cast walkers were compared with therapeutic shoes in two studies.^{16,37}

No studies compared irremovable cast walkers with therapeutic shoes. No studies compared any of the interventions with custom braces, ankle and foot orthoses, or non-offloading ulcer treatments.

The studies were conducted in the United States^{16,29,32,35-38} and Europe.^{27,28,30,31,33,34}

In all studies that evaluated total contact casting (except for two in which the information was not provided^{34,35}) the cast was prepared by wrapping fibreglass tape around the patient's lower leg and foot. Some used a mix of plaster (inner layer) and fibreglass.^{32,37,38} In five of the studies that used only fibreglass, casting tapes of two different rigidities were used.^{27,28,30,31,33} One study reported that patients were given crutches or a cane to aid with balance, if needed.³⁴

The studies that evaluated removable and/or irremovable cast walkers used different walker brands. Irremovable cast walkers were prepared by wrapping a cohesive bandage^{29,35,36} or straps^{27,28} around a removable cast walker. The studies used different types of therapeutic shoes as comparators, such as healing sandals,^{16,38} half-shoes,³⁷ custom-made temporary shoes,³⁴ and therapeutic shoes with a rocker-bottom sole.³⁰

Sample sizes were small, with 11 to 30 patients per study group. The duration of follow-up was 3 months in most studies, 4 months in one study,³⁴ and 1 month in another,³⁰ or until ulcer closure, whichever came first.

The studies evaluated the percentage of ulcers healed, time to healing, and discontinuations. Three studies also assessed patient adherence to treatment by measuring the daily level of activity with a pedometer or an activity sensor.^{16,29,37} Five studies assessed patient quality of life and/or satisfaction with treatment using the visual analogue scale or the Short-Form 36 questionnaire.^{16,27,28,30,39} Treatment complications were among the outcomes defined a priori in some studies.^{27,28,30,34,35,38} One study prospectively assessed the occurrence of ulcer infection, but no other treatment complications.¹⁶ The other studies reported some treatment complications without prespecifying complications as a study outcome.^{29,31-33,36,37}

Appendix 3 provides more detailed information about study design and characteristics.

Definitions and Patient Characteristics in the Included Studies

Most study participants were men (56% to 91%).^{16,27-30,32-38} Two studies reported patients' ethnicity. One reported that 34% of participants were white, 59% were Hispanic, and 5% were African-American.¹⁶ The other reported that 12% were white, 61% were Hispanic, and 34% were black.³⁵

The studies generally included patients with diabetes who had noninfected neuropathic plantar ulcers. They generally excluded patients with peripheral arterial disease, although some included patients with mild to moderate peripheral arterial disease.^{16,29-31,34,36} The definitions of peripheral neuropathy and peripheral arterial disease used in the studies are presented in Appendix 4.

Some studies included only patients with forefoot ulcers,^{16,27,28,33,36} and some included patients with midfoot (13% to 27%)^{29,32,34,35,38} and heel ulcers^{29,35,38} (5%³⁵ and 7.5%³⁸ in the studies that provided this information).

The ulcers evaluated in the studies were classified as grade 1 or 2 according to the University of Texas Wound Grading System (Appendix 4). Five studies included mostly grade 1 ulcers (superficial wound not involving tendon, capsule, or bone): 100% in three studies^{33,36,37} and 70% to 75% in two studies.^{27,38} The remaining studies included grade 1 and 2 ulcers (wound penetrating to tendon or capsule), except for three that did not provide this information.²⁹⁻³¹

The mean ulcer area at baseline varied between 1 and 4 cm² in most studies. In one study that compared irremovable and removable cast walkers, the mean (SD) ulcer areas at baseline were 6.5 (8.5) and 10.1 (12.0) cm², respectively,²⁹ but ulcer classification and duration were not reported.

Ulcer healing was defined as complete re-epithelialization of the ulcerated area. Patients who discontinued treatment were considered unhealed (Appendix 4).

In most studies, information was not available on ulcer duration before study enrolment, ulcer history, or prior amputation. None of the studies provided information on ulcer treatment prior to enrolment.

Additional patient baseline characteristics are presented in Appendix 5.

Methodological Quality of the Included Studies

Complete results of the methodology checklist for included studies are presented in Appendix 2.

It was not possible to blind the patients or the treating physician to the treatment assignment, although some studies did attempt to blind the outcome assessor to the treatment group. Nevertheless, we did not consider lack of blinding to confer a high risk of bias for the main outcomes of ulcer healing and time to ulcer healing. There were very few losses to follow-up in the studies identified. The sample sizes were small; as a result, despite adequate randomization, differences in baseline characteristics between study groups could not be ruled out.

Overall, the risk of bias was low in the studies identified, especially for ulcer healing.

Intention-to-treat analysis was used for ulcer healing; patients whose ulcer did not heal and patients who discontinued treatment or were lost to follow-up were considered to be unhealed.

Results for Total Contact Casting Versus Irremovable Cast Walkers

Three studies compared total contact casting with irremovable cast walkers.^{27,28,35}

Table 1: Total Contact Casting Versus Irremovable Cast Walkers

Author, Year N (TCC/ICW) Follow-up	Treatment Discontinuation, n (%)	Ulcer Healing, n (%)	Mean Time to Ulcer Healing, d (SD)
Piaggese et al, 2016 ²⁷ 45 (23/22) 3 months	Overall TCC: 3 (13.0) ICW: 2 (9.1) Voluntary withdrawal TCC: 3 (13.0) ICW: 1 (4.5) Lost to follow-up TCC: 0 ICW: 1 (4.5)	TCC: 19 (82.6) ICW: 18 (81.8)	TCC: 37.0 (21.6) ICW: 39.6 (12.2) Kaplan-Meier curve showed no statistically significant difference between groups
Piaggese et al, 2007 ²⁸ 40 (20/20) 3 months	No treatment discontinuation reported	TCC: 19 (95.0) ICW: 17 (85.0) <i>P</i> = .21	TCC: 45.5 (30.8) ICW: 46.9 (23.8) <i>P</i> = .87 Kaplan-Meier curve showed no statistically significant difference between groups
Katz et al, 2005 ³⁵ 41 (20/21) 3 months	Overall TCC: 4 (20.0) ICW: 3 (14.3) Lost to follow-up TCC: 4 (20.0) ICW: 2 (9.5) Osteomyelitis (before starting treatment) TCC: 0 ICW: 1 (4.8)	TCC: NA (74.0) ICW: NA (80.0) <i>P</i> = .65	Median (IQR) TCC: 35 (21–49) ICW: 28 (21–49) <i>P</i> = .65

Abbreviations: ICW, irremovable cast walker; IQR, interquartile range; NA, not available; SD, standard deviation; TCC, total contact casting.

Treatment Discontinuation

One study reported no treatment discontinuations.²⁸ In the other two, treatment discontinuations occurred in 13% and 20% of the total contact casting group and 9% and 14% of the irremovable cast walker group.^{27,35} Treatment discontinuations resulted from voluntary withdrawal and losses to follow-up (Table 1). We found no statistically significant difference in treatment discontinuations between groups based on the results of the two studies (Figure 2).




Figure 2: Total Contact Casting Versus Irremovable Cast Walkers, Treatment Discontinuations

Abbreviations: CI, confidence interval; M-H, Mantel-Haenszel; TCC, total contact casting.

Sources: Katz et al³⁵ and Piaggese et al.²⁷

Ulcer Healing

At 3 months' follow-up, the percentage of patients with a healed ulcer was between 74% and 95% for total contact casting, and between 80% and 85% for irremovable cast walkers (Table 1). We found no statistically significant difference between the two groups when we combined the results of the studies (Figure 3).




Figure 3: Total Contact Casting Versus Irremovable Cast Walkers, Percentage of Healed Ulcers^a

Abbreviations: CI, confidence interval; M-H, Mantel-Haenszel; TCC, total contact casting.

^aKatz et al provided the percentage of healed ulcers, but not the exact number of patients who had a healed ulcer. We calculated the number of patients with a healed ulcer based on the total number of patients in each treatment group and the percentage of healed ulcers in each group.

Sources: Katz et al⁸⁵ and Piaggese et al.^{27,28}

Time to Ulcer Healing

Based on survival (Kaplan-Meier) analyses from two studies, we found no statistically significant difference in time to healing between the two groups over 3 months of follow-up (Table 1).^{27,28}

Patient Satisfaction

One study reported that patients treated with irremovable cast walkers had a higher level of satisfaction (visual analogue scale; mean [SD] 8.45 [1.79] for irremovable cast walkers and 6.85 [2.39] for total contact casting; $P < .05$).²⁸ However, another study found no difference between the two groups (figures not provided).²⁷

Complications

In one study, 6 patients (30%) in the total contact casting group and 5 (25%) in the irremovable cast walker group experienced complications, none of which resulted in treatment discontinuation (Table 2).²⁸ In another,³⁵ 13 patients (65%) in the total contact casting group and eight patients (38%) in the irremovable cast walker group reported complications that were considered to be potential side effects of treatment (some patients had more than one complication). In the third study, 7 patients in the total contact casting group (30%) and two patients (9%) in the irremovable cast walker group reported complications, none of them serious or leading to discontinuation.²⁷ However, differences in the proportion of complications between the two groups were difficult to interpret owing to the small number of events reported.

Table 2: Total Contact Casting Versus Irremovable Cast Walkers, Complications

Author, Year N (TCC/ICW)	Complication, n (%)								
	Skin Maceration	Ulcer Infection	New Ulcer	Amputation	Broken Cast	Fall	Abrasion	Trauma	Other
Piaggese et al, 2016 ²⁷ 45 (23/22)	TCC: 0 ICW: 1 (4.5)	Not reported	Not reported	Not reported	Broken cast TCC: 3 (13.0) ICW: 0	Not reported	TCC: 4 (17.4) ICW: 0	Accidental minor trauma in contralateral foot TCC: 0 ICW: 1 (4.5)	Not reported
Piaggese et al, 2007 ²⁸ 40 (20/20)	TCC: 4 (20.0) ICW: 2 (10.0)	TCC: 1 (5.0) ICW: 1 (5.0) Did not lead to discontinuation	TCC: 0 ICW: 0	Not reported	Partial cast rupture TCC: 1 (5.0) ICW: 0	Not reported	Not reported	Not reported	Transient paresthesia TCC: 0 ICW: 1 (5.0) Superficial hematoma of the calf due to accidental trauma TCC: 0 ICW: 1 (5.0)
Katz et al, 2005 ³⁵ 41 (20/21)	TCC: 7 (35.0) ICW: 6 (28.6) <i>P</i> = .49	Not reported	Second ulcer TCC: 2 (10.0) ICW: 1 (5.0) <i>P</i> = .53 Kissing ulcer TCC: 1 (5.0) ICW: 0 <i>P</i> = .33	Toe TCC: 1 (5.0; kissing ulcer) ICW: 1 (5.0; nonadherence) <i>P</i> = .97	Broken cast TCC: 3 (15.0) ICW: 1 (5.0) <i>P</i> = .29	TCC: 0 ICW: 1 (5.0) <i>P</i> = .35	TCC: 2 (10.0) ICW: 0 <i>P</i> = .15	Not reported	Edema TCC: 1 (5.0) ICW: 0 <i>P</i> = .33

Abbreviations: ICW, irremovable cast walker; TCC, total contact casting.

Quality of Evidence

Table 3 provides the GRADE evidence profile for total contact casting versus irremovable cast walkers.

Table 3: GRADE Evidence Profile for Total Contact Casting Versus Irremovable Cast Walkers

Number of Studies (Design)	Risk of Bias	Inconsistency	Indirectness	Imprecision	Publication Bias	Upgrade Considerations	Quality
Percentage of Patients with a Healed Ulcer							
3 (RCTs) ^{27,28,35}	No serious limitations	No serious limitations	No serious limitations	Very serious limitations (–2) ^a	Undetected	None	⊕⊕ Low
Time to Healing (Kaplan-Meier Analysis)							
2 (RCTs) ^{27,28}	No serious limitations	No serious limitations	No serious limitations	Very serious limitations (–2) ^b	Undetected	None	⊕⊕ Low
Patient Satisfaction With Treatment							
2 (RCTs) ^{27,28}	No serious limitations	Serious limitations (–1) ^c	No serious limitations	Serious limitations (–1) ^d	Undetected	None	⊕⊕ Low
Complications							
3 (RCTs) ^{27,28,35}	No serious limitations	No serious limitations	No serious limitations	Very serious limitations (–2) ^e	Undetected	None	⊕⊕ Low

Abbreviations: GRADE, Grading of Recommendations Assessment, Development, and Evaluation; RCT, randomized controlled trial.

^aVery low statistical power to detect a statistically significant difference between groups.

^bNo statistically significant difference between the two groups in the studies identified.

^cStudy results were inconsistent.

^dSome of the studies did not find a statistically significant difference between the study groups.

^eVery few events reported in the studies, leading to very low statistical power to detect a difference between groups.

Results for Total Contact Casting Versus Removable Cast Walkers

Six studies compared total contact casting with removable cast walkers.^{16,27,31-33,37}

Table 4: Total Contact Casting Versus Removable Cast Walkers

Author, Year N (TCC/RCW) Follow-up	Treatment Discontinuation, n (%)	Ulcer Healing, n (%)	Mean Time to Ulcer Healing, d (SD)
Piaggese et al, 2016 ²⁷ 43 (23/20) 3 months	<i>Overall</i> TCC: 3 (13.0) RCW: 0 <i>Voluntary withdrawal</i> TCC: 3 (13.0) RCW: 0	TCC: 19 (82.6) RCW: 16 (80.0)	TCC: 37.0 (21.6) RCW: 43.2 (15.1) Kaplan-Meier curve showed no statistically significant difference between groups
Lavery et al, 2015 ¹⁶ 50 (23/27) 3 months	<i>Overall</i> TCC: 5 (21.7) RCW: 12 (44.4) <i>Complications</i> TCC: 1 (4.3; infection) RCW: 5 (18.5; infection 4, device-related ulcer 1) <i>Voluntary withdrawal</i> TCC: 4 (17.4) RCW: 4 (14.8) <i>Nonadherence</i> TCC: 0 RCW: 3 (11.1)	TCC: 16 (69.6) RCW: 6 (22.2) Statistically significant (<i>P</i> -value not provided)	TCC: 37.8 (20.3) RCW: 46.9 (30.1) <i>P</i> = .22
Gutekunst et al, 2011 ³² 23 (11/12) >3 months	Not reported	TCC: 9 (81.8) RCW: 5 (41.7) <i>P</i> < .05	TCC: 95 (61) RCW: 94 (64) Not statistically significant
Faglia et al, 2010 ³³ 48 (25/23) 3 months	<i>Overall</i> TCC: 2 (8.0) RCW: 1 (4.3) <i>Complications</i> TCC: 1 (4.0; ulcer on contralateral foot) RCW: 1 (4.3; ulcer infection requiring antibiotic therapy and more frequent clinic visits) <i>Voluntary withdrawal</i> TCC: 1 (4.0) RCW: 0	TCC: 17 (68.0) RCW: 16 (69.6)	TCC: 35.3 (3.1) RCW: 39.7 (4.2) <i>P</i> = .71 Kaplan-Meier curve showed no difference between groups <i>P</i> = .79
Caravaggi et al, 2007 ³¹ 60 (30/30) 3 months	<i>Overall</i> TCC: 6 (20.0) RCW: 7 (23.3) <i>Complications</i> TCC: 5 (16.7) RCW: 6 (20.0) <i>Nonadherence</i> TCC: 1 (3.3) RCW: 1 (3.3)	TCC: 24 (80.0) RCW: 23 (76.7) Not statistically significant	TCC: 48 (NA) RCW: 71 (NA) Statistically significant (<i>P</i> - value not provided) Kaplan-Meier curve showed a faster healing rate with TCC vs. RCW <i>P</i> < .005
Armstrong et al, 2001 ³⁷ 50 (25/25) 3 months	<i>Overall</i> TCC: 6 (24.0) RCW: 5 (20.0) <i>Discomfort</i> TCC: 4 (16.0) RCW: 3 (12.0) <i>Lost to follow-up</i> TCC: 2 (8.0) RCW: 2 (8.0)	TCC: 17 (68.0) RCW: 13 (52.0)	TCC: 33.5 (24.3) RCW: 50.4 (26.0) <i>P</i> = .07 Kaplan-Meier curve showed a faster healing rate with TCC vs. RCW <i>P</i> = .033

Abbreviations: NA, not available; RCW, removable cast walker; TCC, total contact casting.

Treatment Discontinuation

There was a large variation across studies in the percentage of patients who discontinued treatment. Treatment discontinuations occurred in 8% to 24% of patients in the total contact casting group and 0% to 44% of patients in the removable cast walker group. Reasons for discontinuation included complications, voluntary withdrawal, and nonadherence (Table 4). When we pooled the results, we found no statistically significant difference between groups (Figure 4).




Figure 4: Total Contact Casting Versus Removable Cast Walkers, Treatment Discontinuations

Abbreviations: CI, confidence interval; M-H, Mantel-Haenszel; TCC, total contact casting.

Sources: Armstrong et al,³⁷ Caravaggi et al,³¹ Faglia et al,³³ Lavery et al,¹⁶ and Piaggese et al.²⁷

Ulcer Healing

At 3 months of follow-up, the percentage of patients with a healed ulcer varied between 68% and 83% with total contact casting, and between 22% and 80% with removable cast walkers. Pooling the results yielded an absolute increase of 17% (risk difference 0.17 [95% confidence interval 0.00–0.33]) in the percentage of healed ulcers with total contact casting compared with removable cast walkers (Figure 5).




Figure 5: Total Contact Casting Versus Removable Cast Walkers, Percentage of Healed Ulcers

Abbreviations: CI, confidence interval; M-H, Mantel-Haenszel; TCC, total contact casting.

Sources: Armstrong et al,³⁷ Caravaggi et al,³¹ Faglia et al,³³ Gutekunst et al,³² Lavery et al,¹⁶ and Piaggese et al.²⁷

The level of heterogeneity we found ($I^2 = 61\%$) may be partially explained by the different rates of discontinuation across the studies. According to Lavery et al,¹⁶ the large proportion of treatment discontinuations with removable cast walkers affects treatment success and may explain the large variation among studies in the percentage of ulcers healed. This suggestion was corroborated by other authors' comments that poor adherence to the removable cast walker may affect its healing ability and its inferior results compared to total contact casting.^{32,33} Piaggese et al²⁷ acknowledged that the lack of difference they found in ulcer healing between the two groups was in contrast to what other studies had demonstrated. They believed that this finding may have been due in part to high patient adherence with the removable cast walker in their study, possibly because it included weekly reinforcement of the importance of adherence.²⁷

The small sample sizes may also explain the heterogeneity we found. Although these studies were randomized, we could not rule out the possibility that differences in baseline characteristics may still have been present because of the small sample sizes, and this could explain the differences in point estimates across studies.

Time to Ulcer Healing

Among four studies that evaluated time to ulcer healing using survival (Kaplan-Meier) analysis, two found no statistically significant difference between the groups,^{27,33} and two showed statistically significantly faster healing with total contact casting than with removable cast walkers (Table 4).^{31,37}

Adherence to Treatment and Daily Activity

Two studies assessed treatment adherence by measuring the level of daily activity.^{16,37} The difference between total contact casting and removable cast walkers was not statistically significant, with a mean (SD) daily number of steps of 1,447 (1,310) versus 1,404 (1,234) in one study,¹⁶ and 600 (320) versus 768 (563)³⁷ in the other.

Quality of Life and Patient Satisfaction

Armstrong et al³⁹ showed that the change in physical and mental health scores before and after treatment (measured using the Short-Form 36-item health survey) did not differ between the two groups.

Among two studies that evaluated patient satisfaction using a visual analogue scale, one found no statistically significant difference between the two groups,¹⁶ and the other reported statistically significantly higher patient satisfaction with removable cast walkers.²⁷

Complications

Five studies reported complications with total contact casting or removable cast walkers (Table 5).^{16,27,31,33,37} Differences in the proportion of complications between the two groups were difficult to interpret owing to the small sample sizes and the small number of events.

Table 5: Total Contact Casting Versus Removable Cast Walkers, Complications

Author, Year N (TCC/RCW)	Complication, n (%)						
	Skin Maceration	Ulcer Infection	New Ulcer	Cast Rupture	Fall	Hitching	Abrasion
Piaggese et al, 2016 ²⁷ 43 (23/20)	Not reported	<i>Fungal intertrigo</i> TCC: 0 RCW: 1 (5.0)	Not reported	<i>Broken cast</i> TCC: 3 (13.0) RCW: 0	Not reported	Not reported	<i>Traumatic abrasion</i> TCC: 3 (13.0) RCW: 0
Lavery et al, 2015 ¹⁶ 50 (23/27)	Not reported	<i>Infection leading to treatment discontinuation</i> TCC: 1 (4.3) RCW: 4 (14.8)	<i>Iatrogenic ulcers</i> TCC: 0 RCW: 1 (3.7)	Not reported	Not reported	Not reported	Not reported
Faglia et al, 2010 ³³ 48 (25/23)	TCC: 0 RCW: 1 (4.3)	<i>Infection leading to treatment discontinuation</i> TCC: 0 RCW: 1 (4.3)	<i>Ulcer on the contralateral foot</i> TCC: 1 (4.0) RCW: 0	<i>Stirrup rupture (replaced without removing cast)</i> TCC: 1 (4.0) RCW: 0	Not reported	TCC: 1 (4.0; resolved after removal of the German cotton) RCW: 0 after removal of the German cotton	Not reported
Caravaggi et al, 2007 ³¹ 60 (30/30)	Not reported	<i>Serious infection requiring discontinuation, antibiotics, and surgical debridement</i> TCC: 5 (17.2) RCW: 6 (20.7) Not significant	Not reported	Not reported	Not reported	Not reported	Not reported
Armstrong et al, 2001 ³⁷ 50 (25/25)	Not reported	Not reported	<i>Device-related ulcerations</i> TCC: 0 RCW: 0	Not reported	TCC: 0 RCW: 0	Not reported	Not reported

Abbreviations: RCW, removable cast walker; TCC, total contact casting.

Quality of Evidence

Table 6 provides the GRADE evidence profile for total contact casting versus removable cast walkers.

Table 6: GRADE Evidence Profile for Total Contact Casting Versus Removable Cast Walkers

Number of Studies (Design)	Risk of Bias	Inconsistency	Indirectness	Imprecision	Publication Bias	Upgrade Considerations	Quality
Percentage of Patients with a Healed Ulcer							
6 (RCTs) ^{16,27,31-33,37}	No serious limitations	Serious limitations (–1) ^a	No serious limitations	No serious limitations ^b	Undetected	None	⊕⊕⊕ Moderate
Time to Healing (Kaplan-Meier Analysis)							
4 (RCTs) ^{27,31,33,37}	No serious limitations	Serious limitations (–1) ^a	No serious limitations	Serious limitations (–1) ^c	Undetected	None	⊕⊕ Low
Patient Satisfaction With Treatment							
2 (RCTs) ^{16,27}	No serious limitations	Serious limitations (–1) ^a	No serious limitations	Serious limitations (–1) ^d	Undetected	None	⊕⊕ Low
Quality of Life							
1 (RCT) ³⁹	No serious limitations	Could not be evaluated	No serious limitations	Very serious limitations (–2) ^e	Undetected	None	⊕⊕ Low
Complications							
5 (RCTs) ^{16,27,31,33,37}	Serious limitations (–1) ^f	No serious limitations	No serious limitations	Very serious limitations (–2) ^g	Undetected	None	⊕ Very Low

Abbreviations: GRADE, Grading of Recommendations Assessment, Development, and Evaluation; RCT, randomized controlled trial.

^aThe results were inconsistent across studies.

^bThe lower limit of the confidence interval included the null; however, we did not determine that this warranted further downgrading the evidence, because it was already downgraded for inconsistency (which may have been the cause of the imprecision). Furthermore, the optimal information size was achieved when the studies were combined.

^cSome studies found a statistically significant difference in time to healing between the two groups, but other studies did not.

^dSome studies did not find a statistically significant difference between groups.

^eNo statistically significant difference between groups. Only one small study (21 patients/study group) assessed the outcome.

^fTreatment complications were not defined as an outcome a priori in the studies included in this analysis.

^gVery few events were reported in the studies, leading to very low statistical power to detect a difference between groups.

Results for Total Contact Casting Versus Therapeutic Shoes

Five studies compared total contact casting with therapeutic shoes.^{16,30,34,37,38} The length of follow-up was 1 month in one study³⁰ and 3 to 4 months in the others. Different types of shoes were used in the comparator group, including healing sandals,^{16,38} custom-made shoes,³⁴ half-shoes,³⁷ and therapeutic shoes.³⁰

Table 7: Total Contact Casting Versus Therapeutic Shoes

Author, Year N (TCC/Shoes) Follow-up	Treatment Discontinuations, n (%)	Ulcer Healing, n (%)	Mean Time to Ulcer Healing, d (SD)
Lavery et al, 2015 ¹⁶ 46 (23/23) 3 months	<i>Overall</i> TCC: 5 (21.7) Shoes: 3 (13.0) <i>Complications</i> TCC: 1 (4.3) Shoes: 3 (13.0) <i>Voluntary withdrawal</i> TCC: 4 (17.4) Shoes: 0	TCC: 16 (69.6) Shoes: 10 (43.5) Not statistically significant	TCC: 37.8 (20.3) Shoes: 62.3 (24.5) $P < .001$
Van de Weg et al, 2008 ³⁴ 43 (23/20) 4 months	TCC: 5 (21.7; 3 before starting treatment) Shoes: 0 Reasons for discontinuation: lost to follow-up 2 (8.7); death 1 (4.3); amputation 1 (4.3); crossover 1 (4.3) Unclear if death or amputation occurred before or after start of treatment	TCC: 6 (26.1) Shoes: 6 (30.0)	TCC: 59 (39) Shoes: 90 (12) $P = .11$
Armstrong et al, 2001 ³⁷ 50 (25/25) 3 months	<i>Overall</i> TCC: 6 (24.0) Shoes: 1 (4.0) <i>Discomfort</i> TCC: 4 (16.0) Shoes: 0 <i>Instability</i> TCC: 0 Shoes: 1 (4.0) <i>Lost to follow-up</i> TCC: 2 (8.0) Shoes: 0	TCC: 17 (68.0) Shoes: 14 (56.0) $P = .03$	TCC: 33.5 (24.3) Shoes: 61.0 (23.4) $P = .005$ Kaplan-Meier curve showed a faster healing rate with TCC vs. half-shoe $P = .012$
Caravaggi et al, 2000 ³⁰ 50 (26/24) 30 days	Not reported	TCC: 13 (50.0) Shoes: 5 (20.8) $P = .032$	Not reported
Mueller et al, 1989 ³⁸ 40 (21/19) Duration of follow-up unclear	<i>Overall</i> TCC: 1 (4.8; voluntary withdrawal) Shoes: unclear	TCC: 19 (90.5) Shoes: 6 (31.6) $P < .05$	TCC: 42 (29) Shoes: 65 (29)

Abbreviations: Shoes, therapeutic shoes; SD, standard deviation; TCC, total contact casting.

Treatment Discontinuation

Based on the results of four studies, 5% to 24% of patients in the total contact casting group and 0 to 13% of patients in the therapeutic shoes group discontinued treatment^{16,34,37} (unclear in one study³⁸). One study did not report on treatment discontinuations.³⁰ Reasons for discontinuations included complications, voluntary withdrawal, and losses to follow-up (Table 5). When we pooled the results of the studies, treatment discontinuations occurred more frequently with total contact casting than with therapeutic shoes (Figure 6).




Figure 6: Total Contact Casting Versus Therapeutic Shoes, Treatment Discontinuations

Abbreviations: CI, confidence interval; M-H, Mantel-Haenszel; TCC, total contact casting.
 Sources: Armstrong et al,³⁷ Lavery et al,¹⁶ Mueller et al,³⁸ and Van de Weg et al.³⁴

Ulcer Healing

One study provided results for only 1 month of follow-up. The percentage of patients with a healed ulcer were 50% with total contact casting and 21% with therapeutic shoes.³⁰

Three studies reported ulcer healing in 68% to 90% of patients in the total contact casting group and 32% to 56% in the therapeutic shoes group after 3 to 4 months of follow-up.^{16,37,38} In contrast, Van de Weg et al³⁴ reported ulcer healing of 26% in the total contact casting group and 30% in the therapeutic shoes group. It is not clear why the findings of this study were different from those of the other three.

Our meta-analysis showed a statistically significant improvement in ulcer healing with total contact casting compared with therapeutic shoes within 1 to 4 months of follow-up (Figure 7).

The studies used different types of therapeutic shoes, which may have contributed to the heterogeneity we observed. Moreover, although these studies were randomized, we could not rule out the possibility that differences in baseline characteristics may have been present in some studies given the small sample sizes; this could also have explained part of the heterogeneity.




Figure 7: Total Contact Casting Versus Therapeutic Shoes, Percentage of Healed Ulcers

Abbreviations: CI, confidence interval; M-H, Mantel-Haenszel; TCC, total contact casting.

Sources: Armstrong et al,³⁷ Caravaggi et al,³⁰ Lavery et al,¹⁶ Mueller et al,³⁸ and Van de Weg et al.³⁴

Time to Ulcer Healing

One study evaluated the time to ulcer healing using survival analysis and found a statistically significantly shorter healing time with total contact casting than with a half-shoe (Table 7).³⁷

Adherence to Treatment and Daily Activity

Two studies assessed treatment adherence as measured by level of daily activity.^{16,37} The mean (SD) number of daily steps was lower with total contact casting than with therapeutic shoes in both studies: 1,447 (1,310) versus 4,022 (4,652), $P = .014$; and 600 (320) versus 1,462 (1,452), $P = .04$.^{16,37}

Quality of Life and Patient Acceptance

The study by Armstrong et al³⁹ showed that changes in physical and mental health scores before and after treatment as measured by the Short-Form 36-item health survey did not differ between the two groups.

Caravaggi et al³⁰ measured patient acceptance of treatment at the end of 1-month follow-up with a visual analogue scale (1–100). They observed no statistically significant difference between the total contact casting group (mean 88.3, SD 17.3) and the therapeutic shoes group (mean 91.2, SD 9.9). Similarly, Lavery et al¹⁶ found no statistically significant difference in patient satisfaction between the groups.

Complications

Five studies reported complications with total contact casting or therapeutic shoes (Table 8).^{16,30,34,37,38} Differences in the proportion of complications between the two groups were difficult to interpret because of the small sample sizes and low number of events.

Van de Weg et al³⁴ reported five complications believed to be associated with total contact casting that led to treatment discontinuation, but they did not specify the types of complications. The study also reported one death and one amputation in the total contact casting group; however, based on the information provided by the authors, we could not determine whether these complications were associated with the treatment.³⁴ Moreover, given that three patients were assigned to total contact casting but did not receive treatment, we could not tell whether these events occurred before or after the treatment started. We attempted to contact the authors of the study for clarification, but we received no response.

Table 8: Total Contact Casting Versus Therapeutic Shoes, Complications

Author, Year N (TCC/Shoes)	Complication, n (%)					
	Skin Abrasion	Ulcer Infection	Amputation	New Ulcer	Fall	Edema
Lavery et al, 2015 ¹⁶ 46 (23/23)	Not reported	TCC: 1 (4.3) Shoes: 3 (13.0)	Not reported	TCC: 0 Shoes: 0	Not reported	Not reported
Van de Weg et al, 2008 ³⁴ 43 (23/20)	Minor abrasion TCC: 0 Shoes: 2 (10.0)	Not reported	Unclear	Not reported	Not reported	Not reported
Armstrong et al, 2001 ³⁷ 50 (25/25)	Not reported	Not reported	Not reported	Device-related ulcerations TCC: 0 Shoes: 0	TCC: 0 Shoes: 0	Not reported
Caravaggi et al, 2000 ³⁰ 50 (26/24)	0	Not reported	Not reported	0	Not reported	0
Mueller et al, 1989 ³⁸ 40 (21/19)	TCC: 0 Shoes: not reported	Serious infection requiring admission to hospital TCC: 0 Shoes: 5 (26.3) $P < .05$ Fungal infection TCC: 3 (14.3) Shoes: 0 Did not lead to discontinuation	Forefoot amputation due to serious infection TCC: 0 Shoes: 2 (10.5)	Not reported	Not reported	Not reported

Abbreviations: Shoes, therapeutic shoes; TCC, total contact casting.

Quality of Evidence

Table 9 provides the GRADE evidence profile for total contact casting versus therapeutic shoes.

Table 9: GRADE Evidence Profile for Total Contact Casting Versus Therapeutic Shoes

Number of Studies (Design)	Risk of Bias	Inconsistency	Indirectness	Imprecision	Publication Bias	Upgrade Considerations	Quality
Percentage of Patients with a Healed Ulcer							
5 (RCTs) ^{16,30,34,37,38}	No serious limitations	No serious limitations	Serious limitations (–1) ^a	No serious limitations	Undetected	None	⊕⊕⊕ Moderate
Time to Healing (Kaplan-Meier Analysis)							
1 (RCT) ³⁷	No serious limitations	Could not be evaluated	Serious limitations (–1) ^a	No serious limitations	Undetected	None	⊕⊕⊕ Moderate
Patient Satisfaction With Treatment							
2 (RCTs) ^{16,30}	No serious limitations	No serious limitations	Serious limitations (–1) ^a	Serious limitations (–1) ^b	Undetected	None	⊕⊕ Low
Quality of Life							
1 (RCT) ³⁹	No serious limitations	Could not be evaluated	Serious limitations (–1) ^a	Very serious limitations (–2) ^c	Undetected	None	⊕ Very Low
Complications							
5 (RCTs) ^{16,30,34,37,38}	No serious limitations	No serious limitations	Serious limitations (–1) ^a	Very serious limitations (–2) ^d	Undetected	None	⊕ Very Low

Abbreviations: GRADE, Grading of Recommendations Assessment, Development, and Evaluation; RCT, randomized controlled trial.

^aDifferent types of therapeutic shoes were used in the studies; the results with one type of shoe may not be applicable to other types.

^bSome of the studies did not find a statistically significant difference between study groups.

^cNo statistically significant difference between groups. Only one small study (21 patients/study group) assessed the outcome.

^dVery few events reported in the studies, leading to very low statistical power to detect a difference between groups.

Results for Irremovable Cast Walkers Versus Removable Cast Walkers

Three studies compared irremovable cast walkers with removable cast walkers.^{27,29,36}

Table 10: Irremovable Cast Walkers Versus Removable Cast Walkers

Author, Year N (ICW/RCW) Follow-up	Treatment Discontinuation, n (%)	Ulcer Healing, n (%)	Mean Time to Ulcer Healing, d (SD)
Najafi et al, 2016 ²⁹ 49 (23/26 ^a) 3 months	<i>Overall</i> ICW: 4 (17.4) RCW: 2 (7.7) <i>Infection</i> ICW: 2 (8.7) RCW: 0 <i>Surgical closure of the wound</i> ICW: 1 (4.3) RCW: 1 (3.8) <i>Lost to follow-up</i> ICW: 1 (4.3) RCW: 1 (3.8)	ICW: 16 (69.6) RCW: 10 (38.5)	Not provided
Piaggese et al, 2016 ²⁷ 42 (22/20) 3 months	<i>Overall</i> ICW: 2 (9.1) RCW: 0 <i>Voluntary withdrawal</i> ICW: 1 (4.5) RCW: 0 <i>Lost to follow-up</i> ICW: 1 (4.5) RCW: 0	ICW: 18 (81.8) RCW: 16 (80.0)	ICW: 39.6 (12.2) RCW: 43.2 (15.1) Kaplan-Meier curve showed no statistically significant difference between groups
Armstrong et al, 2005 ³⁶ 50 (23/27) 3 months	<i>Overall</i> ICW: 1 (4.3) RCW: 3 (11.1) <i>Discomfort/weight of device</i> ICW: 1 (4.3) RCW: 1 (3.7) <i>Lost to follow-up</i> ICW: 0 RCW: 2 (7.4)	ICW: 19 (82.6) RCW: 14 (51.9) <i>P</i> = .02	ICW: 41.6 (18.7) RCW: 58 (15.2) <i>P</i> = .02 Kaplan-Meier curve showed a shorter time to healing with irremovable vs. removable cast walkers <i>P</i> = .003

Abbreviations: ICW, irremovable cast walker; RCW, removable cast walker; SD, standard deviation.

^aBased on personal communication with the author.

Treatment Discontinuations

Treatment discontinuations varied between 4% and 17% in the irremovable cast walker group and 0% and 11% in the removable cast walker group.^{27,29,36} Reasons for discontinuation included discomfort, voluntary withdrawal, and losses to follow-up. Additional information is presented in Table 10. When we pooled the results of the studies, we found no statistically significant difference between groups (Figure 8).




Figure 8: Irremovable Cast Walkers Versus Removable Cast Walkers, Treatment Discontinuations

Abbreviations: CI, confidence interval; M-H, Mantel-Haenszel.
 Sources: Armstrong et al,³⁶ Najafi et al,²⁹ and Piaggese et al.²⁷

Ulcer Healing

At 3 months' follow-up, the percentage of patients with a healed ulcer ranged from 70% to 83% with the irremovable cast walkers, and 39% to 80% with the removable cast walkers.

Pooling the results of the studies yielded an absolute increase of 21% (risk difference 0.21 [95% confidence interval: 0.01–0.40]) in the percentage of patients with a healed ulcer with the irremovable cast walkers (Figure 9).




Figure 9: Irremovable Cast Walkers Versus Removable Cast Walkers, Percentage of Healed Ulcers

Abbreviations: CI, confidence interval; M-H, Mantel-Haenszel.
 Sources: Armstrong et al,³⁶ Najafi et al,²⁹ and Piaggese et al.²⁷

The meta-analysis showed some inconsistency in the study results, however. Two studies showed a significant increase in ulcer healing with the irremovable cast walker,^{29,36} but one study showed no significant difference between the two groups.²⁷ The authors of the latter study acknowledged that the lack of difference was in contrast to what other studies had demonstrated (i.e., better healing rates with irremovable cast walkers).²⁷ They believed that their finding may have been partly due to high patient adherence with the removable cast walker, possibly because weekly reinforcement of the importance of treatment adherence was part of the study.²⁷ Najafi et al²⁹ corroborated this point, noting that low treatment adherence may have partially explained the low percentage of ulcer healing they observed with removable cast walkers.

Time to Ulcer Healing

Armstrong et al³⁶ reported shorter healing time with the irremovable cast walkers than with the removable cast walkers, but Piaggese et al²⁷ found no statistically significant difference between the two groups (Table 10).

Adherence to Treatment and Daily Activity

Najafi et al²⁹ evaluated activity patterns in the two study groups. At baseline, patterns were similar between the two groups, but from week 4 onward, patients in the removable cast walker group had a 50% longer walking period ($P = .049$), 56% longer unbroken walking episodes ($P = .048$), and a 43% longer average daily standing period ($P = .03$) than patients in the irremovable cast walker group. As noted above, the authors believed that the increased activity patterns seen with the removable cast walkers may have indicated low adherence to treatment, and that may have partially explained the differences in ulcer healing between the groups.

The authors also noted that the patients in the irremovable cast walker group spent almost twice as much time lying on their side as patients in the removable cast walker group, possibly due to limitations caused by the irremovable cast walker during sleep.²⁹

Patient Satisfaction

In the study by Piaggese et al,²⁷ patients in the removable cast walker group reported higher satisfaction with treatment than those assigned to irremovable devices (total contact casting or irremovable cast walkers, $P < .05$). However, we could not determine whether the difference between removable cast walkers and the irremovable cast walkers alone was statistically significant.

Complications

Three studies reported complications in at least one of the study groups.^{27,29,36} Differences in the proportion of complications between the two groups were difficult to interpret because of the small number of events reported (Table 11).

Najafi et al²⁹ did not assess treatment complications as part of the outcomes defined a priori, but did report complications if they led to treatment discontinuation. The study by Piaggese et al²⁷ was designed to collect information on treatment complications, but the authors reported that no patient in any of the groups experienced severe complications; nonsevere complications (none leading to treatment discontinuation) are presented in Table 11.²⁷

Table 11: Irremovable Cast Walkers Versus Removable Cast Walkers, Complications

Author, Year N (ICW/RCW)	Complication, n (%)			
	Skin Maceration	Ulcer Infection	Trauma	Fall
Najafi et al, 2016 ²⁹ 49 (23/26)	None reported	ICW: 2 (8.7) RCW: 0	Not reported	Not reported
Piaggese et al, 2016 ²⁷ 42 (22/20)	ICW: 1 (4.5) RCW: 0	<i>Fungal intertrigo</i> ICW: 0 RCW: 1 (5)	<i>Accidental minor trauma in the contralateral foot</i> ICW: 1 (4.5) RCW: 0	Not reported
Armstrong et al, 2005 ³⁶ 50 (23/27)	ICW: 15 (65.2) RCW: 9 (33.3)	<i>Antibiotics to treat soft-tissue infection (no device-related infections reported)</i> ICW: 6 (26.1) RCW: 10 (37.0)	Not reported	ICW: 0 RCW: 0

Abbreviations: ICW, irremovable cast walker; RCW, removable cast walker.

Quality of Evidence

Table 12 provides the GRADE evidence profile for irremovable cast walkers versus removable cast walkers.

Table 12: GRADE Evidence Profile for Irremovable Cast Walkers Versus Removable Cast Walkers

Number of Studies (Design)	Risk of Bias	Inconsistency	Indirectness	Imprecision	Publication Bias	Upgrade Considerations	Quality
Percentage of Patients with a Healed Ulcer							
3 (RCTs) ^{27,29,36}	Serious limitations (–1) ^a	Serious limitations (–1) ^b	No serious limitations	No serious limitations	Undetected	None	⊕⊕ Low
Time to Healing (Kaplan-Meier Analysis)							
2 (RCTs) ^{27,36}	No serious limitations	Serious limitations (–1) ^b	No serious limitations	Serious limitations (–1) ^c	Undetected	None	⊕⊕ Low
Patient Satisfaction With Treatment							
1 (RCT) ³⁶	No serious limitations	Could not be evaluated	No serious limitations	Very serious limitations (–2) ^d	Undetected	None	⊕⊕ Low
Complications							
3 (RCTs) ^{27,29,36}	Serious limitations (–1) ^e	No serious limitations	No serious limitations	Very serious limitations (–2) ^f	Undetected	None	⊕ Very Low

Abbreviations: GRADE, Grading of Recommendations Assessment, Development, and Evaluation; RCT, randomized controlled trial.

^aIn two of the studies included there was some indication of possible differences in baseline characteristics between the groups (ulcer area²⁹ and glycated hemoglobin.³⁶).

^bThe results were inconsistent across studies.

^cOne study showed a statistically significant difference in time to healing between the groups, and the other study did not.

^dThe study did not provide separate information on irremovable vs. removable cast walker groups (i.e., the authors reported on the comparison of removable cast walkers and irremovable devices [total contact casting + irremovable cast walkers]. Additionally, only one small study (n = 22 and 20 in each study group) assessed the outcome.

^eTreatment complications were not defined as an outcome a priori in the studies included in this analysis.

^fVery few events were reported in the studies, leading to very low statistical power to detect a difference between groups.

Results for Removable Cast Walkers Versus Therapeutic Shoes

Two studies compared removable cast walkers with therapeutic shoes.^{16,37}


Table 13: Removable Cast Walkers Versus Therapeutic Shoes

Author, Year N (RCW/Shoes) Follow-up	Treatment Discontinuation, n (%)	Ulcer Healing, n (%)	Mean Time to Ulcer Healing, d (SD)
Lavery et al, 2015 ¹⁶ 50 (27/23) 3 months	<i>Overall</i> RCW: 12 (44.4) Shoes: 3 (13.0) <i>Infection</i> RCW: 4 (14.8) Shoes: 3 (13.0) <i>Voluntary withdrawal</i> RCW: 4 (14.8) Shoes: 0 <i>Device-related wounds</i> RCW: 1 (3.7) Shoes: 0 <i>Nonadherence</i> RCW: 3 (11.1) Shoes: 0	RCW: 6 (22.2) Shoes: 10 (43.5)	RCW: 46.9 (30.1) Shoes: 62.3 (24.5)
Armstrong et al, 2001 ³⁷ 50 (25/25) 3 months	<i>Overall</i> RCW: 5 (20.0) Shoes: 1 (4.0) <i>Discomfort</i> RCW: 3 (12.0) Shoes: 0 <i>Instability</i> RCW: 0 Shoes: 1 (4.0) <i>Lost to follow-up</i> RCW: 2 (8.0) Shoes: 0	RCW: 13 (52.0) Shoes: 14 (56.0)	RCW: 50.4 (7.2) Shoes: 61.0 (23.4) Kaplan-Meier curve shown, but difference between the two groups not reported No apparent difference between the groups based on visual inspection

Abbreviations: RCW, removable cast walker; SD, standard deviation; Shoes, therapeutic shoes.

Treatment Discontinuation

Treatment discontinuations were observed in 20% and 44% of the patients in the removable cast walker group and 4% and 13% of the patients in the therapeutic shoes group.^{16,37} Reasons for discontinuation included discomfort, voluntary withdrawal, and loss to follow-up (Table 13). When we pooled the results of the two studies, we found more treatment discontinuations with removable cast walkers than with therapeutic shoes (Figure 10).

**Figure 10: Removable Cast Walkers Versus Therapeutic Shoes, Treatment Discontinuations**


Abbreviations: CI, confidence interval; M-H, Mantel-Haenszel.

Sources: Armstrong et al,³⁷ Lavery et al.¹⁶

Ulcer Healing

At 3 months of follow-up, the percentage of patients with a healed ulcer in each study was 22% and 52% with removable cast walkers, and 44% and 56% with therapeutic shoes (Table 13).

We found no statistically significant difference in ulcer healing between the two groups (Figure 11).

**Figure 11: Removable Cast Walkers Versus Therapeutic Shoes, Percentage of Healed Ulcers**

Abbreviations: CI, confidence interval; M-H, Mantel-Haenszel.

Sources: Armstrong et al,³⁷ Lavery et al.¹⁶

Time to Ulcer Healing

Based on the survival curve provided in the study by Armstrong et al,³⁹ it was not clear whether there was a difference in time to healing between removable cast walkers and therapeutic shoes (Table 13).

Adherence to Treatment and Daily Activity

Both studies assessed treatment adherence as measured by the level of daily activity. In the study by Lavery et al,¹⁶ the mean (SD) number of daily steps was lower with removable cast walkers than with therapeutic shoes (1,404 [1,234] vs. 4,022 [4,652], $P = .007$). The study by Armstrong et al³⁷ did not find a difference between the two groups (768 [563] vs. 1,462 [1,452], $P = .15$).

Quality of Life and Patient Satisfaction

Armstrong et al³⁹ found that changes in physical health and mental health scores before and after treatment, as measured with the Short-Form 36-item health survey, did not differ between groups.

Lavery et al¹⁶ found no statistically significant difference in satisfaction with treatment between patients treated with removable cast walkers or therapeutic shoes.

Complications

Treatment complications reported in the two studies are shown in Table 14. Differences in the proportion of complications between the two groups were difficult to interpret owing to the small sample sizes and low number of events.

Table 14: Removable Cast Walkers Versus Therapeutic Shoes, Complications

Author, Year N (RCW/Shoes)	Complication, n (%)		
	Ulcer Infection	New Ulcer	Fall
Lavery et al, 2015 ¹⁶ 50 (27/23)	RCW: 4 (14.8) Shoes: 3 (13.0)	RCW: 1 (3.7) Shoes: 0	Not reported
Armstrong et al, 2001 ³⁷ 50 (25/25)	Not reported	0 (device-related)	0

Abbreviations: RCW, removable cast walker; Shoes, therapeutic shoes.

Quality of Evidence

Table 15 provides the GRADE evidence profile for removable cast walkers versus therapeutic shoes.

Table 15: GRADE Evidence Profile for Removable Cast Walkers Versus Therapeutic Shoes

Number of Studies (Design)	Risk of Bias	Inconsistency	Indirectness	Imprecision	Publication Bias	Upgrade Considerations	Quality
Percentage of Patients with a Healed Ulcer							
2 (RCTs) ^{16,37}	No serious limitations	No serious limitations	Serious limitations (–1) ^a	Very serious limitations (–2) ^b	Undetected	None	⊕ Very Low
Time to Healing (Kaplan-Meier Analysis)							
1 (RCT) ³⁷	No serious limitations	Could not be evaluated	Serious limitations (–1) ^a	Very serious limitations (–2) ^c	Undetected	None	⊕ Very Low
Patient Satisfaction With Treatment							
1 (RCTs) ¹⁶	No serious limitations	Could not be evaluated	Serious limitations (–1) ^a	Very serious limitations (–2) ^d	Undetected	None	⊕ Very Low
Quality of Life							
1 (RCT) ³⁹	No serious limitations	Could not be evaluated	Serious limitations (–1) ^a	Very serious limitations (–2) ^e	Undetected	None	⊕ Very Low
Complications							
2 (RCTs) ^{16,37}	Serious limitations (–1) ^f	No serious limitations	Serious limitations (–1) ^a	Very serious limitations (–2) ^g	Undetected	None	⊕ Very Low

Abbreviations: GRADE, Grading of Recommendations Assessment, Development, and Evaluation; RCT, randomized controlled trial.

^aDifferent types of therapeutic shoes were used in the studies; the results for one type of shoe may not be applicable to other types.

^bVery low statistical power to detect a difference between groups.

^cNo statistically significant difference between the two groups in the studies identified. The statistical power to detect a difference in healing rates among the studies was very low.

^dNo statistically significant difference between the two groups. Only one small study (n = 27 and 23 in each group) assessed the outcome.

^eNo statistically significant difference between the groups. Only one small study (21 patients/study group) assessed the outcome.

^fTreatment complications were not defined as an outcome a priori in the studies included in this analysis.

^gVery few events were reported in the studies, leading to very low statistical power to detect a difference between groups.

Discussion

The evidence suggests that total contact casting, removable cast walkers, and irremovable cast walkers are beneficial in the treatment of neuropathic, noninfected foot ulcers in patients with diabetes but without severe peripheral arterial disease. The results of the studies showed that ulcer healing occurred in 68% to 95% of patients treated with total contact casting, 22% to 80% of patients treated with removable cast walkers, and 70% to 85% of patients treated with irremovable cast walkers, all within 3 to 4 months of follow-up. Based on the results of our meta-analyses both total contact casting and irremovable cast walkers healed more ulcers than removable cast walkers.

Treatment discontinuation occurred with all devices, mostly because of voluntary withdrawal, lack of adherence, or complications (8% to 24% with total contact casting; 4% to 17% with irremovable cast walkers; and 0% to 44% with removable cast walkers). According to the clinical experts we consulted, patients who discontinue treatment may require an alternative offloading device until their ulcer is healed.

Several study authors noted that treatment success was affected by adherence and acceptance, factors that may partially explain the differences we found in ulcer healing across studies.

Cast walkers (removable or irremovable) do not fit all patients properly; patients with short legs, wide feet, or severe foot deformities would benefit from total contact casting instead, because it is moulded to the patient's foot and lower leg.¹⁶ On the other hand, total contact casting must be applied by a qualified technician to avoid injuries. Geographical isolation may hinder the use of irremovable devices because of potential difficulties in returning for frequent clinic visits to remove and reapply the device. In these circumstances, removable devices may be a better option (expert opinion).

Convenience is also a factor: irremovable devices (total contact casting and irremovable cast walkers) affect daily activities such as bathing and sleeping more than removable cast walkers. However, ease of removal by the patient affects treatment adherence and ulcer healing. These factors should be taken into account when choosing an offloading device.

Strengths and Limitations

The included studies had small sample sizes, so we could not draw conclusions for some of the outcomes evaluated (time to healing and treatment complications), and the study results may not be generalizable to clinical practice. We were also unable to make associations between ulcer healing and factors such as ulcer characteristics, glycemic control, sex, ethnicity, or any other PROGRESS-Plus categories.

Most patients included in the studies presented with noninfected superficial ulcers (most grade 1A, some grade 2A, University of Texas Classification System).⁴¹ It is not clear whether patients with Grade 3 ulcers (penetrating to bone or joint) or infected ulcers would experience outcomes similar to those seen in the included studies.

Study follow-up was relatively short (3 to 4 months), so we could not assess the course of progression for patients whose ulcers did not heal within the study time frame or for patients who discontinued treatment. None of the studies provided follow-up information after ulcer closure.

Conclusions

The evidence suggests that fibreglass total contact casting and cast walkers (removable or irremovable) may be beneficial for treating neuropathic noninfected diabetic foot ulcers. The results of the treatment comparisons are summarized in Table 16.

Table 16: Treatment Comparisons—Summary

Comparison	Risk Difference, % Ulcer Healing (95% CI)	GRADE
Total contact casting vs. irremovable cast walkers	0.02 (−0.11 to 0.14)	Low
Total contact casting vs. removable cast walkers	0.17 (0–0.33)	Moderate
Total contact casting vs. therapeutic shoes	0.25 (0.04–0.46)	Moderate
Irremovable cast walkers vs. removable cast walkers	0.21 (0.01–0.40)	Low
Removable cast walkers vs. therapeutic shoes	−0.13 (−0.31 to 0.06)	Very low
Irremovable cast walkers vs. therapeutic shoes	No studies identified	

Abbreviations: CI, confidence interval; GRADE, Grading of Recommendations Assessment, Development, and Evaluation.

The studies showed a relatively high frequency of treatment discontinuation with all treatments evaluated. Patients who discontinue one type of treatment may need to continue treatment with an alternative offloading device until the ulcer is healed. Each treatment evaluated has different characteristics and may not be appropriate for all patients.

ECONOMIC EVIDENCE

Research Question

What is the cost-effectiveness of fibreglass total contact casting, removable cast walkers, and irremovable cast walkers for patients with noninfected diabetic neuropathic foot ulcers?

Methods

Literature Search

We performed an economic literature search on August 18, 2016, for studies published from inception to the search date. To retrieve relevant studies, the search was developed using the clinical search strategy with an economic filter applied. Database auto-alerts were created in MEDLINE, Embase, and CINAHL and monitored for the duration of the HTA review.

We performed targeted grey literature searching of HTA agency sites and clinical trial registries. Finally, we reviewed reference lists of included economic literature for any additional relevant studies not identified through the systematic search. See Clinical Evidence, Literature Search, above, for further details on methods used, and Appendix 1 for literature search strategies, including all search terms.

Literature Screening

A single reviewer reviewed titles and abstracts, and, for those studies meeting the inclusion/exclusion criteria, we obtained full-text articles.

Types of Studies

We looked at economic evaluations that reported incremental cost-effectiveness ratios (ICERs; e.g., cost per quality-adjusted life-year [QALY]/life-year gained or cost per event avoided) and cost studies.

We did not include narrative reviews, letters/editorials, abstracts, posters, or unpublished studies.

Types of Participants

We looked at studies in patients with noninfected diabetic neuropathic foot ulcers.

Types of Interventions

We looked at studies that reported on fibreglass total contact casting, removable cast walkers, and irremovable cast walkers.

Types of Outcomes Measures

Outcomes of interest were full economic evaluations: cost-utility analyses, cost-effectiveness analyses, or cost-benefit analyses.

Data Extraction

We extracted relevant data on the following:

- Source (i.e., name, location, year)
- Population and comparator
- Interventions
- Outcomes (i.e., health outcomes, costs, and incremental cost-effectiveness ratios)

Study Applicability

We determined the usefulness of each identified study for decision-making by applying a modified applicability checklist for economic evaluations that was originally developed by the National Institute for Health and Care Excellence (NICE) in the United Kingdom. The original checklist is used to inform development of clinical guidelines by NICE. We retained questions from the NICE checklist related to study applicability and modified the wording of the questions to remove references to guidelines and make it Ontario-specific. A summary of the number of studies judged to be directly applicable, partially applicable, or not applicable to the research question is presented.

Results

Literature Search

The database search yielded 117 citations published before August 18, 2016 (with duplicates removed). We excluded a total of 113 articles based on information in the title and abstract. We then obtained the full texts of four potentially relevant articles for further assessment. Figure 12 presents the flow diagram for the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA).




Figure 12: PRISMA Flow Diagram

Abbreviation: PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-analyses.
 Source: Adapted from Moher et al.⁴⁰

One study met the inclusion criteria.⁴² We hand-searched the reference lists of the included study to identify other relevant studies, but no additional citations were identified.

Review of Included Economic Studies

Craig et al.⁴² conducted two decision-tree models to compare the cost consequences of soft-heel casting and orthotic footwear in patients with diabetes who were at high risk of ulceration (preventative pathway) or who had a foot ulcer (curative pathway). The analysis was undertaken from the perspective of the National Health Service (NHS) Borders in the United Kingdom.

In the preventative pathway model, the clinical endpoints were new ulcers or no new ulcers. In the curative pathway model, the clinical endpoints were healed ulcers, improved ulcers,

amputation, or death. The authors obtained data from an audit of patient outcomes associated with casting at NHS Borders for inpatients, and from a 3-year study of patients treated in a multidisciplinary foot care clinic for outpatients.

The authors combined their findings with other published data and expert opinion. They modelled the benefits of preventative and curative casting compared with standard practice, and they estimated the costs of healed and unhealed ulcers based on the treatment pathways adopted. Data from the economic models suggested that soft-heel casting could reduce the net costs of managing ulcers in these patients by approximately 10% because of increased rates of healing: about £500 per inpatient and £425 per outpatient with an ulcer (curative cohort); and £205 per patient at high risk for an ulcer (preventative cohort). The authors concluded that preventative and curative soft-heel casting could lead to cost savings in the management of patients with diabetes.

Table 17: Results of Economic Literature Review—Summary

Name, Year, Location	Study Design and Perspective	Populations	Interventions	Results	
				Health Outcomes	Costs
Craig et al, 2013, ⁴² United Kingdom	<ul style="list-style-type: none"> Cost-consequence analysis (cost per patient) Decision-tree model NHS Borders perspective 	<ul style="list-style-type: none"> Patients at high risk of ulceration (preventative cohort; n = 508) Patients with a foot ulcer (curative cohort; n = 178) Mean age 77 (\pm 12.1) years 	<ul style="list-style-type: none"> Intervention: Soft-heel casting Comparator: Orthotic footwear 	<p><i>Preventative pathway</i></p> <ul style="list-style-type: none"> Soft-heel casting: no ulcer 84%; new foot ulcer 16% Orthotic footwear: no ulcer 82%; new foot ulcer 18% <p><i>Curative pathway</i></p> <ul style="list-style-type: none"> Inpatients <ul style="list-style-type: none"> Soft-heel casting: healed ulcer 44%; improved ulcer 22%; amputation 6%; death 28% Orthotic footwear: healed ulcer 42%; improved ulcer 21%; amputation 5%; death 32% Outpatients <ul style="list-style-type: none"> Soft-heel casting: healed ulcer 50%; improved ulcer 27%; amputation 7%; death 16% Orthotic footwear: healed ulcer 48%; improved ulcer 26%; amputation 8%; death 18% 	<ul style="list-style-type: none"> 2013 British pounds Expected costs per patient <ul style="list-style-type: none"> Preventative pathway: soft-heel casting £1,637; orthotic footwear £1,413 Curative pathway: <ul style="list-style-type: none"> Inpatients: soft-heel casting £7,540; orthotic footwear £6,991 Outpatients: soft-heel casting £5,977; orthotic footwear £5,359

Abbreviations: NHS, National Health Service.

Applicability of Included Studies

The results of the methodology checklist for economic evaluations applied to the included articles are presented in Appendix 6. The included study was partially applicable to the research question, but it was not relevant for the Ontario setting.

Conclusions

The included study found net cost savings from using soft-heel casting to treat diabetic foot ulcers. However, it was neither a cost-effectiveness nor a cost-utility study, and it did not investigate total contact casting, removable cast walkers, or irremovable cast walkers to treat diabetic foot ulcers from a Canadian perspective.

PRIMARY ECONOMIC EVALUATION

The published economic evaluation identified in the literature addressed the interventions of interest, but it was neither a cost-effective nor a cost-utility study, and it did not take a Canadian perspective. Owing to these limitations, we conducted a primary economic evaluation.

Research Questions

- What is the cost-effectiveness of fibreglass total contact casting, removable cast walkers, and irremovable cast walkers in treating patients with noninfected diabetic neuropathic foot ulcers in the context of the Ontario Ministry of Health and Long-Term Care?
- What is the cost utility of fibreglass total contact casting, removable cast walkers, and irremovable cast walkers in treating patients with noninfected diabetic neuropathic foot ulcers in the context of the Ontario Ministry of Health and Long-Term Care?

Methods

The information presented in this report follows the reporting standards set out by the Consolidated Health Economic Evaluation Reporting Standards Statement.⁴³

Type of Analysis

We conducted cost-effectiveness and cost-utility analyses to measure the costs and benefits of adopting total contact casting, removable cast walkers, and irremovable cast walkers, compared with each other and with therapeutic shoes.

Target Population

The study population was men and women aged 18 or older who present with a diabetic neuropathic foot ulcer.

Perspective

We conducted this analysis from the perspective of the Ontario Ministry of Health and Long-Term Care.

Interventions

We evaluated fibreglass total contact casting, removable cast walkers, and irremovable cast walkers, compared with each other and with therapeutic shoes (e.g., specially made footwear, over-the-counter footwear, and orthopedic sandals).

Discounting and Time Horizon

The time horizon for the cost-effectiveness analysis was 3 months, based on the follow-up time in the identified randomized controlled trials (RCTs).^{16,27,28,31-35,37,38}

The time horizon for the cost-utility analysis was 6 months after the first use of total contact casting, a removable cast walker, an irremovable cast walker, or therapeutic shoes. To capture the long-term treatment effects of an offloading device, the ideal time horizon would be longer

than this. However, the RCTs followed patients for only a short period (12 weeks), so information was unavailable on patients who were lost to follow-up, patients who did not heal from using an offloading device, patients who had a recurrence of the ulcer, patients who experienced delayed healing (i.e., after 12 weeks), or patients who developed a new ulcer. For this reason, a model with a time horizon longer than 6 months would have required many assumptions, and results would have been uncertain.

Because the time horizon was less than 1 year, we did not apply discounting.

Model Structure

For the cost-utility analysis, we developed a decision-analytic model (Figure 13a) to capture short-term costs and effects associated with the treatment of diabetic foot ulcer using total contact casting, removable cast walkers, irremovable cast walkers, or therapeutic shoes. In this model, a patient with a diabetic foot ulcer would receive treatment with one of the four offloading devices. Following the assigned treatment, an ulcer would be healed or unhealed. If the ulcer was healed, the patient would enter a maintenance phase, not needing active treatment but continuing to use orthotics to prevent ulcer recurrence for the rest of the model (expert opinion). We assumed that there would be no new ulcer or recurrence of an old ulcer once an ulcer had healed. If the ulcer was not healed, the patient would remain “unhealed” in the model and continue treatment or undergo amputation.





Figure 13a: Decision-Analytic Model

Clinical evidence from RCTs was limited, so we proposed three scenarios to describe the treatment pathways after unsuccessful primary treatment of a diabetic foot ulcer (Figure 13b).

- Base-case scenario, a combination of primary and secondary treatments: If a patient had an unhealed ulcer at 3 months and did not undergo amputation, we assumed that they had a 50% chance of continuing with the primary treatment and a 50% chance of switching to a secondary treatment (a new offloading device). We applied device and treatment costs from the secondary treatment until the end of the model, and patients were considered unhealed. Choices of secondary treatment depended on the primary treatment, and were confirmed by expert consultation. If a patient

- underwent amputation as a result of an unhealed ulcer, they were considered amputated
- Scenario 1, all patients switched to a secondary treatment: If a patient had an unhealed ulcer and did not undergo amputation, they would switch to a secondary treatment (a new offloading device). We applied costs from the secondary treatment until the end of the model, and patients were considered unhealed. Choices of secondary treatment depended on the primary treatment, and were confirmed by expert consultation. If a patient underwent amputation as a result of an unhealed ulcer, they were considered amputated
 - Scenario 2, all patients continued on the primary treatment: If a patient had an unhealed ulcer and did not undergo amputation, they would continue on the primary treatment until the end of the model and be considered unhealed. If the patient underwent amputation as a result of an unhealed ulcer, they would be considered amputated



p = proportion of patients who remain on primary treatment if unhealed after 3 months

Base-case: $p = 50\%$, half switching and half continuing primary treatment

Scenario 1: $p = 0\%$, all switching

Scenario 2: $p = 100\%$, no switching

Figure 13b: Scenario Model

^aSwitch from total contact casting to removable cast walker; from irremovable cast walker to removable cast walker; from removable cast walker to total contact casting; from therapeutic shoes to removable cast walker (expert consultation).

We defined ulcer healing as complete re-epithelialization, without signs of exudate, as in the clinical evidence review. Also for consistency with the clinical evidence review, we considered patients who discontinued treatment to be unhealed (definition in Appendix 4). Because of the short time horizon, we did not consider death from a diabetic foot ulcer in the model.

Clinical Outcome and Utility Parameters

We used a number of different input parameters to populate the model:

- Probability of ulcer healing
- Time to ulcer healing
- Complications
- Health utilities

Tables 18 and 19 describe the model inputs.

Table 18: Clinical Outcome Parameters Used in the Economic Model

Variable	Outcome (Base Case)	Range	Reference ^a
Total Contact Casting			
Probability of ulcer healing	0.741	0.677–0.915	Meta-analysis ^{16,27,28,31-35,37,38}
Time to healing, weeks	5.097	3.823–6.371	Meta-analysis ^{16,27,28,32-34,37,38}
Probability of amputation from an unhealed ulcer	0.0092	0.0065–0.0153	CDA ⁴⁴
Removable Cast Walkers			
Risk ratio of ulcer healing (total contact casting vs. removable cast walkers)	1.25	0.95–1.65	Meta-analysis ^{31-33,37}
Probability of ulcer healing	0.593	0.449–0.779	Calculation
Mean difference in time to healing (total contact casting vs. removable cast walkers), weeks	–1.013	–1.816 to –0.209	Meta-analysis ^{31-33,37}
Time to healing, weeks	6.11	5.31–6.12	Calculation
Probability of amputation from an unhealed ulcer	0.0145	0.0102–0.0240	CDA ⁴⁴
Irremovable Cast Walkers			
Risk ratio of ulcer healing (total contact casting vs. irremovable cast walkers)	1.02	0.87–1.19	Meta-analysis ^{27,28,35}
Probability of ulcer healing	0.726	0.623–0.852	Calculation
Mean difference in time to healing (total contact casting vs. irremovable cast walkers), weeks	–0.329	–1.59 to 0.939	Meta-analysis ^{27,28,35}
Time to healing, weeks	5.425	4.164–6.687	Calculation
Probability of amputation from an unhealed ulcer	0.0097	0.0068–0.0161	CDA ⁴⁴
Therapeutic Shoes			
Risk ratio of ulcer healing (total contact casting vs. therapeutic shoes)	1.62	1.11–2.38	Meta-analysis ^{16,31,37,38}
Probability of ulcer healing	0.457	0.311–0.667	Calculation
Mean difference in time to healing (total contact casting vs. therapeutic shoes), weeks	–3.73	–5.25 to –2.22	Meta-analysis ^{16,31,37,38}
Time to healing, weeks	8.83	7.32–10.34	Calculation
Probability of amputation from an unhealed ulcer	0.0193	0.0136–0.0320	CDA ⁴⁴

Abbreviation: CDA, Canadian Diabetes Association.

^aMeta-analysis included studies reported in the clinical evidence review.^{16,27,28,31-35,37,38}

Table 19: Utility Parameters Used in the Economic Model

Health State	Utility (Base Case)	Range	Reference
Unhealed ulcer	0.44	0.37–0.51	Ragnarson Tennvall et al, 2000 ⁴⁵
Healed ulcer, no amputation	0.60	0.57–0.63	Ragnarson Tennvall et al, 2000 ⁴⁵
Amputation	0.51 ^a	0.47–0.55	Ragnarson Tennvall et al, 2000 ⁴⁵

^aUtility of amputation = proportion of patients with a diabetic foot ulcer who experienced a minor amputation × utility of minor amputation + proportion of diabetic foot ulcer patients who experienced a major amputation × utility of major amputation.

Probability of Ulcer Healing

We used an intention-to-treat analysis to calculate the percentage of ulcers healed. For this reason, we considered patients whose ulcers did not heal, patients who discontinued treatment, and patients who were lost to follow-up all to be unhealed (see the clinical evidence review for more details). Six studies compared total contact casting with removable cast walkers.^{16,27,31-33,37} Three studies compared total contact casting with irremovable cast walkers.^{27,28,35} Four studies compared total contact casting with therapeutic shoes.^{16,34,37,38}

To calculate the probability of ulcer healing for each of the treatments, we first calculated the probability for total contact casting using a random-effects model. We then calculated the probability for the other devices by dividing the probability for total contact casting by the risk ratios of ulcer healing for total contact casting versus the other devices (Table 18). We took the risk ratios for each comparison from the clinical evidence review. We calculated the probability of ulcer healing by total contact casting over those of other offloading devices, because data on ulcer healing were available in the clinical evidence review that compared total contact casting with the other devices.

Time to Ulcer Healing

We estimated the time to ulcer healing for patients who were healed during the model period. Several studies reported time to ulcer healing for total contact casting versus the other offloading devices.^{16,27,28,31-33,35,37,38} We calculated time to ulcer healing for total contact casting because of data availability. First, we conducted a meta-analysis of time to ulcer healing for total contact casting using a random-effects model. We took the mean difference in time to ulcer healing for total contact casting versus removable cast walkers, irremovable cast walkers, and therapeutic shoes from the clinical evidence review. Based on the time to ulcer healing for total contact casting and the mean difference compared with removable cast walkers, irremovable cast walkers, and therapeutic shoes, we calculated the time to ulcer healing for the other offloading devices (Table 18).

Complications

We defined amputation as a complication that happened as a consequence of an unhealed ulcer when using any offloading device. We derived the probability of amputation from the literature (Table 18).⁴⁴

Health Utilities

We quantified health outcomes as QALYs. Ragnarson Tennvall et al⁴⁵ collected health utility data from 457 people with diabetes who were treated for foot ulcers and assessed their health status using the EQ-5D quality-of-life questionnaire.⁴⁵ Table 19 provides the utility values for

patients who had an unhealed ulcer, a healed ulcer, and an amputation. We calculated the utility for amputation using the utilities for both minor and major amputations. We then adjusted these values to the respective proportions of patients with minor and major amputations.

Cost Parameters

All cost parameters included in our study originated from consultation with experts, from the Ontario *Schedule of Benefits for Physician Services*,⁴⁶ and from previous publications.^{44,46,47} We obtained information about the following:

- Offloading devices (i.e., raw materials, dressings, plasters, and devices)
- Treatment (i.e., cost of initial treatment when a patient receives an offloading device until an ulcer is healed; cost of a second treatment for unhealed ulcers; and maintenance costs, including orthotics and monthly follow-up visits to a clinic)
- Labour (i.e., salaries of physicians, cast technicians, or nurses)
- Complications (amputation costs as a consequence of an unhealed ulcer)

Costs

We estimated the costs of healed and unhealed ulcers based on the treatment pathways for each offloading device. Table 20 shows the items and associated costs used in the economic model.

Table 20: Costs Used in the Economic Model

Variable	Value (Base Case)	Range	Reference
Total Contact Casting			
Cost of cast	\$90	\$80–\$100	Expert opinion
Removable Cast Walkers			
Cost of removable cast walker	\$150	—	Expert opinion
Irremovable Cast Walkers			
Cost of removable cast walker	\$150	—	Expert opinion
Cost of Coban wrap	\$25	\$15–\$30	Expert opinion
Therapeutic Shoes			
Cost of shoes	\$100	—	Expert opinion and assumption
Other Materials			
Cost per dressing	\$15	—	Expert opinion
Professional Labour			
Cost of putting on a cast	\$10.25	—	OHIP ⁴⁶
Cost of taking off a cast	\$24.10	—	OHIP ⁴⁶
Cost of seeing a new patient	\$75	—	Expert opinion
Cost of seeing a follow-up patient	\$55	—	Expert opinion
Cost per nursing visit	\$65	—	Expert opinion
Complications			
Cost of amputation	\$75,081	\$8,848–\$100,000	CDA ^{44,47} and calculation

Abbreviations: CDA, Canadian Diabetes Association; OHIP, Ontario Health Insurance Plan.

Resource Utilization

Resource utilization consisted of casts, the number of devices, and dressing changes for each offloading device per patient with a diabetic foot ulcer (Table 21).

Table 21: Resource Utilization Used in the Economic Model

Variable	Value (Base Case)	Range	Reference
Total Contact Casting			
First cast	Within the first 3 days	—	Expert opinion
Subsequent casts	Every 7 days	7–10 days	Expert opinion
Dressing change frequency	Every time a cast is replaced	—	Expert opinion
Removable Cast Walkers			
First dressing	Within the first 3 days	—	Expert opinion
Subsequent dressings	Once a week	1–3 times per week	Expert opinion
Number of devices per patient	1	1–4	Assumption
Dressing change frequency	3	—	Expert opinion
Irremovable Cast Walkers			
First dressing	Within the first 3 days	—	Expert opinion
Subsequent dressings	Every 7 days	7–10 days	Expert opinion
Number of devices per patient	1	1–4	Assumption
Dressing change frequency	3	—	Expert opinion
Therapeutic Shoes			
First dressing	Within the first 3 days	—	Expert opinion
Subsequent dressings	Once a week	1–3 times per week	Expert opinion
Number of devices per patient	1	1–4	Assumption
Dressing change frequency	3	—	Expert opinion

Analysis

Cost-Effectiveness Analysis

The primary outcome of the base case analysis was incremental cost per healed ulcer in the treatment of diabetic foot ulcers. We determined this by comparing one offloading device with another. We calculated the average cost per patient to treat a diabetic foot ulcer and the number of healed ulcers per 1,000 patients for each offloading device. Because we were evaluating more than two treatment strategies, we conducted a full incremental cost-effectiveness analysis. We ranked offloading devices by treatment cost; the treatment with the lowest cost was ranked first.

The average treatment cost per patient with a diabetic foot ulcer consisted of the management costs for an ulcer, the management costs for a healed ulcer, and the management costs for complications. The treatment cost also included the cost of the offloading device (e.g., device, dressing, and bandages), the number of visits to a health care professional, and treatments for healed and unhealed ulcers, as well as the number of amputations.

The base case analysis provided the best estimates of the cost of managing a patient with a diabetic foot ulcer using total contact casting, removable cast walkers, irremovable cast walkers, and therapeutic shoes, but we wanted to address the uncertainty of the model inputs and clinical scenarios. Therefore, we assessed possible variabilities and uncertainties in the model using one-way sensitivity analyses.

Cost-Utility Analysis

The primary outcome of the base case analysis was the incremental cost per QALY gained comparing the four treatment modalities: total contact casting, removable cast walkers, and irremovable cast walkers, compared with one another and with therapeutic shoes. We calculated ICERs by dividing the difference between the expected costs by the difference between the expected QALYs of treatment for the two offloading devices being compared. We presented the ICERs in three scenarios that reflected different treatment options: the base case, in which 50% of diabetic foot ulcer patients with an unhealed ulcer remained on the primary treatment and 50% switched to a secondary treatment; scenario 1, in which all patients with an unhealed ulcer switched to a secondary treatment; and scenario 2, in which all patients with an unhealed ulcer stayed on the primary treatment.

Because of the uncertainties and assumptions used in the model, we have presented the primary outcomes in the base case analysis via probabilistic sampling by running 10,000 simulations of the model parameters. We applied beta distributions to probabilities and utility parameters. We applied lognormal distributions to the risk ratios of the probability of ulcer healing, comparing total contact casting with removable cast walkers, irremovable cast walkers, and therapeutic shoes. We applied gamma distributions to cost parameters.

We assessed the variability and uncertainty of the model parameters by conducting one-way sensitivity analyses and varied the model variables over plausible ranges. Tables 18 to 20 show the impact this would have on the ICERs from each scenario.

Main Assumptions

We made a number of major assumptions in the cost-utility analysis:

- Patients with a diabetic foot ulcer who were healed after the primary treatment would enter the maintenance phase and remain healed for the rest of the model cycle
- Each patient with a diabetic foot ulcer experienced only one ulcer
- There were no new ulcers, and there was no recurrence of an ulcer once it was healed
- Only patients with a diabetic foot ulcer who were treated as outpatients were included

Generalizability

The findings of this economic analysis cannot be generalized to all patients with diabetic foot ulcers. They may, however, be used to guide decision-making about the specific patient populations in Ontario addressed in the studies evaluated by Health Quality Ontario.

Expert Consultation

Throughout the development of the model, we consulted clinicians who specialized in treating diabetic foot ulcers. The role of the expert advisors was to review the structure and inputs of the economic model to confirm that the information we used reasonably reflected the clinical setting. The statements, conclusions, and views expressed in this report do not necessarily represent the views of the consulted experts.

Results

Cost-Effectiveness Analysis

Base Case Analysis

Cost-effectiveness results for the base case analysis are presented in Table 22. We ranked the four offloading devices from lowest to highest by treatment cost per 1,000 patients with a diabetic foot ulcer. A gain of a healed ulcer with total contact casting would cost \$17,923 more than with irremovable cast walkers. Removable cast walkers were dominated by total contact casting, because they were more expensive and less effective than total contact casting. Therapeutic shoes were also dominated by total contact casting for the same reasons.

Table 22: Base Case Cost-Effectiveness Analysis

Strategy	Cost Per Patient	Cost Per 1,000 Patients	Number of Healed Ulcers Per 1,000 Patients	Incremental Cost Per 1,000 Patients ^a	Incremental Healed Ulcers Gained per 1,000 Patients ^b	Sequential ICER
Irremovable cast walkers	\$876.50	\$876,500	726	—	—	Reference
Total contact casting	\$1,136.92	\$1,136,920	741	\$260,420	15	\$17,923
Removable cast walkers	\$1,628.98	\$1,628,980	593	\$492,060	–148	Dominated
Therapeutic shoes	\$1,933.75	\$1,933,750	457	\$796,830	–284	Dominated

Abbreviation: ICER, incremental cost-effectiveness ratio.

^aIncremental cost = average cost (treatment A) – average cost (treatment B).

^bIncremental healed ulcers gained = total healed ulcers gained (treatment A) – total healed ulcers gained (treatment B).

Sensitivity Analysis

In the treatment of diabetic foot ulcers, removable cast walkers, and therapeutic shoes were both dominated by irremovable cast walkers and total contact casting. Interestingly, the experts we consulted indicated that irremovable cast walkers are not a common treatment choice. For this reason, we conducted one-way sensitivity analyses on the number of weekly clinic visits for a patient with a diabetic foot ulcer to explore the changes in cost-effectiveness when comparing total contact casting with irremovable cast walkers (Table 23). When weekly visits increased to 1.5 or 2 times per week, the average treatment cost was lower for total contact casting than for irremovable cast walkers, and total contact casting was associated with more healed ulcers. In the sensitivity analysis, total contact casting was a dominant strategy compared to irremovable cast walkers.

Table 23: Sensitivity Analysis—Change of Irremovable Cast Walker Weekly Visits

Irremovable Cast Walker Weekly Visits	Strategy	Cost per Patient	Incremental Cost per Patient ^a	Number of Healed Ulcers Per 1,000 Patients	Incremental Healed Ulcers Gained Per 1,000 Patients ^b	ICER (\$/Ulcer Healed)
1 ^c	Irremovable cast walkers	\$876.50	—	726	—	—
	Total contact casting	\$1,136.92	\$260.42	741	15	\$17,923
1.5	Irremovable cast walkers	\$1,239.75	—	726	—	Dominated
	Total contact casting	\$1,136.92	–\$102.82	741	15	—
2	Irremovable cast walkers	\$1,603.00	—	726	—	Dominated
	Total contact casting	\$1,136.92	–\$466.07	741	15	—

Abbreviation: ICER, incremental cost-effectiveness ratio.

^aIncremental cost = average cost (treatment A) – average cost (treatment B).

^bIncremental healed ulcers gained = total healed ulcers gained (treatment A) – total healed ulcers gained (treatment B).

^cBase case cost-effectiveness results.

Cost-Utility Analysis

Base Case Analysis

For the base case, in which there was a 50% chance a patient with an unhealed diabetic foot ulcer would stay on the primary treatment and a 50% chance they would switch to a secondary treatment, both therapeutic shoes and removable cast walkers were dominated by irremovable cast walkers and total contact casting (Table 24). When we compared total contact casting with irremovable cast walkers, we found that gaining a QALY with total contact casting would require an additional \$198,928.

Table 24: Base Case Cost-Utility Analysis

Treatment Option	Strategy	Cost per Patient	Incremental Cost Per Patient ^a	QALYs	Incremental QALYs Gained ^b	Sequential ICER (\$/QALY)
Combining primary and secondary treatment	Irremovable cast walkers	\$2,584	—	0.266	—	Reference
	Total contact casting	\$2,982	\$398	0.268	0.002	\$198,928
	Removable cast walkers	\$3,999	\$1,017	0.257	–0.011	Dominated
	Therapeutic shoes	\$4,990	\$2,008	0.245	–0.023	Dominated

Abbreviations: ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.

^aIncremental cost = average cost (treatment A) – average cost (treatment B).

^bIncremental QALYs gained = QALYs (treatment A) – QALYs (treatment B).

Scenario Analysis

The findings of the scenario analysis are presented in Table 25.

For scenario 1, in which all patients with an unhealed diabetic foot ulcer would switch to a secondary treatment, therapeutic shoes and removable cast walkers were dominated by irremovable cast walkers and total contact casting. When we compared total contact casting with irremovable cast walkers, we found that gaining a QALY using total contact casting would require an additional \$176,807.

For scenario 2, in which all patients would continue on their primary treatment if an ulcer was not healed, therapeutic shoes and removable cast walkers were dominated by irremovable cast walkers and total contact casting. When we compared total contact casting with irremovable cast walkers, we found that gaining a QALY using total contact casting would require an additional \$289,140.

Table 25: Scenario Analysis

Scenario	Strategy	Cost Per Patient	Incremental Cost Per Patient ^a	QALYs	Incremental QALYs Gained ^b	ICER (\$/QALY)
Scenario 1: All switching	Irremovable cast walkers	\$2,742	—	0.266	—	Reference
	Total contact casting	\$3,021	\$279	0.268	0.002	\$176,807
	Removable cast walkers	\$3,980	\$959	0.257	-0.011	Dominated
	Therapeutic shoes	\$5,036	\$2,015	0.245	-0.023	Dominated
Scenario 2: No switching	Irremovable cast walkers	\$2,431	—	0.266	—	Reference
	Total contact casting	\$2,924	\$493	0.268	0.002	\$289,140
	Removable cast walkers	\$4,005	\$1,080	0.257	-0.011	Dominated
	Therapeutic shoes	\$4,940	\$2,015	0.245	-0.023	Dominated

Abbreviation: ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.

^aIncremental cost = average cost (treatment A) – average cost (treatment B).

^bIncremental QALYs gained = QALYs (treatment A) – QALYs (treatment B).

Sensitivity Analysis

One-Way Sensitivity Analysis

Figure 14 presents the results of the one-way sensitivity analysis for the base case (a 50% chance that a patient with an unhealed diabetic foot ulcer would remain on the primary treatment and a 50% chance they would switch to a secondary treatment). The model was most sensitive to time to healing for total contact casting, time to healing for irremovable cast walkers, healing probability for total contact casting, and the number of weekly visits and healing probability for irremovable cast walkers. When time to healing for total contact casting was reduced to 3.82 weeks, it was less costly and more effective (dominant) than irremovable cast walkers. Similarly, when time to healing for irremovable cast walkers was increased to 6.69 weeks, total contact casting was less costly and more effective (dominant). When the healing probability of total contact casting was increased to 84%, it dominated irremovable cast walkers. When the number of visits using irremovable cast walkers increased to three times per week, total contact casting also dominated.




Figure 14: One-Way Sensitivity Analysis, Base Case, Total Contact Casting Versus Irremovable Cast Walkers^a

Abbreviations: ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year; TCC, total contact casting.

^aX-axis represents range of ICERs when base-case values are varied (ranges shown in parentheses). Vertical line represents the ICER for total contact casting (\$198,928 per QALY gained). The variables that could cause TCC to dominate irremovable cast walkers are as follows: when time to healing for TCC decreases to 3.82 weeks; when time to healing for irremovable cast walkers increases to 6.69 weeks; when healing probability for TCC increases to 84%; when weekly visits for irremovable cast walkers increase to 3 times; or when healing probability for irremovable cast walkers decreases to 62%.

Figure 15 presents the results of the one-way sensitivity analysis for scenario 1 (all patients with an unhealed diabetic foot ulcer would switch to a secondary treatment). The model was most sensitive to time to healing for total contact casting, time to healing for irremovable cast walkers, the number of weekly visits using irremovable cast walkers, the healing probability for total contact casting, and the healing probability for irremovable cast walkers.




Figure 15: One-Way Sensitivity Analysis, Scenario 1, Total Contact Casting Versus Irremovable Cast Walkers^a

Abbreviations: ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year; TCC, total contact casting.

^aX-axis represents range of ICERs when base-case values are varied (ranges shown in parentheses). Vertical line represents the ICER for total contact casting (\$176,807 per QALY gained). The variables that could cause TCC to dominate irremovable cast walkers are as follows: when time to healing for TCC decreases to 3.82 weeks; when time to healing for irremovable cast walkers increases to 6.69 weeks; when weekly visits for irremovable cast walkers increases to 3 times; when healing probability for TCC increases to 84%; or when healing probability for irremovable cast walkers decreases to 62%.

Figure 16 presents the results of the one-way sensitivity analysis for scenario 2 (no switching of treatment for patients with unhealed diabetic foot ulcers). The model was most sensitive to time to healing for total contact casting, time to healing for irremovable cast walkers, healing probability for total contact casting, healing probability for irremovable cast walkers, and the number of weekly visits using irremovable cast walkers.




Figure 16: One-Way Sensitivity Analysis, Scenario 2, Total Contact Casting Versus Irremovable Cast Walkers^a

Abbreviations: ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year; TCC, total contact casting.

^aX-axis represents range of ICERs when base-case values are varied (ranges shown in parentheses). Vertical line represents the ICER for total contact casting (\$289,140 per QALY gained). The variables that could cause TCC to dominate irremovable cast walkers are as follows: when time to healing for TCC decreases to 3.82 weeks; when time to healing for irremovable cast walkers increases to 6.69 weeks; when healing probability for TCC increases to 84%; when healing probability for irremovable cast walkers decreases to 62%; or when weekly visits for irremovable cast walkers increases to 3 times.

Discussion

Resources for health care are scarce relative to needs or wants, and an economic evaluation is intended to inform the choices that decision-makers face in these circumstances. This study investigated resource allocations, cost-effectiveness, and cost utility for total contact casting, removable cast walkers, and irremovable cast walkers, compared with each other and with therapeutic shoes.

The cost-effectiveness analysis showed that treating diabetic foot ulcers with therapeutic shoes and removable cast walkers was more costly and less effective than using total contact casting or irremovable cast walkers. This left total contact casting and irremovable cast walkers as the two strategies for consideration. When we compared total contact casting with irremovable cast walkers, we found that gaining a healed ulcer with total contact casting would require an additional \$17,923. One-way sensitivity analyses showed that these cost-effectiveness results were sensitive to the number of weekly clinic visits if patients used an irremovable cast walker. One of the strengths of this cost-effectiveness analysis was that the results were calculated based on data from RCTs, without assumptions, reflecting the clinical evidence.

The cost-utility analysis showed that total contact casting and irremovable cast walkers were less expensive and more effective than removable cast walkers and therapeutic shoes, and that irremovable cast walkers were as effective as total contact casting but at a lower cost. One-way sensitivity analyses showed that the time to healing for total contact casting, the time to healing for irremovable cast walkers, the healing probability of total contact casting and irremovable cast walkers, and the number of weekly visits for irremovable cast walkers had the most influence on ICER values.

In Ontario, clinicians regularly use removable cast walkers and total contact casting, and it is unclear how often irremovable cast walkers are used. The reasons for this are unclear, but may relate to clinician preference or feasibility.

Our findings were consistent with those of other studies in terms of treatment costs. Piaggese and colleagues concluded that total contact casting was more expensive than irremovable cast walkers.²⁸ This finding was verified in a more recent study by the same authors.²⁷ In another study by Katz and colleagues, the authors also reported that total contact casting was more expensive than irremovable cast walkers.³⁵

This analysis had several limitations. First, the care pathway has been simplified. The model followed patients for only 6 months. As a result, long-term effects such as death have not been captured. As well, we were unable to obtain information from RCTs about treatment pathways for patients with unhealed ulcers, or about outcomes for patients who were lost to follow-up, who had unhealed ulcers, or who had recurring or new ulcers. The 6-month duration of this model was reasonable for capturing the short-term treatment effects of offloading devices and did allow us to explore treatment options for unhealed ulcers.

The second limitation was the assumptions made about the treatment pathway. When a diabetic foot ulcer went unhealed from the primary treatment, the patient would continue to be treated. Because the treatment trajectories and sequence of offloading devices are not standardized, we chose to review different scenarios for switching treatment. We consulted with several experts about their opinions on treatment pathways. The information provided in our analysis represented feasible treatment options based on available data from RCTs and from expert opinion. Furthermore, we presented the cost-utility results as probabilistic rather than deterministic sampling to avoid uncertainties and assumptions.

Another limitation was related to other major assumptions in the cost-utility model. We assumed that there would be no recurrence of an old ulcer, that no new ulcer would form after a healed ulcer, and that each patient had only one ulcer treatment at a time. In addition, since the RCTs had small sample sizes, it was difficult to quantify the outcomes and complications among patients with diabetic foot ulcers. We included amputation as the only complication in the model. Data from more patients with longer follow-up would provide an opportunity to consolidate the results of our analysis. A Markov model may have been more suitable for monitoring patients over a long time. This type of model could have captured the long-term consequences of treatment, particularly in cases of unhealed ulcers. However, given the short-term nature of the available data on clinical outcomes from the various offloading devices, a Markov model in this study was not possible.

Conclusions

Therapeutic shoes and removable cast walkers were more costly and had fewer health outcome gains than irremovable cast walkers and total contact casting. From a health economic point of view, irremovable cast walkers were as effective as total contact casting for treating diabetic foot ulcers and were associated with fewer costs. Irremovable cast walkers should be the preferred option when they are acceptable to patients and clinicians. When they cannot be used, total contact casting may be a reasonable alternative. Removable cast walkers would be a preferred option for patients who are not eligible for or have not had success with total contact casting or irremovable cast walkers.

BUDGET IMPACT ANALYSIS

We conducted a budget impact analysis from the perspective of the Ontario Ministry of Health and Long-Term Care to determine the estimated cost burden of implementing total contact casting, irremovable cast walkers, and removable cast walkers over the next 5 years (2016–2020). All costs are reported in 2016 Canadian dollars.

Research Question

What is the budget impact of implementing fibreglass total contact casting, removable cast walkers, and irremovable cast walkers over the next 5 years from the perspective of the Ontario Ministry of Health and Long-Term Care?

Methods

Target Population

The target population was patients with diabetic neuropathic foot ulcers who were eligible for treatment with total contact casting, removable cast walkers, and irremovable cast walkers.

The prevalence of diabetes in Ontario was estimated at 10.20% in 2015 and predicted to increase to 11.9% by 2020.⁴⁸ Assuming that the number of people diagnosed with diabetes would increase at a steady rate between 2015 and 2020, we estimated prevalence for the years 2016 to 2020 (Table 26).

Using the projected Ontario population and the estimated diabetes prevalence, we estimated the number of people with diabetes over the next 5 years (Table 26).⁴⁸

Approximately 2% to 3% of patients with diabetes will develop a foot ulcer each year.⁴⁸ We assumed that 2.5% of people with diabetes in Ontario would develop a diabetic foot ulcer and estimated the annual number of diabetic foot ulcer cases in Ontario, based on the diabetes prevalence estimates (Table 26).

Table 26: Estimated Diabetes Prevalence in Ontario, 2016–2020

	2016	2017	2018	2019	2020
Ontario population, n ^a	13,930,021	14,069,321	14,210,014	14,352,115	14,495,635
Diabetes prevalence, %	10.54	10.88	11.22	11.55	11.90
People with diabetes, n	1,468,224	1,530,561	1,593,815	1,657,999	1,723,122
Diabetic foot ulcer prevalence, % ^b	2.5	2.5	2.5	2.5	2.5
Patients with diabetic foot ulcer, n ^b	36,705	38,264	39,845	41,450	43,078

^aData from Statistics Canada.⁴⁹

^bBased on yearly probabilities of developing a diabetic foot ulcer among people with diabetes in Ontario.

Resource

Access to Offloading Devices

Based on information from a published in a report by the Canadian Diabetes Association, we estimated the annual usage of offloading devices for three possible scenarios of access to an offloading device: 50%, 75%, and 100% (Table 27).⁴⁴

Table 27: Estimated Annual Number of Patients With Diabetic Foot Ulcers and Access to an Offloading Device in Ontario, 2016–2020

Access to An Offloading Device ^a	2016	2017	2018	2019	2020
50%	18,353	19,132	19,923	20,725	21,539
75%	27,529	28,698	29,884	31,087	32,309
100%	36,706	38,264	39,845	41,450	43,078

^aCategorized by rates of access to an offloading device per annum among patients with diabetic foot ulcers in Ontario.
Source: Canadian Diabetes Association.⁴⁴

Proportion of Use of the Different Offloading Devices

We estimated the proportion of patients with a diabetic foot ulcer who would use each of the offloading devices, based on information from a published report.¹⁵ According to the report, 40% of patients would use total contact casting, 30% would use removable cast walkers, and 30% would use other offloading devices (e.g., custom braces, ankle and foot orthoses, postoperative shoes) to treat a diabetic foot ulcer. We excluded other devices from the analysis. No data were available on the proportion of patients who would use an irremovable cast walker. Based on expert opinion, we estimated that 50% of patients who would use a removable cast walker might use an irremovable cast walker. We used these estimates in both the base case and the scenario analyses. The proportions of use of total contact casting, removable cast walkers, and irremovable cast walkers were 57%, 21.5%, and 21.5%, respectively.

Number of Amputations

The number of amputations among patients with diabetic foot ulcers depends on the proportion of patients who have access to offloading devices. The probability of amputation as a result of an unhealed ulcer has been estimated at 7.1%.⁴⁴ We estimated the number of amputations among patients with diabetic foot ulcers who did or did not have access to an offloading device based on the access scenarios described in Table 27. The expected number of expected amputations is presented in Table 28.

Table 28: Estimated Amputations Among Patients With Diabetic Foot Ulcers by Access to an Offloading Device in Ontario, 2016–2020

	2016			2017			2018			2019			2020		
Access to an Offloading Device	50%	75%	100%	50%	75%	100%	50%	75%	100%	50%	75%	100%	50%	75%	100%
Amputations among patients without access to an offloading device	1,303	652	—	1,358	679	—	1,415	707	—	1,471	736	—	1,529	765	—
Amputations among patients with access to total contact casting	96	145	193	101	151	201	105	157	209	109	163	218	113	170	226
Amputations among patients with access to removable cast walkers	57	85	114	59	89	119	62	93	123	64	96	128	67	100	133
Amputations among patients with access to irremovable cast walkers	38	57	76	40	60	80	41	62	83	43	65	86	45	67	90
Total amputations	1,495	939	383	1,558	979	399	1,622	1,019	416	1,688	1,060	433	1,754	1,102	450
Change in amputations with 25% increase in access to an offloading device	—	–556	–556	—	–579	–579	—	–603	–603	—	–628	–628	—	–652	–652

Canadian Costs

Costs included in the analysis were the cost of an offloading device, labour and professional costs, and the treatment costs of amputation (taken from the primary economic evaluation).

We calculated the 1-year cost as follows. We took the first 3-month treatment cost per patient from the cost-effectiveness analysis. To calculate the subsequent 9-month treatment cost per patient, we assumed that if a patient had a healed ulcer from the primary treatment, they would continue in a maintenance phase of 9 months, during which orthotics would be used. If an ulcer was unhealed from the primary treatment, the patient would continue with a secondary treatment. For simplicity, we assumed that therapeutic shoes would be the secondary treatment, regardless of the primary treatment. Since the probability of ulcer healing was approximately 50% for therapeutic shoes, 50% of patients with an unhealed ulcer would continue for 9 months with the secondary treatment. Therefore, we assumed that on average, a patient would receive 4.5 months of a secondary treatment.

We based the total 1-year treatment cost on the following formula:

Total cost per patient per year = Average cost per patient (first 3 months) + (1 – probability of ulcer healing of primary treatment) × average cost per patient (next 9 months) + probability of ulcer healing of primary treatment × average cost of maintenance (next 9 months)

Details of the cost components are provided in Table 29. The cost of offloading devices and Coban wrap are not publicly funded. The costs of physicians, nurses, and the dressing are publicly funded.

Table 29: One-Year Costs Per Patient to Adopt Offloading Devices^{a,b}

Offloading Device	Resource Item	Cost
Fibreglass total contact casting	Device cost	\$620
	Treatment cost	\$1,763
	Total cost	\$2,383
Removable cast walkers	Device cost	\$150
	Treatment cost	\$3,107
	Total cost	\$3,257
Irremovable cast walkers	Device cost	\$331
	Treatment cost	\$1,817
	Total cost	\$2,148

^aCost data were provided in consultation with experts.

^bTreatment costs included professional labour and dressings.

Analysis

We calculated the required budget for funding total contact casting, removable cast walkers, and irremovable cast walkers when access to an offloading device was 50%, 75%, and 100%. We also calculated the net budget impact when access was increased by 25% (50% to 75% and 75% to 100%) and by 100% (0% to 100%).

Base Case Analysis

In the base case analysis, we assumed all three offloading devices (total contact casting, removable cast walkers, and irremovable cast walkers) would be funded. We assumed that the proportion of use of total contact casting, removable cast walkers, and irremovable cast walkers would be 57%, 21.5%, and 21.5%, respectively, and that those proportions would remain the same for all three access scenarios.

Scenario Analysis

In the scenario analyses, we explored the possibility of each device being exclusively funded. We increased the proportional use to 100% for each device for the three scenarios of access.

Because irremovable cast walkers are not commonly used, we also explored the budget impact of funding total contact casting, removable cast walkers, and irremovable cast walkers by varying the proportional use of irremovable cast walkers.

Results

Base Case Analysis

The budget impact of adopting total contact casting, removable cast walkers, and irremovable cast walkers would range from \$8.4 million to \$20 million (device costs only) per year over the next 5 years, depending on level of access to offloading devices (Tables 30 to 32).

Table 30: Budget Impact of Adopting Offloading Devices at 50% Access in Ontario, 2016–2020

Year	Cost	Total Contact Casting	Removable Cast Walkers	Irremovable Cast Walkers	Total
2016	Device cost	\$6,498,285	\$589,912	\$1,300,146	\$8,388,343
	Treatment cost	\$18,495,619	\$12,218,435	\$7,148,435	\$37,862,489
	Total cost	\$24,993,904	\$12,808,347	\$8,448,581	\$46,250,832
2017	Device cost	\$6,774,185	\$614,958	\$1,355,347	\$8,744,489
	Treatment cost	\$19,280,892	\$12,218,435	\$7,451,938	\$38,951,266
	Total cost	\$26,055,077	\$12,833,393	\$8,807,285	\$47,695,755
2018	Device cost	\$7,054,146	\$640,372	\$1,411,360	\$9,105,878
	Treatment cost	\$20,077,726	\$13,263,595	\$7,759,909	\$41,101,230
	Total cost	\$27,131,872	\$13,903,967	\$9,171,269	\$50,207,108
2019	Device cost	\$7,338,218	\$666,160	\$1,468,196	\$9,472,574
	Treatment cost	\$20,886,260	\$13,797,723	\$8,072,402	\$42,756,385
	Total cost	\$28,224,478	\$14,463,883	\$9,540,598	\$52,228,959
2020	Device cost	\$7,626,448	\$692,326	\$1,525,864	\$9,844,637
	Treatment cost	\$21,706,630	\$14,339,669	\$8,389,470	\$44,435,769
	Total cost	\$29,333,078	\$15,031,995	\$9,915,334	\$54,280,406

Note: Numbers may appear inexact due to rounding.

Table 31: Budget Impact of Adopting Offloading Devices at 75% Access in Ontario, 2016–2020

Year	Cost	Total Contact Casting	Removable Cast Walkers	Irremovable Cast Walkers	Total
2016	Device cost	\$9,747,428	\$884,867	\$1,950,219	\$12,582,514
	Treatment cost	\$27,743,428	\$18,327,653	\$10,722,653	\$56,793,733
	Total cost	\$37,490,856	\$19,212,520	\$12,672,872	\$69,376,248
2017	Device cost	\$10,161,277	\$922,436	\$2,033,020	\$13,116,734
	Treatment cost	\$28,921,338	\$18,327,653	\$11,177,907	\$58,426,898
	Total cost	\$39,082,615	\$19,250,089	\$13,210,928	\$71,543,632
2018	Device cost	\$10,581,219	\$960,558	\$2,117,040	\$13,658,817
	Treatment cost	\$30,116,589	\$19,895,392	\$11,639,864	\$61,651,845
	Total cost	\$40,697,807	\$20,855,951	\$13,756,904	\$75,310,662
2019	Device cost	\$11,007,327	\$999,240	\$2,202,294	\$14,208,861
	Treatment cost	\$31,329,390	\$20,696,584	\$12,108,604	\$64,134,577
	Total cost	\$42,336,716	\$21,695,824	\$14,310,897	\$78,343,438
2020	Device cost	\$11,439,672	\$1,038,488	\$2,288,795	\$14,766,956
	Treatment cost	\$32,559,945	\$21,509,504	\$12,584,205	\$66,653,654
	Total cost	\$43,999,617	\$22,547,992	\$14,873,000	\$81,420,609

Note: Numbers may appear inexact due to rounding.

Table 32: Budget Impact of Adopting Offloading Devices at 100% Access in Ontario, 2016–2020

Year	Cost	Total Contact Casting	Removable Cast Walkers	Irremovable Cast Walkers	Total
2016	Device cost	\$12,996,571	\$1,179,823	\$2,600,292	\$16,776,686
	Treatment cost	\$36,991,237	\$24,436,871	\$14,296,870	\$75,724,978
	Total cost	\$49,987,808	\$25,616,694	\$16,897,163	\$92,501,664
2017	Device cost	\$13,548,370	\$1,229,915	\$2,710,694	\$17,488,978
	Treatment cost	\$38,561,784	\$24,436,871	\$14,903,877	\$77,902,531
	Total cost	\$52,110,154	\$25,666,786	\$17,614,570	\$95,391,509
2018	Device cost	\$14,108,292	\$1,280,745	\$2,822,720	\$18,211,756
	Treatment cost	\$40,155,452	\$26,527,190	\$15,519,819	\$82,202,460
	Total cost	\$54,263,743	\$27,807,935	\$18,342,539	\$100,414,217
2019	Device cost	\$14,676,435	\$1,332,320	\$2,936,392	\$18,945,148
	Treatment cost	\$41,772,520	\$27,595,445	\$16,144,805	\$85,512,770
	Total cost	\$56,448,955	\$28,927,766	\$19,081,197	\$104,457,917
2020	Device cost	\$15,252,896	\$1,384,651	\$3,051,727	\$19,689,275
	Treatment cost	\$43,413,260	\$28,679,338	\$16,778,940	\$88,871,538
	Total cost	\$58,666,156	\$30,063,990	\$19,830,667	\$108,560,813

Note: Numbers may appear inexact due to rounding.

When access to all three offloading devices increased by 25% (50% to 75%, and 75% to 100%) and 100% (0% to 100%), the net budget impact was a cost savings for the health care system (Table 33), because increased access to an offloading device would lead to fewer amputations.

Table 33: Net Budget Impact of Adopting Offloading Devices When Access Increased by 25% and 100% in Ontario, 2016–2020, Base Case Analysis

Year	Cost	Change in Accessibility		
		50% to 75%	75% to 100%	0% to 100%
2016	Device cost	\$4,194,171	\$4,194,171	\$16,776,684
	Treatment cost	\$18,931,244	\$18,931,244	\$75,724,976
	Amputation costs	–\$41,680,264	–\$41,680,264	–\$166,721,056
	Total cost	–\$18,554,848	–\$18,554,848	–\$74,219,392
2017	Device cost	\$4,372,245	\$4,372,245	\$17,488,980
	Treatment cost	\$19,475,633	\$19,475,633	\$77,902,532
	Amputation costs	–\$43,449,895	–\$43,449,895	–\$173,799,580
	Total cost	–\$19,602,017	–\$19,602,017	–\$78,408,068
2018	Device cost	4,552,939	\$4,552,939	\$18,211,756
	Treatment cost	20,550,615	\$20,550,615	\$82,202,460
	Amputation costs	–\$45,245,576	–\$45,245,576	–\$180,982,304
	Total cost	–\$20,142,022	–\$20,142,022	–\$80,568,088
2019	Device cost	\$4,736,287	\$4,736,287	\$18,945,148
	Treatment cost	\$21,378,192	\$21,378,192	\$85,512,768
	Amputation costs	–\$47,067,625	–\$47,067,625	–\$188,270,500
	Total cost	–\$20,953,145	–\$20,953,145	–\$83,812,580
2020	Device cost	\$4,922,319	\$4,922,319	\$19,689,276
	Treatment cost	\$22,217,885	\$22,217,885	\$88,871,540
	Amputation costs	–\$48,916,346	–\$48,916,346	–\$195,665,384
	Total cost	–\$21,776,142	–\$21,776,142	–\$87,104,568

Note: Numbers may appear inexact due to rounding. Negative numbers mean cost savings.

Scenario Analysis

When access to each of total contact casting, removable cast walkers, and irremovable cast walkers increased by 25% (50% to 75% and 75% to 100%) and by 100% (0% to 100%), there were also cost savings to the health care system, because of fewer amputations with increased access to these three devices (Table 34). Further details are available in Appendix 7.

Budget Impact Analysis

May 2017

Table 34: Net Budget Impact of Adopting Offloading Devices When Access to Offloading Devices Increased by 25% and 100% in Ontario, 2016–2020, Scenario Analysis

Year	Cost	Change in Accessibility								
		50% to 75%			75% to 100%			0% to 100%		
		Total Contact Casting	Irremovable Cast Walkers	Removable Cast Walkers	Total Contact Casting	Irremovable Cast Walkers	Removable Cast Walkers	Total Contact Casting	Irremovable Cast Walkers	Removable Cast Walkers
2016	Device cost	\$5,686,000	\$3,033,674	\$1,376,460	\$5,686,000	\$3,033,674	\$1,376,460	\$22,744,000	\$12,134,696	\$5,505,840
	Treatment cost	\$16,183,666	\$16,679,682	\$28,509,682	\$16,183,666	\$16,679,682	\$28,509,682	\$64,734,664	\$66,718,728	\$114,038,728
	Amputation cost	-\$42,532,022	-\$42,177,123	-\$38,912,051	-\$42,532,022	-\$42,177,123	-\$38,912,051	-\$170,128,088	-\$168,708,492	-\$155,648,204
	Total cost	-\$20,662,356	-\$22,463,766	-\$9,025,909	-\$20,662,356	-\$22,463,766	-\$9,025,909	-\$82,649,424	-\$89,855,064	-\$36,103,636
2017	Device cost	\$5,927,412	\$3,162,476	\$1,434,901	\$5,927,412	\$3,162,476	\$1,434,901	\$23,709,648	\$12,649,904	\$5,739,604
	Treatment cost	\$16,870,781	\$17,387,856	\$29,720,126	\$16,870,781	\$17,387,856	\$29,720,126	\$67,483,124	\$69,551,424	\$118,880,504
	Amputation cost	-\$44,337,816	-\$43,967,849	-\$40,564,151	-\$44,337,816	-\$43,967,849	-\$40,564,151	-\$177,351,264	-\$175,871,396	-\$162,256,604
	Total cost	-\$21,539,623	-\$23,417,517	-\$9,409,124	-\$21,539,623	-\$23,417,517	-\$9,409,124	-\$86,158,492	-\$93,670,068	-\$37,636,496
2018	Device cost	\$6,172,378	\$3,293,174	-\$7,577,412	\$6,172,378	\$3,293,174	\$1,494,202	\$24,689,512	\$13,172,696	\$5,976,808
	Treatment cost	\$17,568,010	\$18,106,455	-\$52,873,665	\$17,568,010	\$18,106,455	\$30,948,388	\$70,272,040	\$72,425,820	\$123,793,552
	Amputation cost	-\$46,170,193	-\$24,385,307	-\$53,559,960	-\$46,170,193	-\$45,784,936	-\$42,240,572	-\$184,680,772	-\$183,139,744	-\$168,962,288
	Total cost	-\$22,429,805	-\$24,385,307	-\$9,797,981	-\$22,429,805	-\$24,385,307	-\$9,797,981	-\$89,719,220	-\$97,541,228	-\$39,191,924
2019	Device cost	\$6,420,940	\$17,155,221	-\$7,882,556	\$6,420,940	\$3,425,790	\$1,554,374	\$25,683,760	\$13,703,160	\$6,217,496
	Treatment cost	\$18,275,477	-\$48,831,019	-\$55,002,898	\$18,275,477	\$18,835,606	\$32,194,686	\$73,101,908	\$75,342,424	\$128,778,744
	Amputation cost	-\$48,029,476	-\$19,264,557	-\$55,716,830	-\$48,029,476	-\$47,628,705	-\$43,941,608	-\$192,117,904	-\$190,514,820	-\$175,766,432
	Total cost	-\$23,333,058	-\$25,367,309	-\$10,192,548	-\$23,333,058	-\$25,367,309	-\$10,192,548	-\$93,332,232	-\$101,469,236	-\$40,770,192
2020	Device cost	\$6,673,142	\$17,829,043	-\$8,192,166	\$6,673,142	\$3,560,348	\$1,615,426	\$26,692,568	\$14,241,392	\$6,461,704
	Treatment cost	\$18,993,301	-\$50,749,002	-\$57,163,300	\$18,993,301	\$19,575,430	\$33,459,228	\$75,973,204	\$78,301,720	\$133,836,912
	Amputation cost	-\$49,915,976	-\$20,021,230	-\$57,905,274	-\$49,915,976	-\$49,499,464	-\$45,667,545	-\$199,663,904	-\$197,997,856	-\$182,670,180
	Total cost	-\$24,249,533	-\$26,363,685	-\$10,592,890	-\$24,249,533	-\$26,363,685	-\$10,592,890	-\$96,998,132	-\$105,454,740	-\$42,371,560

Note: Numbers may appear inexact due to rounding. Negative numbers mean cost savings.

Discussion

Implementing total contact casting, removable cast walkers, and irremovable cast walkers would require \$17 million to \$20 million per year between 2016 and 2020, assuming that access to these three offloading devices was 100% and that the annual probability of developing a diabetic foot ulcer was 2.5%. According to expert opinion, access to offloading devices would increase if these devices were publicly funded. Our analysis showed that increased access to offloading devices would likely result in cost savings to the health care system because of fewer amputations.

Experts indicated that in Ontario, clinicians regularly use removable cast walkers and total contact casting, but irremovable cast walkers are less common. The reasons for this are unclear, but may relate to clinician preference or feasibility. The increase in use of irremovable cast walkers would be directly correlated with the increase in diabetes prevalence, and with training of clinicians in the use of irremovable cast walkers to treat neuropathic diabetic foot ulcers (expert opinion).

The budget impact analysis included the up-front costs (device costs and the frequency of changing offloading devices) and the treatment costs (labour and professional costs). However, increased access to offloading devices led to potential cost savings because of the likelihood of fewer amputations as a result of using the devices.

Conclusions

If total contact casting, removable cast walkers, and irremovable cast walkers were publicly funded in patients with diabetic foot ulcers, the device costs would be \$17 million to \$20 million per year over the next 5 years (2016–2020) at 100% access. However, access to offloading devices could result in cost savings for the health care system if the potential savings from avoiding amputations are taken into account.

PUBLIC AND PATIENT ENGAGEMENT

Objective

The objective of this analysis was to explore the underlying values, needs, impacts, and preferences of those who have lived experience with the treatment of diabetic foot ulcers. The treatment focus was total contact casting, removable cast walkers, and irremovable cast walkers.

Background

Public and patient engagement explores the lived experience of a person with a health condition, including the impact that the condition and its treatment has on the patient, the patient's family or other caregivers, and the patient's personal environment. Public and patient engagement increases awareness and builds appreciation for the needs, priorities, and preferences of the person at the centre of a treatment program. The insights gained through public and patient engagement provide an in-depth picture of lived experience, through an intimate look at the values that underpin the experience.

Lived experience is a unique source of evidence about the personal impact of a health condition and how that condition is managed, including what it is like to navigate the health care system with that condition and how technologies may or may not make a difference in people's lives. Information shared from lived experience can also identify gaps or limitations in published research (for example, outcome measures that do not reflect what is important to those with lived experience).⁵⁰⁻⁵² Additionally, lived experience can provide information or perspectives on the ethical and social values implications of technologies and treatments. Because the needs, priorities, preferences, and values of those with lived experience in Ontario are not often adequately explored by published literature, Health Quality Ontario reaches out to and directly speaks with people who live with the health condition, including those who may have experience with the intervention in question.

The impact of diabetes—in particular diabetic foot ulcers—on patients and families was perceived at the outset of this project to have significant bearing on quality of life. To truly understand impact on quality of life, we spoke with patients who had diabetes and foot ulcers, and who had experience with offloading devices such as total contact casting, removable cast walkers, and irremovable cast walkers. Understanding and appreciating their day-to-day functioning and treatment experience, including with the offloading devices in question, helps to contextualize the potential value of the interventions from a lived experience perspective.

Methods

Engagement Plan

Engagement as a concept captures a range of efforts used to involve the public and patients in various domains and stages of health technology assessment decision-making.⁵³ Rowe and Frewer outline three types of engagement: communication, consultation, and participation.⁵⁴ Communication constitutes a one-way transfer of information from the sponsor to the individual, while participation involves the sponsor and individual collaborating through real-time dialogue. Consultation, on the other hand, refers to the sponsor seeking out and soliciting information (for example, experiential input) from the public, patients, and caregivers affected by the health technology or intervention in question.

The engagement plan for this health technology assessment was consultation.⁵⁵ Within this typology, the engagement design focused on interviews to examine the lived experience of patients with diabetes who have foot ulcers, including those who have experience with total contact casting, removable cast walkers, and irremovable cast walkers.

The qualitative interview was selected as an appropriate methodology because it allowed Health Quality Ontario staff to deeply explore the meaning of central themes in the lived experience of the participants. The main task in interviewing is to understand the meaning of what participants say.⁵⁶ Interviews are particularly useful for getting the story behind a participant's experiences, which was the objective of this portion of the study. The sensitive nature of exploring quality-of-life issues is another reason supporting the use of interviews for this project.

Recruitment of Participants

The recruitment strategy for this project pursued an approach called purposive sampling⁵⁷⁻⁶⁰ to actively recruit individuals with direct lived experience. Patient, Caregiver, and Public Engagement staff reached out to patients, caregivers, and families (including those with experience of the intervention in question) through a variety of partner organizations, including the Ontario Centres for Complex Diabetes Care, wound care advocacy and support groups, diabetes associations, and clinical wound care centres across the province. We asked interview participants to reach out to other patients with diabetes after they completed their interview.

Inclusion Criteria

We sought a broad range of participants, including those who had experience with diabetic foot ulcers and the offloading devices in question (total contact casting, removable cast walkers, and irremovable cast walkers). We wanted to speak with patients of various ages, assuming that different life commitments (work, family, etc.) would affect patients' choices in terms of treatment options and outcomes sought. Finally, we aimed to obtain broad geographic representation as a way of raising possible equity issues and different themes in treatment decision-making across the province.

Exclusion Criteria

We set no exclusion criteria.

Participants

Patient, Caregiver, and Public Engagement staff spoke to 16 patients with diabetic foot ulcers from across Ontario. We interviewed eight patients twice for further clarification and analysis related to the offloading devices. All patients were familiar with a variety of treatments for diabetic foot ulcers, including offloading devices and medical therapy options.

Approach

At the outset of the interview, Patient, Caregiver, and Public Engagement staff at Health Quality Ontario explained the purpose of the health technology assessment process (including the role of Health Quality Ontario and the Ontario Health Technology Advisory Committee), risks to participation, and protection of personal health information. These attributes were explained to participants orally and through a letter of information. Written or verbal consent was then obtained from participants prior to commencing the interview. The letter of information and consent form can be found in Appendix 8. Interviews were recorded and transcribed.

Questions focused on the impact of diabetic foot ulcers on patients', caregivers, and families' quality of life, experiences with other health interventions related to managing diabetic foot ulcers, experiences with total contact casting, removable cast walkers, and irremovable cast walkers, and any perceived benefits and limitations when comparing the different offloading devices. The interview guide is included in Appendix 8.

The interview was semi-structured, consisting of a series of open-ended questions. Interviews lasted approximately 10 to 30 minutes. Questions for the interview were based on a list developed by the Health Technology Assessment International Patient and Citizen Involvement Group to elicit lived experiences specific to the impact of a health technology or intervention.⁶¹

Data Extraction and Analysis

Patient, Caregiver, and Public Engagement staff at Health Quality Ontario selected a modified version of a grounded theory methodology to analyze transcripts of participant interviews, because it captures themes and allows for elements of the lived experience to be organized and compared across participants. The inductive nature of grounded theory follows an iterative process of eliciting, documenting, and analyzing responses while simultaneously collecting and analyzing data using a constant comparative approach.^{62,63} Through this approach, staff coded transcripts and compared themes using NVivo (QSR International, Doncaster, Victoria, Australia). NVivo enables the identification and interpretation of patterns in interview data about the meaning and implications of a lived condition from the patient's perspective of what is important in their daily lived experience with diabetic foot ulcers, before and after the intervention in question.

Results

Physical and Emotional Experience of Living With Diabetic Foot Ulcers

Patients frequently reported multiple health issues related to their diabetes, including recurring foot ulcers. Neuropathy of the lower legs, which could prevent patients from monitoring and caring for their own feet, was one of these. Given these comorbidities and the nature and location of foot ulcers in the patients interviewed, the effect of the ulcers on quality of life was moderate to severe. Patients consistently reported mobility challenges, and also spoke about their decreased ability to leave home and engage in activities outside of home. They also described reduced quality of life. Walking, visiting with friends, vacations, and driving were all affected by diabetic foot ulcers. For people who were employed, challenges arose with performing work duties, often requiring leaves of absence or modified work duties. These changes affected patients and their families.

"Until it really got bad, I wasn't doing much too differently, because I didn't know. After that, I was being told to stay off my feet as much as possible, and at that time I was working, so I had to take the time off to just stay off my feet."

"Especially now that you can't walk, you're off work, you've got a family to raise and children, and now you can't work, and you're spiralling down into the abyss pretty quick."

Following the first occurrence of a diabetic foot ulcer and dealing with its complexity and treatment, patients reported increased awareness of and vigilance about the status of their feet. They monitored small cuts or bruises closely and reported careful maintenance of the skin on several occasions. They also reported more appointments with physicians, chiropodists, and

wound care clinics, as well as the tendency to get off their feet when swelling, redness, or calluses arose.

"I perform daily wound care, plus I wear custom orthotics, and I'm committed to daily application of moisturizers."

This vigilance could constitute an emotional burden: participants regularly report constant stress and the fear of developing a foot ulcer. Family members also saw this emotional burden. Patients and their family caregivers reported a clear understanding that a foot ulcer could have serious health consequences, such as amputation.

"Her life shrank to her house, essentially. And to her bed. She was spending a lot of time in bed sleeping, and they think she was overwhelmed, trying to deal with all of this and with the inevitable fear of this potential amputation looming over her head ..."

"I live in constant fear that the other shoe will drop and the ulcer will return or occur elsewhere."

"Having these things is incredibly terrifying for people. Most [people with diabetes] will not admit that they have a problem until it becomes evident to the family around them, and they're forced into care."

Frustration with slow healing was a common sentiment among the patients interviewed. This frustration extended to ulcer recurrence: patients reported knowing that it could take up to 2 years for the skin to regain its full strength, and that the reopening of ulcers was a fairly common occurrence.

"It is frustrating at times; you think everything's healed up, but they say the integrity of the skin takes two full years to reach its strong point. Once it heals, then the 2-year period starts, but then if you open up a wound, then that stops and ... then you've gotta start all over again."

Patients reported that this emotional burden often required the support of family members. Those with family supports spoke of gratitude for their aid and acknowledged the physical and emotional difficulties they would have faced if not for family. Because of the physical limitations that diabetic foot ulcers can impose, families often helped get patients to and from treatment centres, and advocated for treatment options.

"Without my family, without my close friends, I don't know where I would have been. I don't think I would have been in my home. I wouldn't have been able to manage on my own those early months."

Treatments for Diabetic Foot Ulcers

Patients reported familiarity with a wide variety of treatment options for diabetic foot ulcers, including dressings, bandages, silver nitrate, packing, and offloading devices (total contact casting, air casts, removable cast walkers, orthopedic shoes, ankle foot orthosis, Charcot restraint orthotic walker [CROW] boots, felt padding, wheelchairs, crutches, canes, and walkers). Patients reported encountering these treatment options at hospitals, wound care clinics, and chiropody clinics, as well as in home nursing visits through a community care access centre.

Preventing amputation was top-of-mind when patients chose offloading and wound care treatments. A number of patients had had experience with amputations, including single-toe, multiple-toe, foot, and below-the-knee. They made the physical and emotional effects of these amputations very clear.

“Got my confidence back and you know, I felt pretty low, I must admit. Not nice ... you’ve had a member of your body attached to you for 66 years and all of sudden, it’s gone. It was a pretty traumatic experience to go through.”

With this mindset, patients said that the main benefit of any therapy was the successful healing of the ulcer. Patients reported high tolerance for devices or treatments that were inconvenient, burdensome, or uncomfortable, as long as they successfully treated the ulcer. Treatments could take a long time, and healing was often slow, frustrating, and inconsistent. Patients also reported frequent setbacks: treatments halted and newly healed ulcers reopened. For this reason, patients were willing to try other treatments if their health care practitioner recommended them, or if those treatments showed faster healing.

“Well, it was a little bit cumbersome and heavy and hot, but I knew the downside if it didn’t get healed up: I would probably face a further amputation.”

“A few years ago, we tried the air cast. It didn’t work. We tried orthopedic shoes. They didn’t work. We tried different types of shoes. They didn’t work. We even tried a sort of cap, like a brace, that keeps the foot straight, that comes down the back of the calf and under the foot. These were all specifically made to my foot and my leg, and they didn’t work. I would have problems, then the wound would open up, then I’d be back in the cast again.”

“This home care and the ulcer had been going on for 2½ years, approximately. And this was a last-ditch effort for me, so I was going to do whatever had to be done to get this over with.”

Of all the offloading devices, patients reported that total contact casting and removable cast walkers were the most commonly used and the most effective. Patients were often familiar with therapeutic shoes, but they described a wide range of these devices and stressed that therapeutic shoes were often used after total contact casting or removable cast walkers had healed the ulcer. The interview questions focused on three devices: total contact casting, removable cast walkers, and irremovable cast walkers.

We categorized comparisons between these devices as follows: the treatment process, effectiveness, comfort and mobility, and cost and access.

Total Contact Casting

Treatment Process

A health care professional is needed to apply total contact casting to a diabetic foot ulcer. Patients received total contact casting in clinic or hospital settings. Patients reported that their preparation for total contact casting was very transparent: information was readily available from a variety of sources. Patients also reported that health care staff were willing to explain the benefits, risks, and alternatives of total contact casting to their satisfaction. No patients reported surprises or being faced with unexpected consequences. Patients were aware of the standard weekly or bi-weekly appointments required to remove the old cast, examine and dress the wound inside, and reapply a new cast. These appointments typically lasted 1 to 3 hours.

Patients mostly said that the time commitment was inconvenient, but that they were willing to accept it, given the successful healing they observed with the cast. Similarly, patients were willing to travel to clinics that offered total contact casting, although they lamented the time spent travelling and wished for more convenient locations.

A few patients reported mild levels of anxiety once their foot was in the cast, because the ulcer was hidden. Having become hyper-aware of their feet and their ulcer(s), some patients imagined degradation of the wound when they couldn't see it.

"All the time I was in the cast, my mind was focused on what was happening to my wound. Was it getting worse? Would this help? What would happen when the cast came off? What options did I have left?"

Effectiveness

Patients reported high satisfaction with the healing of total contact casting. Because these patients had experience with other types of offloading devices, they could compare and contrast wound healing between devices. Patients often felt that contact casting healed ulcers more quickly than patients anticipated. Several patients reported that they had had chronic foot ulcers for several years, only to switch to total contact casting and achieve quick and effective healing. However, chronic ulcers could recur when patients' feet were unprotected. At each recurrence, patients reported seeking immediate treatment with total contact casting, avoiding other types of treatment.

"Well, like I told [the nurse], I said, 'Just put me into a cast for the rest of my life, you know, it seems to be the only thing that works.'"

"And the healing. For the first couple of weeks, the healing on the ulcer was dramatic—absolutely unbelievable—the most we had seen in 2½ years. And she just kept it going: maybe changed the cast every week for, I'm going to guess, 6 weeks, and then every 2 weeks after that. And then finally she said to me, that's enough; we're done."

Several patients also reported that total contact casting reduced leg edema.

"I do have a fair bit of leg edema, and the cast actually treats that quite well, too. So I've got one leg of normal size now; the other one is still fairly swollen. But the cast is actually a really effective compression device."

Comfort and Mobility

Patients reported moderate comfort and moderate impact on mobility with total contact casting. They noted that the casting was designed to allow them an ease of mobility that closely mirrored their gait. However, this was not always completely successful, and the cast could still be inconvenient to wear. A commonly mentioned drawback was that the cast could not be removed when showering or at bedtime, unlike other types of offloading devices, such as removable cast walkers. However, patients reported a willingness to accept these inconveniences for the sake of ulcer healing.

"Walking around was a little more difficult, but not to the point where I would just say 'Never mind, I'm not going to do this. Just skip it.' I still tried to do it anyway."

"Actually, I didn't find it bad at all. When I came out of the total cast I went into a mobile cast, a plastic one. And that's when [the ulcer] broke open again, because I could still

have a little bit of movement in the plastic cast, where the other cast, it was good, there was no movement.”

Cost and Access

The cost of total contact casting affected patients differently depending on their income. Typical costs per cast were \$50 to \$100 depending on the clinic, but several clinics offered discounted unit costs for an up-front payment. The total financial burden depended on speed of healing and the total number of casts needed. For patients on a fixed income, this could become untenable, but others reported that the costs were fairly reasonable. Patients also mentioned additional out-of-pocket costs, such as parking and transportation to and from the clinic.

“But before that, I thought that the prices were really decent. You know, I didn’t find it that much. So I was prepared to pay if I had to. It didn’t bother me or my wife at all if we ended up paying for it, because we thought it was a reasonable price.”

“It may not be all the much money to somebody else, but on a fixed income, you know \$120, \$170, or whatever, even \$60 a month, that’s a lot of money.”

“I think it’s fair, but you know, I can see people with limited income [having trouble] ... But we could afford it; it wasn’t an overwhelming cost by any means.”

A small number of patients reported that the cost of total contact casting was too much of a burden and had resorted to a cheaper air cast (removable cast walker), although it did not heal their ulcers.

“So because I can’t afford to do that—even with insurance it’s not very affordable— we’re trying the air cast, and this past 2 weeks, it hasn’t really been helping with the ulcer at all. If anything, it’s made it worse.”

Removable Cast Walkers

Treatment Process

Patients reported no difficulty in acquiring removable cast walkers. Unlike total contact casting, removable cast walkers do not have to be applied by a health care professional. Patients reported acquiring removable cast walkers from hospitals, clinics, medical supply stores, and even from family members. One of the main reported benefits of removable cast walkers compared to total contact casting was that removable cast walkers did not require weekly appointments to check ulcer status and reapply. Patients appreciated this difference.

Although removable cast walkers were easy to obtain, a number of patients mentioned challenges in using them consistently. Some models contain air bags, which can have mechanical malfunctions. Patients also reported issues with the straps that held the walker in place.

“It was easy enough to work. There were two sides to it, and one side you’d push the little pump, and then the other side, push the little pump. I didn’t know how tight I was supposed to make it. ... I tried to make it feel like it did when I left the clinic. They’re not the toughest of plastic bags, so one of them would constantly deflate—I forget which side.”

“It was relatively easy, when you do fill in the air bags. Trying to make sure that your foot doesn’t move around too much—that was a trickier part about how much pressure to put in. And it would never stay constant. You’d always have to adjust it throughout the day.”

*“And I’ve been trying to ask the chiroprapist to explain ... how should I use the air bags?
The one I have right now has two. The previous one had three, and I’m not too sure what
support I’m supposed to be using during the day. And it does break.”*

Several patients also reported that, as a symptom of their diabetes, they had neuropathy in their extremities. This led to a loss of sensation in both the lower legs and in the fingers. This loss of sensation caused difficulties when patients applied or removed the removable cast walkers, and could cause problems if their device contained air bags that required inflating. Patients were often unsure about the degree to which the air bags should be inflated.

*“...[the removable cast walker] was very difficult for somebody like me with low vision and
not too much feeling in my fingers ... That would have been very difficult for me to use.”*

Effectiveness

Patients reported familiarity with the healing benefit of removable cast walkers. Most patients spoke about the need to remove pressure from the ulcer to promote healing. The removable cast walkers allowed patients to maintain their mobility while at the same time immobilizing the ankle and foot and removing pressure from the ulcer.

*“So the foot cast is really just to make sure that the skin continues to strengthen before
you add any movement ... Even in a shoe or an orthotic, there is still going to be some
shearing or other kinds of movement and friction on that corner of the foot.”*

However, patients reported less satisfaction with ulcer healing when using a removable cast walker. Time frames to complete healing were longer, and frustration was a common sentiment expressed by the patients interviewed.

*“Yeah, the past 2 weeks I’ve been in the air boot, and it doesn’t seem like it’s helped at
all. I was in the cast for 3 weeks, and the ulcer was closing. Then I went to the air cast,
and in 1 week the hole had reopened to three times the size it was the week before.”*

Many patients who reported slower healing with removable cast walkers did not know why this was the case, but several reported that the devices did not adequately immobilize their foot, allowing for small movements that irritated the ulcer and perhaps prevented healing.

“... the air cast doesn’t heal as fast. I don’t know why, but it doesn’t heal as fast.”

*“I’ll be perfectly blunt; it was a waste of time for me. The problem was (a) because of my
diabetes and (b) because of my kidney transplant and the rejection drugs I was on.
Healing was a definite problem for me and ... the air cast did not keep my heel
immobilized.”*

Comfort and Mobility

Patients perceived removable cast walkers to have a moderate effect on their mobility. Removable cast walkers are designed to allow mobility while removing pressure from the ulcer, but patients reported that they could still be bulky and awkward to wear, leading to decreased activity levels and more challenges to participating in daily events. Because of the inconvenience, several patients reported having to remind themselves of the ultimate benefit of wearing such a device: a healed ulcer.

"I had to buy an offloading boot, which wasn't very easy to walk with. It altered my stance, and I ended up getting hip problems. And it was bulky, and it wasn't very easy to get around at all."

Given the bulk of the removable cast walker, patients reported great satisfaction and appreciation for being able to remove it when they needed to. Common points at which patients removed the device were for sleeping and taking a shower.

"The air cast is walkable; you can walk with it. You can't really run with it, and people give you a lot of room at the grocery store when they see you coming down the aisle. To be able to take it off at night ... it gives you so much more freedom than the other cast, but it doesn't really immobilize your foot in the same way."

"That is one of the major, major benefits to me of that air cast was to not have to wear it to bed."

"The air cast I wore for quite some time, and I was so thankful to be able to take it off at night and, if I had an itch in my leg to be able to put some cream on it or something or give it a little scratch or whatever. So it is, in terms of mobility and living your life, a lot better."

Cost and Access

Patients reported a range of costs for removable cast walkers, depending on the type and model. Typical costs ranged from \$100 to \$260, but patients generally had to buy only one device. Most patients reported that the cost of a removable cast walker was less burdensome than that of total contact casting, although they were sympathetic to those on fixed incomes, for whom even this lower cost could be an untenable. Patients also reported that it was much simpler to have a removable cast walker covered by insurance, unlike total contact casting.

"Yeah, you had to pay for it. It was \$100-ish. It's much easier ... it was no trouble getting that covered by my insurance."

However, several patients who had more chronic foot ulcers reported that they had been forced to use several removable cast walkers over time, and that the cost became more burdensome. For this reason, better healing could become a financial reason to switch to total contact casting.

"So the thing is that even at my salary, sometimes it becomes an issue because [for] the air cast not the total contact cast, because I've used it so much I've had to replace it, and ... my insurance carrier will pay for an air cast once. So I've already had mine, so the next time I had to cough up the \$160. Not that bad for me, but it could be an issue for others. So I can see why it would be financially easier just to go on the total contact cast, because it went so much quicker to heal than wearing an air cast."

Irremovable Cast Walkers

We asked all patients about a range of offloading devices. While every patient was able to comment on several devices, including total contact casting and removable cast walkers, no one could provide first-hand experience with irremovable cast walkers. No patients had heard of them or seen them applied. When we described the device and its application, patients expressed skepticism and confusion about its benefits and purpose. Patients were unsure about who would be the target for such a device. In particular, several pointed to the overwhelming benefit of removable cast walkers—the ability to remove them while sleeping:

"I could see it maybe in a youngster, who would not really understand the reason, the importance, of keeping it on a lot. Maybe they do that, but ... I wouldn't like to have had to wear that air cast in my bed. I would rather have had a total contact cast to sleep in than that air cast, because the boot is just so big and bulky."

Summary

When asked to compare total contact casting and removable cast walkers, patients spoke most often about faster healing with total contact casting. The burden in terms of cost and time commitment could be higher for total contact casting, but patients said it was bearable if the ulcer healed more quickly. Several patients reported great surprise and relief at the speed of healing with total contact casting after several years of using removable cast walkers; they felt that casting improved their quality of life and allowed them to resume their regular routines. In terms of comfort and mobility, patients often rated removable cast walkers more highly than total contact casting, mainly because it was convenient to be able to remove the walker at night or in the shower. Ultimately, however, patients valued a device's effectiveness at healing the ulcer, preferring total contact casting.

"I really had to choose. I want my foot to be better, and that's the way it has to be. So if that's the way it is, if walking in this air cast is not going to allow my foot to heal and I have to go back to [total contact casting], well, I absolutely will do that, but you have to want to be better for sure to have that big cast on."

"Well, the contact cast is a hassle. You can't shower, and it's an awkward walking position, because your foot's elevated on that rubber heel striker they attach to the bottom. The air cast is removable, which is more comfortable in bed, and you can shower with it. So from a comfort standpoint, the air cast is preferable."

"Whatever works the best, whatever is going to be most successful for the care of my feet, is what I'm interested in. So that's why when she said total casting, I said, okay, I'm in. Whatever you think works the best is what I'm in for ... I mean, don't get me wrong, I'm happy to be working with the boot at the moment. ... And they did give me a choice whether I wanted it or not, but if the boot's not working, I'll be back into the cast without hesitation."

Discussion

We interviewed a large number of patients about their experiences with diabetic foot ulcers and different offloading devices. Patients represented different areas of the province and reported different levels of ulcer severity. Despite these differences, however, all patients clearly reported that they and their families faced many challenges in dealing with their ulcers and their overall disease burden. All patients described the physical toll of dealing with ulcers: reductions in social life and physical activity were mentioned most often. Patients also spoke about the emotional burden of dealing with their ulcers, including the weight of constant vigilance and the dread of waiting for the next wound to occur. These emotional reflections were consistent across interviews.

Patients saw the pursuit of a variety of therapies and treatments as necessary to avoid the frightening possibility of amputation, or to prevent further amputations. The goal of all treatments was the same: to reduce the size of a foot ulcer, have it heal over, and prevent its recurrence. The wide variety of wound care options and offloading devices allowed patients to seek a balance between convenience, cost, and efficacy, but all patients were willing to deal with the inconvenience and physical burden of an offloading device, as long as it could heal their ulcers.

A particular strength of our findings was that all patients were familiar with more than one type of offloading device. Patients could speak directly to their experiences with total contact casting and removable cast walkers, and a large number had experience with other devices, such as therapeutic shoes, felt pads, and crutches. This patient expertise allowed for informed direct comparisons between different off-loading devices.

Conclusions

There is a significant daily burden of care and emotional weight associated with diabetic foot ulcers. The worrisome possibility of amputation leads patients to monitor their feet carefully and seek out effective means of treatment and healing. The wide variety of wound care treatments and offloading devices gives patients many opportunities to find an effective and convenient treatment option. Patients with diabetic foot ulcers reported a preference for total contact casting over removable cast walkers, largely because they perceived healing to be faster with total contact casting. However, cost, comfort, and convenience are concerns for patients. Patients reported no experience or familiarity with irremovable cast walkers.

CONCLUSIONS

The clinical evidence suggests that fibreglass total contact casting, removable cast walkers, and irremovable cast walkers are beneficial in the treatment of neuropathic, noninfected foot ulcers in patients with diabetes but without severe peripheral arterial disease. Compared to removable cast walkers, ulcer healing was improved with total contact casting (moderate quality evidence; risk difference 0.17 [95% confidence interval: 0.00–0.33]) and irremovable cast walkers (low quality evidence; risk difference 0.21 [95% confidence interval 0.01–0.40]). Irremovable cast walkers were as effective as total contact casting for treating diabetic foot ulcers and were associated with fewer costs.

The device costs of publicly funding total contact casting, removable cast walkers, and irremovable cast walkers in patients with diabetic foot ulcers would be \$17 million to \$20 million per year over the next 5 years. However, increased access to offloading devices could result in cost savings for the health system because of fewer amputations.

Patients with diabetic foot ulcers reported a preference for total contact casting over removable cast walkers, largely because they felt their wounds healed more quickly with total contact casting. However, cost, comfort, and the convenience of total contact casting were concerns for patients.

ABBREVIATIONS

CI	Confidence interval
GRADE	Grading of Recommendations Assessment, Development, and Evaluation
ICER	Incremental cost-effectiveness ratio
PRISMA	Preferred Reporting Items for Systematic Reviews and Meta-analyses
QALY	Quality-adjusted life-year
SD	Standard deviation

GLOSSARY

Cost–utility analysis	A type of analysis that estimates the value for money of an intervention by weighing the cost of the intervention against the improvements in length of life and quality of life. The result is expressed as a dollar amount per “quality-adjusted life-year” or QALY.
Diabetic neuropathy	Diabetic neuropathy is a type of nerve damage that can occur in people with diabetes. Nerves throughout the body can become injured, but diabetic neuropathy most often damages nerves in the legs and feet.
Incremental cost-effectiveness ratio (ICER)	Determines “a unit of benefit” for an intervention by dividing the incremental cost by the effectiveness. The incremental cost is the difference between the cost of the treatment under study and an alternative treatment. The effectiveness is usually measured as additional years of life or as “quality-adjusted life years.”
Intent-to-treat analysis	An approach to study analysis in which the results of individual participants assume they followed the treatment of their assigned study group, without regard to whether they followed instructions, changed treatment, or even finished the study. The purpose is to mimic world application, in which many people using the drug or treatment will not perfectly follow the recommended course.
Offloading	Shifting weight from sensitive or injured parts of the feet using orthotics, specialized shoes or casts.
Quality-adjusted life-year (QALY)	A measurement that takes into account both the number of years gained by a patient from a procedure and the quality of those extra years (ability to function, freedom from pain, etc.). The QALY is commonly used as an outcome measure in cost–utility analyses.
Randomized controlled trial	A type of study in which subjects are assigned randomly into different groups, with one group receiving the treatment under study and the other group(s) receiving a different treatment or a placebo (no treatment) in order to determine the effectiveness of one approach compared with the other.

APPENDICES

Appendix 1: Literature Search Strategies

Clinical Evidence Search

Search date: Aug 17, 2016

Librarians: Corinne Holubowich and Melissa Walter

Databases searched: All Ovid MEDLINE, Embase, Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects, CRD Health Technology Assessment Database, Cochrane Central Register of Controlled Trials, NHS Economic Evaluation Database, and CINAHL

Database: EBM Reviews - Cochrane Central Register of Controlled Trials <July 2016>, EBM Reviews - Cochrane Database of Systematic Reviews <2005 to August 10, 2016>, EBM Reviews - Database of Abstracts of Reviews of Effects <1st Quarter 2016>, EBM Reviews - Health Technology Assessment <3rd Quarter 2016>, EBM Reviews - NHS Economic Evaluation Database <1st Quarter 2016>, Embase <1980 to 2016 Week 33>, Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) <1946 to Present>

Search Strategy:

-
- 1 Diabetic Foot/ (18301)
 - 2 Foot Ulcer/ (6031)
 - 3 Diabetic Neuropathies/ (25269)
 - 4 ((diabet* adj4 (foot or feet or ulcer* or toe or toes or plantar* or neuropath* or neural* or wound*)) or DFU or (ulcer* adj2 (foot or feet)) or (plantar adj2 (ulcer* or neuropath*))).tw. (54615)
 - 5 or/1-4 (72522)
 - 6 Foot Diseases/ (18889)
 - 7 Foot Dermatoses/ (55427)
 - 8 Foot Injuries/ (7026)
 - 9 Wound Healing/ (177675)
 - 10 (skin ulcer* or ((foot or feet) adj2 (disease* or injur* or wound*)) or (wound* adj2 heal*)).tw. (124866)
 - 11 or/6-10 (312475)
 - 12 exp Diabetes Mellitus/ (1092969)
 - 13 exp Diabetes Complications/ (837363)
 - 14 (diabet* or MODY or IDDM or NIDDM).tw. (1230603)
 - 15 or/12-14 (1443106)
 - 16 11 and 15 (20659)
 - 17 5 or 16 (80634)
 - 18 Casts, Surgical/ (16787)
 - 19 walkers/ (1033)
 - 20 (cast or casts or casting* or total contact or TCC).tw. (99262)
 - 21 (ITCC or walking boot* or aircast* or stabil d or stabil d or optima diab or removable boot*).tw. (552)
 - 22 (walker or walkers).ti,ab. (21428)
 - 23 ((offloading or off loading) adj2 (device* or technique* or intervention*)).tw. (208)
 - 24 (offloading or off loading).ti. (307)

25 or/18-24 (131605)
26 17 and 25 (1224)
27 Meta-Analysis/ or Meta-Analysis as Topic/ or exp Technology Assessment, Biomedical/
(234270)
28 Meta Analysis.pt. (73021)
29 (((systematic* or methodologic*) adj3 (review* or overview*)) or pooled analysis or
published studies or published literature or hand search* or handsearch* or medline or pubmed
or embase or cochrane or cinahl or data syntheses* or data extraction* or HTA or HTAs or
(technolog* adj (assessment* or overview* or appraisal*))).tw. (559201)
30 (meta analy* or metaanaly* or health technolog* assess*).mp. (365248)
31 Clinical Trials as Topic/ or Randomized Controlled Trials as Topic/ (402170)
32 (randomized controlled trial or controlled clinical trial).pt. (994669)
33 trial.ti. (531193)
34 (randomi#ed or randomly or RCT\$1 or placebo* or sham).tw. (2424063)
35 or/27-34 (3608007)
36 26 and 35 (255)
37 36 use ppez (86)
38 26 use cctr,coch,dare,clhta,cleed (101)
39 or/37-38 (187)
40 exp Animals/ not (exp Animals/ and Humans/) (13633757)
41 39 not 40 (187)
42 limit 41 to english language [Limit not valid in CDSR,DARE; records were retained] (168)
43 diabetic foot/ (18301)
44 foot ulcer/ (6031)
45 diabetic neuropathy/ (33520)
46 ((diabet* adj4 (foot or feet or ulcer* or toe or toes or plantar* or neuropath* or neural* or
wound*)) or DFU or (ulcer* adj2 (foot or feet)) or (plantar adj2 (ulcer* or neuropath*))).tw.
(54615)
47 or/43-46 (75899)
48 foot disease/ (21606)
49 skin disease/ (122151)
50 foot injury/ (7831)
51 wound healing/ (177675)
52 (skin ulcer* or ((foot or feet) adj2 (disease* or injur* or wound*)) or (wound* adj2 heal*)).tw.
(124866)
53 or/48-52 (380916)
54 exp diabetes mellitus/ (1092969)
55 (diabet* or MODY or IDDM or NIDDM).tw. (1230603)
56 or/54-55 (1443106)
57 53 and 56 (22660)
58 47 or 57 (85694)
59 exp orthopedic cast/ (8144)
60 cast application/ (2063)
61 walker/ (1032)
62 walking aid/ (4024)
63 plaster walking cast/ (12)
64 (cast or casts or casting* or total contact or TCC).tw. (99262)
65 (ITCC or walking boot* or aircast* or stabil d or stabilid or optima diab or removable
boot*).tw. (552)
66 (walker or walkers).ti,ab. (21428)
67 ((offloading or off loading) adj2 (device* or technique* or intervention*)).tw. (208)

68 (offloading or off loading).ti. (307)
69 or/59-68 (130904)
70 58 and 69 (1264)
71 Meta Analysis/ or "Meta Analysis (Topic)"/ or Biomedical Technology Assessment/
(231708)
72 (((systematic* or methodologic*) adj3 (review* or overview*)) or pooled analysis or
published studies or published literature or hand search* or handsearch* or medline or pubmed
or embase or cochrane or cinahl or data syntheses* or data extraction* or HTA or HTAs or
(technolog* adj (assessment* or overview* or appraisal*))).tw. (559201)
73 (meta analy* or metaanaly* or health technolog* assess*).mp. (365248)
74 exp "controlled clinical trial (topic)"/ (109878)
75 randomized controlled trial/ or controlled clinical trial/ (1071158)
76 trial.ti. (531193)
77 (randomi#ed or randomly or RCT\$1 or placebo* or sham).tw. (2424063)
78 or/71-77 (3493022)
79 70 and 78 (260)
80 (exp animal/ or nonhuman/) not exp human/ (9869733)
81 79 not 80 (260)
82 limit 81 to english language [Limit not valid in CDSR,DARE; records were retained] (245)
83 82 use emez (102)
84 42 or 83 (270)
85 84 use ppez (82)
86 84 use emez (102)
87 84 use cctr (48)
88 84 use coch (20)
89 84 use clhta (4)
90 84 use cleed (6)
91 84 use dare (8)
92 remove duplicates from 84 (174)

CINAHL

#	Query	Results
S1	(MH "Diabetic Foot")	6,111
S2	(MH "Foot Ulcer")	1,001
S3	(MH "Diabetic Neuropathies")	3,943
S4	((diabet* N4 (foot or feet or ulcer* or toe or toes or plantar* or neuropath* or neural* or wound*)) or DFU or (ulcer* N2 (foot or feet)) or (plantar N2 (ulcer* or neuropath*)))	12,214
S5	S1 OR S2 OR S3 OR S4	12,214
S6	(MH "Foot Diseases")	1,758
S7	(MH "Foot Injuries")	1,235
S8	(MH "Wound Healing")	15,282
S9	(skin ulcer* or ((foot or feet) N2 (disease* or injur* or wound*)) or (wound* N2 heal*))	24,056

S10	S6 OR S7 OR S8 OR S9	24,056
S11	(MH "Diabetes Mellitus+")	110,223
S12	(diabet* or MODY or IDDM or NIDDM)	146,106
S13	S11 OR S12	146,710
S14	S10 AND S13	3,009
S15	S5 OR S14	12,777
S16	(MH "Casts")	1,192
S17	(MH "Cast Application")	204
S18	(MH "Walkers")	316
S19	(cast or casts or casting* or total contact or TCC)	6,055
S20	(ITCC or walking boot* or aircast* or stabil d or stabild or optima diab or removable boot*)	102
S21	(walker or walkers)	2,091
S22	((offloading or off loading) N2 (device* or technique* or intervention*))	56
S23	(TI offloading or off loading)	267
S24	S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23	8,324
S25	S15 AND S24	418
S26	(MH "Meta Analysis")	24,989
S27	(PT "Meta Analysis") or (PT "Systematic Review")	57,007
S28	((systematic* or methodologic*) N3 (review* or overview*)) or pooled analysis or published studies or published literature or hand search* or handsearch* or medline or pubmed or embase or cochrane or cinahl or data synthes* or data extraction* or HTA or HTAs or (technolog* N1 (assessment* or overview* or appraisal*))	109,742
S29	(PT "randomized controlled trial")	56,679
S30	TI trial	63,043
S31	(randomi?ed or randomly or RCT or RCTs or placebo* or sham)	186,792
S32	S26 OR S27 OR S28 OR S29 OR S30 OR S31	303,016
S33	S25 AND S32	48
S34	(MH "Animals+") not (MH "Animals+" and MH "Human")	61,724
S35	S33 NOT S34	48
S36	S33 NOT S34 Limiters - English Language	48

Grey Literature

Performed on:
August 17, 2016

Websites searched:

HTA Database Canadian Repository, Alberta Health Technologies Decision Process reviews, Canadian Agency for Drugs and Technologies in Health (CADTH), Institut national d'excellence en santé et en services sociaux (INESSS), Institute of Health Economics (IHE), McGill University Health Centre Health Technology Assessment Unit, National Institute for Health and Care Excellence (NICE), Agency for Healthcare Research and Quality (AHRQ) Evidence-based Practice Centers, Australian Government Medical Services Advisory Committee, Blue Cross Blue Shield Center for Clinical Effectiveness, Centers for Medicare & Medicaid Services Technology Assessments, Institute for Clinical and Economic Review, Ireland Health Information and Quality Authority Health Technology Assessments, Washington State Health Care Authority Health Technology Reviews

Keywords used:

Cast, casts, casting, walker, walkers, walking boot, walking cast, offloading, off loading, diabetic foot, foot ulcer

Results: 11

Economic Evidence Search

Databases searched: All Ovid MEDLINE, Embase, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects (DARE), Centre for Reviews and Dissemination (CRD) Health Technology Assessment Database, National Health Service (NHS) Economic Evaluation Database and Cumulative Index to Nursing and Allied Health Literature (CINAHL)

Database: EBM Reviews - Cochrane Central Register of Controlled Trials <July 2016>, EBM Reviews - Cochrane Database of Systematic Reviews <2005 to August 17, 2016>, EBM Reviews - Database of Abstracts of Reviews of Effects <1st Quarter 2016>, EBM Reviews - Health Technology Assessment <3rd Quarter 2016>, EBM Reviews - NHS Economic Evaluation Database <1st Quarter 2016>, Embase <1980 to 2016 Week 33>, Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) <1946 to Present>

Search Strategy:

-
- 1 Diabetic Foot/ (18302)
 - 2 Foot Ulcer/ (6031)
 - 3 Diabetic Neuropathies/ (25271)
 - 4 ((diabet* adj4 (foot or feet or ulcer* or toe or toes or plantar* or neuropath* or neural* or wound*)) or DFU or (ulcer* adj2 (foot or feet)) or (plantar adj2 (ulcer* or neuropath*))).tw. (54599)
 - 5 or/1-4 (72507)
 - 6 Foot Diseases/ (18889)
 - 7 Foot Dermatoses/ (55427)

- 8 Foot Injuries/ (7026)
- 9 Wound Healing/ (177695)
- 10 (skin ulcer* or ((foot or feet) adj2 (disease* or injur* or wound*)) or (wound* adj2 heal*)).tw. (124819)
- 11 or/6-10 (312440)
- 12 exp Diabetes Mellitus/ (1093007)
- 13 exp Diabetes Complications/ (837372)
- 14 (diabet* or MODY or IDDM or NIDDM).tw. (1230257)
- 15 or/12-14 (1442766)
- 16 11 and 15 (20656)
- 17 5 or 16 (80619)
- 18 Casts, Surgical/ (16787)
- 19 walkers/ (1033)
- 20 (cast or casts or casting* or total contact or TCC).tw. (99245)
- 21 (ITCC or walking boot* or aircast* or stabil d or stabil d or optima diab or removable boot*).tw. (552)
- 22 (walker or walkers).ti,ab. (21423)
- 23 ((offloading or off loading) adj2 (device* or technique* or intervention*)).tw. (208)
- 24 (offloading or off loading).ti. (307)
- 25 or/18-24 (131583)
- 26 17 and 25 (1223)
- 27 economics/ (252483)
- 28 economics, medical/ or economics, pharmaceutical/ or exp economics, hospital/ or economics, nursing/ or economics, dental/ (739307)
- 29 economics.fs. (384296)
- 30 (econom* or price or prices or pricing or priced or discount* or expenditure* or budget* or pharmacoeconomic* or pharmaco-economic*).tw. (699927)
- 31 exp "costs and cost analysis"/ (514073)
- 32 cost*.ti. (237954)
- 33 cost effective*.tw. (254559)
- 34 (cost* adj2 (util* or efficacy* or benefit* or minimi* or analy* or saving* or estimate* or allocation or control or sharing or instrument* or technolog*)).ab. (159339)
- 35 models, economic/ (136091)
- 36 markov chains/ or monte carlo method/ (120825)
- 37 (decision adj1 (tree* or analy* or model*)).tw. (34361)
- 38 (markov or markow or monte carlo).tw. (102870)
- 39 quality-adjusted life years/ (26928)
- 40 (QOLY or QOLYs or HRQOL or HRQOLs or QALY or QALYs or QALE or QALEs).tw. (52135)
- 41 ((adjusted adj (quality or life)) or (willing* adj2 pay) or sensitivity analys*s).tw. (100499)
- 42 or/27-41 (2310792)
- 43 26 and 42 (118)
- 44 43 use ppez,cctr,coch,dare,clhta (61)
- 45 26 use cleed (6)
- 46 or/44-45 (67)
- 47 limit 46 to english language [Limit not valid in CDSR,DARE; records were retained] (67)
- 48 diabetic foot/ (18302)
- 49 foot ulcer/ (6031)
- 50 diabetic neuropathy/ (33522)

- 51 ((diabet* adj4 (foot or feet or ulcer* or toe or toes or plantar* or neuropath* or neural* or wound*)) or DFU or (ulcer* adj2 (foot or feet)) or (plantar adj2 (ulcer* or neuropath*))).tw. (54599)
- 52 or/48-51 (75884)
- 53 foot disease/ (21606)
- 54 skin disease/ (122163)
- 55 foot injury/ (7831)
- 56 wound healing/ (177695)
- 57 (skin ulcer* or ((foot or feet) adj2 (disease* or injur* or wound*)) or (wound* adj2 heal*)).tw. (124819)
- 58 or/53-57 (380891)
- 59 exp diabetes mellitus/ (1093007)
- 60 (diabet* or MODY or IDDM or NIDDM).tw. (1230257)
- 61 or/59-60 (1442766)
- 62 58 and 61 (22657)
- 63 52 or 62 (85679)
- 64 exp orthopedic cast/ (8144)
- 65 cast application/ (2063)
- 66 walker/ (1032)
- 67 walking aid/ (4024)
- 68 plaster walking cast/ (12)
- 69 (cast or casts or casting* or total contact or TCC).tw. (99245)
- 70 (ITCC or walking boot* or aircast* or stabil d or stabild or optima diab or removable boot*).tw. (552)
- 71 (walker or walkers).ti,ab. (21423)
- 72 ((offloading or off loading) adj2 (device* or technique* or intervention*)).tw. (208)
- 73 (offloading or off loading).ti. (307)
- 74 or/64-73 (130882)
- 75 63 and 74 (1263)
- 76 Economics/ (252483)
- 77 Health Economics/ or exp Pharmacoeconomics/ (215516)
- 78 Economic Aspect/ or exp Economic Evaluation/ (397215)
- 79 (econom* or price or prices or pricing or priced or discount* or expenditure* or budget* or pharmacoeconomic* or pharmaco-economic*).tw. (699927)
- 80 exp "Cost"/ (514073)
- 81 cost*.ti. (237954)
- 82 cost effective*.tw. (254559)
- 83 (cost* adj2 (util* or efficacy* or benefit* or minimi* or analy* or saving* or estimate* or allocation or control or sharing or instrument* or technolog*)).ab. (159339)
- 84 Monte Carlo Method/ (51291)
- 85 (decision adj1 (tree* or analy* or model*)).tw. (34361)
- 86 (markov or markow or monte carlo).tw. (102870)
- 87 Quality-Adjusted Life Years/ (26928)
- 88 (QOLY or QOLYs or HRQOL or HRQOLs or QALY or QALYs or QALE or QALEs).tw. (52135)
- 89 ((adjusted adj (quality or life)) or (willing* adj2 pay) or sensitivity analys*s).tw. (100499)
- 90 or/76-89 (1898969)
- 91 75 and 90 (126)
- 92 limit 91 to english language [Limit not valid in CDSR,DARE; records were retained] (122)
- 93 92 use emez (56)
- 94 47 or 93 (123)

- 95 94 use ppez (34)
- 96 94 use emez (56)
- 97 94 use cctr (4)
- 98 94 use coch (19)
- 99 94 use clhta (1)
- 100 94 use dare (3)
- 101 94 use cleed (6)
- 102 remove duplicates from 94 (99)

CINAHL

#	Query	Results
S1	(MH "Diabetic Foot")	6,111
S2	(MH "Foot Ulcer")	1,001
S3	(MH "Diabetic Neuropathies")	3,943
S4	((diabet* N4 (foot or feet or ulcer* or toe or toes or plantar* or neuropath* or neural* or wound*)) or DFU or (ulcer* N2 (foot or feet)) or (plantar N2 (ulcer* or neuropath*)))	12,215
S5	S1 OR S2 OR S3 OR S4	12,215
S6	(MH "Foot Diseases")	1,758
S7	(MH "Foot Injuries")	1,235
S8	(MH "Wound Healing")	15,285
S9	(skin ulcer* or ((foot or feet) N2 (disease* or injur* or wound*)) or (wound* N2 heal*))	24,063
S10	S6 OR S7 OR S8 OR S9	24,063
S11	(MH "Diabetes Mellitus+")	110,259
S12	(diabet* or MODY or IDDM or NIDDM)	146,132
S13	S11 OR S12	146,736
S14	S10 AND S13	3,009
S15	S5 OR S14	12,778
S16	(MH "Casts")	1,192
S17	(MH "Cast Application")	204
S18	(MH "Walkers")	316
S19	(cast or casts or casting* or total contact or TCC)	6,056
S20	(ITCC or walking boot* or aircast* or stabil d or stabild or optima diab or removable boot*)	102
S21	(walker or walkers)	2,091
S22	((offloading or off loading) N2 (device* or technique* or intervention*))	56

S23	(TI offloading or off loading)	268
S24	S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23	8,326
S25	S15 AND S24	419
S26	(MH "Economics")	10,750
S27	(MH "Economic Aspects of Illness")	6,396
S28	(MH "Economic Value of Life")	506
S29	MH "Economics, Dental"	103
S30	MH "Economics, Pharmaceutical"	1,724
S31	MW "ec"	137,776
S32	(econom* or price or prices or pricing or priced or discount* or expenditure* or budget* or pharmacoeconomic* or pharmaco-economic*)	203,794
S33	(MH "Costs and Cost Analysis+")	82,005
S34	TI cost*	37,815
S35	(cost effective*)	24,736
S36	AB (cost* N2 (util* or efficacy* or benefit* or minimi* or analy* or saving* or estimate* or allocation or control or sharing or instrument* or technolog*))	15,782
S37	(decision N1 (tree* or analy* or model*))	4,465
S38	(markov or markow or monte carlo)	2,473
S39	(MH "Quality-Adjusted Life Years")	2,434
S40	(QOLY or QOLYs or HRQOL or HRQOLs or QALY or QALYs or QALE or QALEs)	4,809
S41	((adjusted N1 (quality or life)) or (willing* N2 pay) or sensitivity analys?s)	9,526
S42	S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR S41	269,283
S43	S25 AND S42	32
S44	S25 AND S42 Limiters - English Language	32

Appendices

Appendix 2: Clinical Evidence Quality Assessment

Table A1: Risk of Bias Among Randomized Controlled Trials for the Comparison of Offloading Devices

Author, Year	Random Sequence Generation	Allocation Concealment	Blinding ^a	Complete Accounting of Patients and Outcome Events ^b	Selective Reporting Bias	Other Limitations
Najafi et al, 2016 ²⁹	Low risk	Low risk	Low risk ^c	Low risk	Low risk	Few baseline characteristics provided; no information on ulcer type; baseline ulcer area larger in the removable cast walker group than in irremovable cast walker group (unclear if clinically significant); complications reported, but not a prespecified outcome
Piaggese et al, 2016 ²⁷	Low risk	Low risk	Low risk ^d	Low risk	Low risk	—
Lavery et al, 2015 ¹⁶	Low risk	Low risk	Low risk ^d	Low risk	Low risk	Complications reported, but not a prespecified outcome
Gutekunst et al, 2011 ³²	Low risk	Low risk	Low risk ^c	Low risk	Low risk	Complications reported, but not a prespecified outcome
Faglia et al, 2010 ³³	Low risk	Low risk	Low risk ^c	Low risk	Low risk	Complications reported, but not a prespecified outcome
Van de Weg et al, 2008 ³⁴	Low risk	Low risk	Low risk ^d	Low risk	Low risk	Possible difference in glycated hemoglobin
Caravaggi et al, 2007 ³¹	Unclear	Unclear	Low risk ^c	Low risk	Low risk	Table with baseline characteristics not provided; complications reported, but not a prespecified outcome
Piaggese et al, 2007 ²⁸	Low risk	Low risk	Low risk ^c	Low risk	Low risk	—
Katz et al, 2005 ³⁵	Low risk	Unclear	Low risk ^c	Low risk	Low risk	—
Armstrong et al, 2005 ³⁶	Low risk	Low risk	Low risk ^c	Low risk	Low risk	Possible baseline differences between the groups: "Wound size was nearly greater in the irremovable cast walker group"; complications reported, but not a prespecified outcome
Armstrong et al, 2001 ³⁷	Low risk	Low risk	Low risk ^c	Low risk	Low risk	Complications reported, but not a prespecified outcome
Caravaggi et al, 2000 ³⁰	Low risk	Low risk	Low risk ^c	Low risk	Low risk	—
Mueller et al, 1989 ³⁸	Unclear	Unclear	Low risk ^c	Low risk	Low risk	—

^aBlinding was not possible in most studies, but we did not consider this to be a risk of bias.^bSome patients discontinued treatment for reasons that may have been related to at least one of the outcomes of interest, and the percentage of discontinuations may have differed between groups in some studies. However, since intention-to-treat analyses were performed, we did not consider this to be a risk of bias. The studies reported very few losses to follow-up.^cNo blinding of the outcome assessor. If the information in the study was not clear, we assumed that no blinding was done.^dBlinding of the outcome assessor.

Appendices

Appendix 3: Design and Characteristics of the Studies Identified

Table A2: Design and Characteristics of the Randomized Controlled Trials

Author, Year Country N (intervention/control) Funding Follow-up	Population	Methods	Intervention	Comparator	Other Treatment Procedures	Outcomes
Najafi et al, 2016 ²⁹ United States 49 (23/26) Qatar National Research Foundation 3 months or complete ulcer healing—whichever came first	Diabetes Noninfected, nonischemic foot ulcers, plantar neuropathic foot ulcers Age ≥18 years Excluded: peripheral arterial disease; major foot amputation; active Charcot arthropathy	Computer-generated randomization Sequentially numbered, opaque envelopes kept at the site Analyses: Chi-square or Fisher's exact test for proportions; Spearman correlation for the association between patient characteristics and outcomes	Removable cast walker (DH Offloading Walker) Patients instructed to cleanse wound daily and apply a dressing Instructions to inspect the wound with dressing change and how to detect signs of worsening Instructions not to walk without the device	Irremovable cast walker (DH Offloading Walker wrapped with a cohesive bandage) Wound care similar to intervention group, but weekly cast walker reapplication	Standard treatment: wound debridement, moisture-retentive dressings	Ulcer size reduction Percent healed ulcers Daily physical activity Largest ulcer used for outcome assessment if >1 ulcer present
Piaggese et al, 2016 ²⁷ Italy 65 (23/22/20) No funding support 3 months or complete ulcer healing—whichever came first	Diabetes type 1 or 2 >5 years' duration Forefoot plantar ulcers grades >1 cm ² Lasting >6 weeks Grades 1A or 2A ^a Peripheral neuropathy Excluded: peripheral arterial disease; osteomyelitis; contralateral ulcers; Charcot foot; lower limb edema; previous amputations in the affected or contralateral limb; metabolic decompensation; BMI >35 kg/m ²	Consecutive patients Computer-generated randomization Outcome assessor was blinded to treatment group Analyses: nonparametric t-tests for continuous variables; Kaplan-Meier test for survival data; chi-square, Fisher's exact tests for proportions	Fibreglass total contact casting (Softcast 3M and Scotchcast 3M) Padding over the ulcer	Irremovable cast walker (Optima Diab) using dedicated straps provided by manufacturer Removable cast walker (Optima Diab) Hole cut in the intermediate layer of the insole in the location of the ulcer to reduce pressure	Standard treatment for neuropathic ulcers Debridement Inert hydrofibre dressing Patient education on how to use devices Weekly reinforcement of the importance of adherence (wearing the removable cast walker at all times)	Ulcer survival ^b Time to healing Ulcer size reduction Percent healed ulcers Complications Patient satisfaction (VAS 0–10)

Author, Year Country N (intervention/control) Funding Follow-up	Population	Methods	Intervention	Comparator	Other Treatment Procedures	Outcomes
Lavery et al, 2015 ¹⁶ United States 73 (23/27/23) United States National Institutes of Health 3 months or complete ulcer healing—whichever came first	Diabetes Grades 1A or 2A forefoot plantar ulcers ^a Excluded: severe peripheral vascular disease; untreated osteomyelitis; Charcot arthropathy with severe residual deformity that would not permit the use of a walker boot	Computer-generated randomization Single-blinded Analyses: ITT and per-protocol analysis; chi-square test for proportions; multivariate ANOVA for continuous outcomes; power calculation not reported	Fibreglass total contact casting (personal communication with the author) Frequency of cast change NR	Shear cast walker (Glidesoft) Healing sandals (Sroufe Deluxe Chevron shoe with 8 mm Plastazote insole)	Debridement Hydrogel dressing Fine-mesh gauze for covering the wound Patients assessed every 7–10 days	Percent healed ulcers ^b Patient satisfaction (VAS 0–10) Patient activity level Complications Reasons for withdrawal Largest ulcer used for outcome assessment if >1 ulcer present
Gutekunst et al, 2011 ³² United States 23 (11/12) United States National Institutes of Health Follow-up NR	Diabetes Peripheral neuropathy ≥1 incident plantar foot ulcer (Grade 1–2) ^c Excluded: wound infection; lower-extremity ischemia or cellulitis	Computer-generated randomization Open-label Analyses: chi-square test for proportions; <i>t</i> -test for continuous variables; power calculation not performed because no difference was expected between groups	Total contact casting (plaster and fibreglass mix) Frequency of cast change NR	Removable cast walker	Antimicrobial sock Pressure-measuring insole in offloading device for both groups	Offloading capacity ^b Percent healed ulcers Time to ulcer healing

Author, Year Country N (intervention/control) Funding Follow-up	Population	Methods	Intervention	Comparator	Other Treatment Procedures	Outcomes
Faglia et al, 2010 ³³ Italy 45 (23/22) Contributions from the removable cast walker manufacturer 3 months	Neuropathic plantar forefoot ulcer Grade 1A ^a Excluded: peripheral neuropathy; clinical signs of infection; osteomyelitis; impaired balance; contralateral foot ulcers	Consecutive patients Randomization using sealed envelopes Open-label Analysis: Kaplan-Meier test/log-rank test for time to healing	Total contact casting (Softcast 3M and Scotchcast 3M) German cotton Tubular stockinet Protective layer of rubber foam to protect bony protrusions Stick made of Scotchcast bandage in the middle of the two malleoli, extending for 20 cm to provide rigidity Rigid plantar sole built with same material as stick Aluminum stirrup for walking Device removed and dressing changed weekly	Removable cast walker with rigid, boat-shaped, full rocker-bottom sole (Stabil D) Device removed and dressing changed weekly	Debridement Paraffin gauze dressing	Ulcer area reduction ^b Percent healed ulcers Time to ulcer healing
Van de Weg et al, 2008 ³⁴ Netherlands 43 (23/20) Partially funded by a manufacturer; unclear whether it was the manufacturer of any of the devices used in the study 4 months	Diabetes Plantar ulcers grades 1 or 2 ^c Peripheral neuropathy Excluded: peripheral arterial disease; osteomyelitis	Randomization using opaque sealed envelopes Ulcer measurement performed by blinded assessor (not easy to maintain) Time of ulcer healing, self-reported Analyses: ITT; type of analysis not provided for outcomes other than ulcer area reduction; power calculation based on ulcer area reduction	Total contact casting (unclear if fibreglass) Adhesive foam over bony prominences Cast shoes with polyphasic rocker Crutch/cane to maintain balance if poor posture stability Cast changed weekly	Custom-made temporary shoe Felt, rigid leather socket stiffened with Rhenoflex Education on the importance of adherence	Debridement Hypertrophic edges removed Dressing (Aquacell) application Antibiotic if necessary	Ulcer area reduction ^b Time to healing Percent healed ulcers Complications Reasons for withdrawal Largest ulcer used for outcome assessment if >1 ulcer present

Author, Year Country N (intervention/control) Funding Follow-up	Population	Methods	Intervention	Comparator	Other Treatment Procedures	Outcomes
Caravaggi et al, 2007 ³¹ Italy 58 (29/29) Funding information NR 3 months	Diabetes Neuropathic ulcer of the plantar surface Included ulcers correlated with Charcot neuroarthropathy deformities Excluded: superficial tissue infections; osteomyelitis; TcPO ₂ >30 mm Hg; peripheral arterial disease; severe visual deficit; amputation of contralateral limb	Consecutive patients Randomization procedure not reported Analyses: Kaplan-Meier to estimate time to healing and healing rate; Fisher's exact test for proportion of ulcer healing; power calculation not reported	Fibreglass total contact cast (Softcast 3M and Scotchcast 3M) Included rubber heel for walking for forefoot ulcers Walking stirrup for midfoot ulcers Frequency of cast changes not provided Before casting: German cotton application, especially over bony protrusions; stockinet on lower limb	Removable cast walker (Aircast Pneumatic Walker, XP Diabetic Walker) Reminder to adhere to treatment at every visit	Surgical debridement every 12 days Dressing: mesh of hyaluronic acid covered with polyurethane foam	Ulcer surface area reduction Time to healing Percent healed ulcers Reasons for withdrawal
Piaggese et al, 2007 ²⁸ Italy 40 (20/20) Contributions from the removable cast walker manufacturer 3 months or ulcer closure—whichever came first	Diabetes (type 1 or 2) >5 years Peripheral neuropathy Forefoot plantar ulcer >3 weeks Grade 1A or 2A, ^a area >1 cm ² Excluded: peripheral vascular disease; infection, edema; osteomyelitis; Charcot neuroarthropathy	All patients attending the foot clinic were screened for eligibility Computer-generated randomization Analyses: ITT analysis; Student's <i>t</i> -test and Kaplan-Meier for survival data; chi-square tests for proportions	Fibreglass total contact casting (Softcast 3M and Scotchcast 3M) Layer of isolating foam over ulcer Layer of cotton wool 1–2 rubber heels for walking Changed every week	Cast walker (Optima Diab) rendered irremovable by using a plastic nonremovable lace Layer of cotton wool 3-layer insoles Changed every week Patient education on how to use device	Standard treatment for neuropathic ulcers Surgical debridement Paraffin gauze dressing, then covered with sterile gauze Patient education on how to use device	Percent healed ulcers ^b Mean healing time Complications Patient satisfaction (VAS 0–10) Length of procedure Cost of treatment (materials)

Author, Year Country N (intervention/control) Funding Follow-up	Population	Methods	Intervention	Comparator	Other Treatment Procedures	Outcomes
Katz et al, 2005 ³⁵ United States 41 (20/21) Contributions from the walker manufacturer 3 months or ulcer healing—whichever came first	Diabetes Chronic (≥ 7 days with surrounding area of callus), noninfected, nonischemic stage 1A or 2A ^a ulcers Peripheral neuropathy Excluded: Charcot arthropathy	Consecutive patients Randomization using a random number table Analyses: log-rank test for survival data; t-test for dichotomous variables; 95% power for 5% difference in primary outcome; 35% power for 25% in complication rates	Total contact casting (unclear if fibreglass) Device replaced every week	Irremovable cast walker (removable cast walker [Royce Medical] wrapped in fibreglass casting material) Device replaced every week	Debridement as needed Dressing application Weekly follow-up	Percent healed ulcers ^b Time to healing Complications Time to place and remove devices Cost
Armstrong et al, 2005 ³⁶ United States 50 (25/25) United States Department of Veteran Affairs 3 months or ulcer healing—whichever came first	Diabetes Peripheral neuropathy Forefoot plantar ulcer Grade 1A ulcer ^a Lack of severe peripheral vascular disease Lack of active infection	Computer-generated randomization Analyses: Kaplan-Meier life table analysis (log-rank test); chi-square test for dichotomous variables; power calculation provided	Irremovable cast walker: removable walker (Active Offloading Walker; Royce Medical) wrapped entirely in a cohesive bandage	Removable cast walker (Active Offloading Walker; Royce Medical)	Surgical debridement as needed Weekly follow-up for device inspection, wound care, and debridement Patients instructed to wear their devices during ambulation	Percent healed ulcers Time to healing Largest ulcer used for outcome assessment if >1 ulcer present
Armstrong et al, 2001 ³⁷ United States 63 (19/20/24) United States Department of Veterans Affairs 3 months or ulcer healing—whichever came first	Neuropathic diabetic plantar foot ulcer Noninfected, Grade 1A ^a At least one palpable foot pulse or TcPO ₂ >40 mm Hg at dorsum of forefoot Excluded: inability to walk without wheelchair assistance; wounds on the heel, rear foot, or nonplantar; severe peripheral vascular disease	Computerized randomization schedule Analyses: ANOVA with correction for multiple comparisons for continuous variables; chi-square test for dichotomous variables; Kaplan-Meier with log-rank test for survival outcomes	Total contact casting (fibreglass and plaster) Casting change frequency NR (weekly wound inspection)	Removable cast walker (Aircast) Half-shoe (Darco, WV)	Wound care and debridement Surgical debridement if needed Weekly visits	Percent healed ulcers ^b Time to healing Reasons for withdrawal Activity level ^b Quality of life (SF-36) in separate publication ³⁹ Largest ulcer used for outcome assessment if >1 ulcer present

Author, Year Country N (intervention/control) Funding Follow-up	Population	Methods	Intervention	Comparator	Other Treatment Procedures	Outcomes
Caravaggi et al, 2000 ³⁰ Italy 50 (26/24) Funding information not available 30 days	Diabetes Peripheral neuropathy Plantar ulcers Excluded: deep or superficial tissue infections; osteomyelitis; peripheral arterial disease; severe balance problems; severe visual deficit; other foot skin lesions; plantar bilateral ulcers; amputation of a limb	Consecutive patients Centralized randomization Analyses: chi-square test for dichotomous variables; <i>t</i> -test for continuous variables; power calculation based on healing rate outcome	Fibreglass total contact cast (Softcast 3M and Scotchcast 3M) Stick made of Scotchcast 3M in the middle of the two malleoli extending for 20 cm to provide rigidity Rigid plantar insole built of same material as stick Aluminum stirrup or rubber heel, depending on position of the ulcer, to allow walking Elevation of the opposite foot to ease walking, patient training Before casting: German cotton especially over bony protrusions; stockinet on lower limb	Therapeutic shoes with rocker-bottom sole Plastazote insole with an area of offloading Unaffected foot received the same shoe without the offloading area Dressing changes every 2 days	Surgical debridement if necessary Paraffin gauze dressing	Ulcer healing rate ^b Percent healed ulcers Patient acceptance (VAS 1–100) Complications

Author, Year Country N (intervention/control) Funding Follow-up	Population	Methods	Intervention	Comparator	Other Treatment Procedures	Outcomes
Mueller et al, 1989 ³⁸ United States 40 (21/19) Funded by the Foundation for Physical Therapy Unclear (approximately 90 days based on ranges for ulcer healing)	Diabetes Peripheral neuropathy Plantar ulcers Grade 1–2 ^d No gross infection Excluded: osteomyelitis; gangrene	Tested the hypothesis of no difference in ulcers healed or time to healing between groups No details about randomization procedure Analysis: chi-square test for dichotomous variables	Total contact cast (plaster [inner layer] and fibreglass) Inner layer: plaster shell reinforced by plaster splints Outer layer: fibreglass for durability and to allow weight bearing sooner Walking heel attached Assistive devices (walkers, crutches) provided if needed First cast change 5–7 days after initial application; if no complications, changes every 2–3 weeks	Traditional dressing treatment Healing sandal, extra- depth shoe with Plastazote insert Dressing change 2–3 times daily; nurse home visit for dressing change if needed Follow-up every 2–4 weeks	—	Percent healed ulcers Time to healing Complications

Abbreviations: ANOVA, analysis of variance; BMI, body mass index; ITT, intention-to-treat; NR, not reported; SF-36, Short-Form 36-item health survey; TcPO₂, transcutaneous oxygen; VAS, visual analogue scale.

^aUniversity of Texas Classification of Diabetic Wounds.⁴¹

^bPrimary outcome.

^cWagner Foot Ulcer Grading System.⁶⁴

Appendix 4: Outcome Definitions and Wound Classification System

Table A3: Definitions Used in the Studies Identified

Author, Year	Peripheral Neuropathy	Peripheral Arterial Disease	Ulcer Healing
Najafi et al, 2016 ²⁹	Not provided	Ankle-brachial index ≤ 0.5	Not provided
Piaggese et al, 2016 ²⁷	Not provided	Ankle-brachial pressure index < 0.90 Absence of 2 palpable pulses in affected foot	Not provided
Lavery et al, 2015 ¹⁶	Pressure sensation evaluated at 10 points on each foot using 10 g monofilaments	Ankle-brachial pressure index < 0.60 or TcPO ₂ < 25 mm/Hg	<i>Healed ulcer</i> : complete re-epithelialization with no drainage <i>Unhealed ulcer</i> : not meeting criteria above; treatment discontinuation, either voluntarily or because of adverse events
Gutekunst et al, 2011 ³²	Sensation to light touch and pressure evaluated at 9 points on the plantar surface using Semmes-Weinstein 5.07 (10 g) and 6.10 monofilaments Sensation of vibration evaluated using a 128 Hz tuning fork Sensation of joint position evaluated at the ankle joint and first metatarsal-phalangeal joint	Not provided	Not provided
Faglia et al, 2010 ³³	Insensitivity to a 10 g Semmes-Weinstein monofilament in > 6 out of 9 areas of the foot Vibration perception threshold of > 25 V measured by a biothesiometer on the malleolus	Ankle-brachial pressure index < 0.9 and/or TcPO ₂ < 50 mm Hg on the dorsum of the foot	Complete re-epithelialization of the ulcerated area
Van de Weg et al, 2008 ³⁴	Somatosensory test using a 10 g Semmes-Weinstein monofilament	Ankle-brachial index < 0.4	<i>Healed ulcer</i> : complete re-epithelialization of the ulcerated area, with no drainage or sinus formation <i>Unhealed ulcer</i> : not meeting criteria above; patient discontinuation
Caravaggi et al, 2007 ³¹	Insensitivity to a 10 g monofilament Vibration perception threshold of ≥ 25 V measured on the malleolus	Ankle-brachial index < 0.6	Not available
Piaggese et al, 2007 ²⁸	Insensitivity to a 10 g monofilament Vibration perception threshold of ≥ 25 V measured on the malleolus	Ankle-brachial index < 0.9	Complete re-epithelialization of the ulcerated area
Katz et al, 2005 ³⁵	Not available	Not available	Complete re-epithelialization
Armstrong et al, 2005 ³⁶	Insensitivity measured with a vibration perception threshold meter > 25 V	No palpable pulse	Complete re-epithelialization
Armstrong et al, 2001 ³⁷	Insensitivity to a 10 g monofilament Vibration perception threshold of > 25 V	No palpable foot pulse	Complete re-epithelialization

Author, Year	Peripheral Neuropathy	Peripheral Arterial Disease	Ulcer Healing
Caravaggi et al, 2000 ³⁰	Insensitivity to a 10 g monofilament Vibration perception threshold of >25 V measured on the malleolus	Ankle-brachial pressure index 0.6 and/or TcPO ₂ 30 mm Hg	Not provided
Mueller et al, 1989 ³⁸	Lowest perception of Semmes-Weinstein monofilament (4.17, 5.07, 6.10) on 7 points	Not available	<i>Healed ulcer:</i> complete skin coverage and no drainage <i>Unhealed ulcer:</i> not meeting criteria above; patient refused to continue treatment assignment before wound healing; grossly infected, increase in size, or no improvement at 6 weeks

Abbreviation: TcPO₂, transcutaneous oxygen pressure.

Table A4: Ulcer Classification Systems

University of Texas Wound Grading System for Diabetic Foot Wounds ^{41a}	Wagner Foot Ulcer Grading System ⁶⁴
0A: Pre- or post-ulcerative lesion, completely epithelialized; not infected; no ischemia	0: No open lesions in the skin; may be evidence of healed lesions
1A: Superficial wound not involving tendon, capsule, or bone; not infected; no ischemia	1: Superficial wound without penetration to deeper layers
2A: Wound penetrating to tendon or capsule; not infected; no ischemia	2: Wound involving tendon, bone, or joint capsule; no abscess or osteomyelitis
3A: Wound penetrating to bone or joint; not infected; no ischemia	3: Deep ulcer with abscess or osteomyelitis
	4: Gangrene to portion of forefoot
	5: Extensive gangrene of foot; amputation must be carried out

^aThe University of Texas Grading System for diabetic foot wounds also includes the categories B, C, and D for each grade (0–3); they were not relevant for the studies included in the clinical evidence review, so we have not described them here.

Appendices

Appendix 5: Baseline Characteristics of Patients Included in the Studies Identified

Table A5: Baseline Characteristics of Patients Included in the Randomized Controlled Trials

Author, Year N (intervention/ control)	Demographics	Mean BMI, kg/m ² (SD)	Mean Diabetes Duration, y (SD)	Mean HbA1C, % (SD)	Ulcer				History	
					Grade, n (%)	Location, n (%)	Duration, weeks (IQR)	Mean area, cm ² (SD; range)	Ulcer, n (%)	Amputation, n (%)
Najafi et al, 2016 ²⁹ 49 (23/26)	Male, n (%) ICW: 21 (89) RCW: 25 (96) Mean age, y (SD) ICW: 52 (8) RCW: 55 (7) Ethnicity NA	ICW: 31 (7) RCW: 28 (5)	NA	ICW: 10.3 (1.7) RCW: 10.3 (2.8)	NA	Forefoot, midfoot, and rear foot ^b (proportions not provided)	NA	ICW: 6.5 (8.5; 0.36–39.0) RCW: 10.1 (12.0; 0.166– 36.8)	NA	NA
Piaggese et al, 2016 ²⁷ 65 (23/22/20)	Male, n (%) 39 (60) Mean age, y (SD) TCC: 61 (10) ICW: 60 (8) RCW: 62 (9) Ethnicity NA	TCC: 30 (4) ICW 33 (4) RCW: 30 (3)	≥5 years	TCC: 8.1 (0.9) ICW: 8.0 (1.1) RCW: 8.4 (1.0)	Grade 1A TCC: 14 (70) ICW 15 (75) RCW: 16 (80) Grade 2A TCC: 6 (30) ICW: 5 (25) RCW: 4 (20)	All forefoot	≥6 weeks	≥1 cm ²	TCC: 12 (50) ICW: 10 (45) RCW: 11 (55)	0 (exclusion criterion)

Appendices

May 2017

Author, Year N (intervention/ control)	Demographics	Mean BMI, kg/m ² (SD)	Mean Diabetes Duration, y (SD)	Mean HbA1C, % (SD)	Ulcer				History	
					Grade, n (%)	Location, n (%)	Duration, weeks (IQR)	Mean area, cm ² (SD; range)	Ulcer, n (%)	Amputation, n (%)
Lavery et al, 2015 ¹⁶ 73 (23/27/23)	Male, n (%) TCC: 14 (61) RCW: 15 (56) Shoes: 12 (52) Mean age NA Ethnicity, n (%) White TCC: 10 (43) RCW: 8 (30) Shoes: 7 (30) Hispanic TCC: 12 (52) RCW: 17 (63) Shoes: 14 (61) African- American TCC: 1 (4) RCW: 2 (7) Shoes: 1 (4)	NA	NA	NA	1A and 2A included (proportions not provided)	All forefoot	NA	TCC: 2.2 (3.5) RCW: 2.3 (4.1) Shoes: 2.0 (3.5)	TCC: 15 (65) RCW: 23 (85) Shoes: 13 (52)	TCC: 10 (44) RCW: 4 (15) Shoes: 15 (65)
Gutekunst et al, 2011 ³² 23 (11/12)	Male, n (%) TCC: 9 (82) RCW: 10 (83) Mean age, y (SD) TCC: 53 (10) RCW: 55 (13) Ethnicity NA	TCC: 32 (5) RCW: 31 (6)	TCC: 19 (14) RCW: 17 (13)	TCC: 8.5 (2.3) RCW: 8.9 (1.8)	Wagner classification Grade 1 or 2 (proportions not provided)	Forefoot TCC: 8 (73) RCW: 11 (92) Midfoot TCC: 3 (27) RCW: 1 (8)	NA	NA	NA	NA
Faglia et al, 2010 ³³ 45 (23/22)	Males, n (%) TCC: 15 (65) RCW: 15 (68) Age, y (SD) TCC: 59 (9) RCW: 62 (10) Ethnicity NA	TCC: 32 (5) RCW: 30 (1)	TCC: 18 (11) RCW: 17 (10)	TCC: 9.1 (2.1) RCW: 7.5 (1.1)	All Grade 1A	All forefoot	NA	TCC: 1.4 (1.2) RCW: 2.2 (2.2)	TCC: 15 (65) RCW: 15 (68)	Minor amputation TCC: 11 (48) RCW: 12 (55)

Appendices

May 2017

Author, Year N (intervention/ control)	Demographics	Mean BMI, kg/m ² (SD)	Mean Diabetes Duration, y (SD)	Mean HbA1C, % (SD)	Ulcer				History	
					Grade, n (%)	Location, n (%)	Duration, weeks (IQR)	Mean area, cm ² (SD; range)	Ulcer, n (%)	Amputation, n (%)
Van de Weg et al, 2008 ³⁴ 43 (23/20)	Male, n (%) TCC: 16 (68) Shoes: 18 (90) Age, y (SD) TCC: 65 (11) Shoes: 58 (11) Ethnicity NA	NA	TCC: 12 (6) Shoes: 12 (7)	TCC: 7.8 (0.3) Shoes: 8.7 (2.2)	Wagner classification Grade 1 TCC: 2 (9) Shoes: 2 (10) Grade 2 TCC: 21 (91) Shoes: 18 (90)	Forefoot TCC: 20 (87) Shoes: 18 (90)	TCC: 4 (3, 8) Shoes: 5 (4, 8)	TCC: 4.2 (3.1) Shoes: 3.0 (3.1)	NA	NA
Caravaggi et al, 2007 ³¹ 58 (29/29)	NA	NA	NA	NA	NA	NA	NA	TCC: 3.9 (3.4) RCW: 3.4 (3.0)	NA	NA
Piaggese et al, 2007 ²⁸ 40 (20/20)	Male NA Age, y (SD) TCC: 60 (8) ICW: 61 (6) Ethnicity NA	NA	TCC: 15 (11) ICW: 13 (8)	TCC: 7.9 (1.1) ICW: 7.6 (0.9)	Grade 1A and 2A (proportions not provided)	All forefoot	≥3 weeks	TCC: 3.7 (1.6) ICW: 3.9 (1.8)	NA	NA
Katz et al, 2005 ³⁵ 41 (20/21)	Male, n (%) TCC: 14 (65) ICW: 15 (71) Age, y (range) TCC: 51 (23–65) ICW: 51 (29–65) Ethnicity, n (%) White TCC: 2 (10) ICW: 3 (14) Hispanic TCC: 12 (60) ICW: 13 (62) Black TCC: 8 (40) ICW: 6 (29)	NA	Mean (range) TCC: 14 (2–27) ICW: 14 (5–33)	NA	Grades 1A and 2A (proportions not provided)	Forefoot TCC: 15 (76) ICW: 14 (65) Midfoot TCC: 5 (24) ICW: 6 (30) Heel TCC: 0 ICW: 1 (5)	TCC: 11 (3–38) ICW: 8 (2–37)	Mean (median, IQR) TCC: 2.9 (1.9, 0.9–3.9) ICW: 3.1 (1.6, 0.9–3.5)	NA	NA

Author, Year N (intervention/ control)	Demographics	Mean BMI, kg/m ² (SD)	Mean Diabetes Duration, y (SD)	Mean HbA _{1c} , % (SD)	Ulcer				History	
					Grade, n (%)	Location, n (%)	Duration, weeks (IQR)	Mean area, cm ² (SD; range)	Ulcer, n (%)	Amputation, n (%)
Armstrong et al, 2005 ³⁶ 50 (25/25)	<i>Males, n (%)</i> ICW: 20 (87.0) RCW: 24 (88.9) <i>Age, y (SD)</i> ICW: 66.9 (10.1) RCW: 64.6 (9.8) <i>Ethnicity</i> NA	ICW: 33.3 (6.8) RCW: 33.5 (6.2)	NA	ICW: 8.5 (1.5) RCW: 8.0 (1.4)	All Grade 1A	All forefoot	NA	ICW: 2.7 (1.3) RCW: 2.0 (1.1)	NA	NA
Armstrong et al, 2001 ³⁷ 63 (19/20/24)	<i>Male, n (%)</i> TCC: 14 (74) RCW: 18 (90) Shoes: 20 (83) <i>Age</i> NA <i>Ethnicity</i> NA	NA	TCC: 18 (9) RCW: 18 (10) Shoes: 15 (8)	NA	All Grade 1A	Forefoot and midfoot (proportions not provided)	<i>Mean (SD)</i> TCC: 17 (100.3) RCW: 22 (111.7) Shoes: 22 (137.2)	TCC: 1.3 (0.8) RCW: 1.4 (1.4) Shoes: 1.3 (1.2)	NA	NA
Caravaggi et al, 2000 ³⁰ 50 (26/24)	<i>Male, n (%)</i> TCC: 18 (69) Shoes: 24 (67) <i>Age, y (SD)</i> TCC: 61 (11) Shoes: 59 (10) <i>Ethnicity</i> NA	TCC: 27 (2) Shoes: 27 (3)	TCC: 17 (11) Shoes: 16 (9)	NA	NA	NA	NA	NA	NA	NA
Mueller et al, 1989 ³⁸ 40 (21/19)	<i>Male, n (%)</i> TCC: 21 (62) Shoes: 14 (74) <i>Age, y (SD)</i> TCC: 54 (10) Shoes: 55 (12) <i>Ethnicity</i> NA	NA	TCC: 17 (6) Shoes: 17 (9)	NA	<i>Wagner classification</i> Grade 1 TCC: 15 (71) Shoes: 13 (68) Grade 2 TCC: 6 (29) Shoes: 6 (32)	Forefoot: 32 (80%) Midfoot: 5 (12.5) Heel: 3 (7.5) Proportions by study group not provided	<i>Mean (SD)</i> TCC: 22 (28) Shoes: 25 (29)	<i>Area</i> TCC: 1.8 (2.5) Shoes: 2.8 (3.4) <i>Depth (mm), mean (SD)</i> TCC: 3.6 (3.2) Shoes: 2.4 (0.9)	NA	NA

Abbreviations: BMI, body mass index; HbA_{1c}, glycated hemoglobin; ICW; irremovable cast walker; IQR, interquartile range; NA, not available; RCW, removable cast walker; SD, standard deviation; Shoes, therapeutic shoes; TCC, total contact casting.

^aUniversity Texas Classification, unless otherwise specified.

^bBased on personal communication with the authors.

Appendix 6: Results of Applicability Checklist for Studies Included in the Economic Literature Review

Table A6: Cost-Consequence Analysis (Cost Per Patient)

Objective: To assess the cost consequences of offloading devices for treatment of diabetic foot ulcers					
Author, Year	Is the study population similar to the question?	Are the interventions similar to the question?	Is the health care system in which the study was conducted sufficiently similar to the current Ontario context?	Was/were the perspective(s) clearly stated and what were they?	Are estimates of relative treatment effect from the best available source?
Craig et al, 2013 ⁴²	Yes	Somewhat	Yes	Yes	Yes

Author, Year	Are all future costs and outcomes discounted? (If yes, at what rate?)	Is the value of health effects expressed in terms of quality-adjusted life-years?	Are costs and outcomes from other sectors fully and appropriately measured and valued?	Overall judgement (directly applicable/partially applicable/not applicable)
Craig et al, 2013 ⁴²	No	No	No	Partially applicable

Appendix 7: Budget Impact Analysis—Scenario Analysis

Tables A7 to A9 show the expected budget impact of adopting total contact casting, removable cast walkers and irremovable cast walkers over the next 5 years if the proportion of use of each device increased to 100%.

In this analysis, under different levels of access for offloading devices (50%, 75%, and 100%), we assumed that all patients with a diabetic foot ulcer would receive either total contact casting, removable cast walkers, or irremovable cast walkers. We then calculated the budget impact for each of these devices.

The budget impact of adopting total contact casting, removable cast walkers, or irremovable cast walkers for the next 5 years would range from \$2.7 million to \$26 million per year at 100% proportion of use.

Table A7: Budget Impact of Adopting Offloading Devices at 50% Access and 100% Proportion of Use for Each Device in Ontario, 2016–2020

Year	Cost	Total Contact Casting	Removable Cast Walkers	Irremovable Cast Walkers
2016	Device cost	\$11,371,999	\$2,752,920	\$6,067,349
	Treatment cost	\$32,367,332	\$57,019,365	\$33,359,364
	Amputation cost	\$110,393,304	\$117,633,246	\$111,103,103
	Total cost	\$154,132,636	\$177,405,531	\$150,529,816
2017	Device cost	\$11,854,823	\$2,869,802	\$6,324,952
	Treatment cost	\$33,741,561	\$59,440,251	\$34,775,712
	Amputation cost	\$115,080,303	\$122,627,633	\$115,820,237
	Total cost	\$160,676,687	\$184,937,686	\$156,920,901
2018	Device cost	\$12,344,755	\$2,988,404	\$6,586,347
	Treatment cost	\$35,136,020	\$61,896,777	\$36,212,910
	Amputation cost	\$119,836,300	\$127,695,543	\$120,606,814
	Total cost	\$167,317,076	\$192,580,724	\$163,406,072
2019	Device cost	\$12,841,881	\$3,108,748	\$6,851,581
	Treatment cost	\$36,550,955	\$64,389,372	\$37,671,211
	Amputation cost	\$124,662,132	\$132,837,869	\$125,463,675
	Total cost	\$174,054,968	\$200,335,989	\$169,986,467
2020	Device cost	\$13,346,284	\$3,230,853	\$7,120,697
	Treatment cost	\$37,986,602	\$66,918,456	\$39,150,860
	Amputation cost	\$129,558,608	\$138,055,471	\$130,391,634
	Total cost	\$180,891,495	\$208,204,780	\$176,663,191

Note: Numbers may appear inexact due to rounding.

Table A8: Budget Impact of Adopting Offloading Devices at 75% Access and 100% Proportion of Use for Each Device in Ontario, 2016–2020

Year	Cost	Total Contact Casting	Removable Cast Walkers	Irremovable Cast Walkers
2016	Device cost	\$17,057,999	\$4,129,381	\$9,101,023
	Treatment cost	\$48,550,999	\$85,529,047	\$50,039,046
	Amputation cost	\$67,861,282	\$78,721,194	\$68,925,980
	Total cost	\$133,470,280	\$168,379,622	\$128,066,049
2017	Device cost	\$17,782,235	\$4,304,703	\$9,487,428
	Treatment cost	\$50,612,342	\$89,160,377	\$52,163,568
	Amputation cost	\$70,742,487	\$82,063,482	\$71,852,389
	Total cost	\$139,137,064	\$175,528,562	\$133,503,384
2018	Device cost	\$18,517,133	\$4,482,606	\$9,879,521
	Treatment cost	\$52,704,030	\$92,845,165	\$54,319,365
	Amputation cost	\$73,666,107	\$85,454,972	\$74,821,878
	Total cost	\$144,887,271	\$182,782,743	\$139,020,764
2019	Device cost	\$19,262,821	\$4,663,122	\$10,277,371
	Treatment cost	\$54,826,432	\$96,584,059	\$56,506,817
	Amputation cost	\$76,632,657	\$88,896,261	\$77,834,971
	Total cost	\$150,721,910	\$190,143,441	\$144,619,158
2020	Device cost	\$20,019,426	\$4,846,279	\$10,681,045
	Treatment cost	\$56,979,903	\$100,377,685	\$58,726,290
	Amputation cost	\$79,642,632	\$92,387,926	\$80,892,170
	Total cost	\$156,641,961	\$197,611,890	\$150,299,506

Note: Numbers may appear inexact due to rounding

Table A9: Budget Impact of Adopting Offloading Devices at 100% Access and 100% Proportion of Use for Each Device in Ontario, 2016–2020

Year	Cost	Total Contact Casting	Removable Cast Walkers	Irremovable Cast Walkers
2016	Device cost	\$22,743,999	\$5,505,841	\$12,134,697
	Treatment cost	\$64,734,665	\$114,038,729	\$66,718,729
	Amputation cost	\$25,329,260	\$39,809,143	\$26,748,857
	Total cost	\$112,807,924	\$159,353,713	\$105,602,283
2017	Device cost	\$23,709,647	\$5,739,604	\$12,649,904
	Treatment cost	\$67,483,122	\$118,880,503	\$69,551,424
	Amputation cost	\$26,404,672	\$41,499,331	\$27,884,540
	Total cost	\$117,597,440	\$166,119,437	\$110,085,868
2018	Device cost	\$24,689,510	\$5,976,808	\$13,172,694
	Treatment cost	\$70,272,040	\$123,793,553	\$72,425,820
	Amputation cost	\$27,495,914	\$43,214,400	\$29,036,943
	Total cost	\$122,457,465	\$172,984,762	\$114,635,457
2019	Device cost	\$25,683,762	\$6,217,495	\$13,703,161
	Treatment cost	\$73,101,910	\$128,778,745	\$75,342,422
	Amputation cost	\$28,603,181	\$44,954,653	\$30,206,266
	Total cost	\$127,388,852	\$179,950,893	\$119,251,850
2020	Device cost	\$26,692,568	\$6,461,706	\$14,241,394
	Treatment cost	\$75,973,204	\$133,836,913	\$78,301,720
	Amputation cost	\$29,726,655	\$46,720,380	\$31,392,707
	Total cost	\$132,392,428	\$187,018,999	\$123,935,821

Note: Numbers may appear inexact due to rounding.

We also explored the budget impact of varying the proportion of use of irremovable cast walkers from 1.5% to 21.5% (Table A10).

Table A10: Proportion of Use of Offloading Devices in Ontario, 2016–2020^a

Year	Total Contact Casting	Removable Cast Walkers	Irremovable Cast Walkers	Total
2016	57.0%	41.5%	1.5%	100%
2017	57.0%	36.0%	7.0%	100%
2018	57.0%	33.0%	10.0%	100%
2019	57.0%	29.0%	14.0%	100%
2020	57.0%	21.5%	21.5%	100%

^aExpert opinion.

When we varied the proportion of use of irremovable cast walkers (using the figures from Table A10) and increased access to an offloading device from 50% to 75% and from 75% to 100%, we observed cost savings as a result of fewer amputations (Table A11).


Table A11: Net Budget Impact of Adopting Offloading Devices at Varying in Proportions of Use for Irremovable Cast Walkers in Ontario, 2016–2020

Year	Cost	Change in Accessibility	
		50% to 75%	75% to 100%
2016	Device cost	\$3,862,729	\$3,862,729
	Treatment cost	\$21,297,245	\$21,297,245
	Amputation cost	–\$41,680,264	–\$41,680,264
	Total cost	–\$16,520,291	–\$16,520,291
2017	Device cost	\$4,125,448	\$4,125,448
	Treatment cost	\$22,693,590	\$22,693,590
	Amputation cost	–\$43,449,895	–\$43,449,895
	Total cost	–\$16,630,857	–\$16,630,857
2018	Device cost	\$4,347,342	\$4,347,342
	Treatment cost	\$22,018,265	\$22,018,265
	Amputation cost	–\$45,245,576	–\$45,245,576
	Total cost	–\$18,879,969	–\$18,879,969
2019	Device cost	\$4,602,614	\$4,602,614
	Treatment cost	\$22,332,413	\$22,332,413
	Amputation cost	–\$47,067,625	–\$47,067,625
	Total cost	–\$20,132,598	–\$20,132,598
2020	Device cost	\$4,922,319	\$4,922,319
	Treatment cost	\$22,217,885	\$22,217,885
	Amputation cost	–\$48,916,346	–\$48,916,346
	Total cost	–\$21,776,142	–\$21,776,142

Note: Numbers may appear inexact due to rounding.

Appendix 8: Public and Patient Engagement—Interview Materials

Figure A1: Letter of Information



LETTER OF INFORMATION

SUMMARY

Health Quality Ontario (HQO) is reviewing offloading devices as treatment for diabetic leg wounds to better understand whether these treatment options should be funded by the healthcare system. Specifically, we are looking at **removable and irremovable cast walkers**. As part of this review, we would like to hear from patients who suffer from diabetic leg wounds to better understand their and their family's lived-experience of the condition, expectations and experiences with accessing and receiving existing treatments, and their experience (if any) with removable cast walkers (such as the "Aircast") or irremovable cast walkers (such as Instant Total Contact Cast).

Currently undergoing these treatment options is not necessary to be involved in this review. We are interested in hearing from patients with diabetic leg wounds and their families who may or may not be considering either of these treatments, or have had experience with either in the past.

WHAT DO YOU NEED FROM ME?

- ✓ Willingness to share your story
- ✓ Indicate your preference for sharing your story:
 - Phone interview
 - In-person interview (for individuals in Toronto)
- ✓ Consent to have your story used and recorded by HQO

WHAT YOUR PARTICIPATION INVOLVES

If you agree to participate, you will be asked questions about your lived experience with diabetic leg wounds, existing therapies, and potentially removable or irremovable cast walkers, if you have used these therapies or may be considering them.

Participation is voluntary. You may refuse to participate, refuse to answer any questions or withdraw before your story is captured. Withdrawal will in no way affect care you receive.

2

2

HOW WILL MY INPUT BE USED?

Health Quality Ontario will be summarizing the input we receive from patients and families and combining this with clinical and economic evidence reviews about [removable and irremovable cast walkers](#). This combined evidence review is then used to support the [Ontario Health Technology Assessment Committee](#) in coming to a recommendation about public funding.

2

CONFIDENTIALITY

All information collected from you will be kept confidential and privacy will be protected except as required by law. The results of this review will be published, however no identifying information will be released or published. Any records containing information from your interview will be stored securely.

2

RISKS OF PARTICIPATION

There are no known physical risks to participating. Some participants may experience discomfort or anxiety after speaking about their lived experience. If this is the case, please contact any staff.

2

HOW CAN I SHARE MY STORY WITH HEALTH QUALITY ONTARIO?

If you are interested in speaking over the phone or in-person, please contact David Wells (contact information below).

2

2

HEALTH QUALITY ONTARIO STAFF

David Wells
Program Analyst, Patient, Family and Public Engagement
Tel: (416) 323-6868 Email: David.Wells@hqontario.ca

2

Consent and Release Form

This form is to be read and completed in accordance with the following instructions before it can be signed.

1. I, Dr. Amy Lang allow Health Quality Ontario (Ontario Health Quality Council) to use to inform the development of an evidence based review: None

Check off all appropriate boxes:

a) None a recording of my voice

b) None a quotation or summary of my opinion that I expressed during an interview

c) None name & contact information

2. Please read the following paragraphs before affixing your signature under Section 3.

a) Personal information collected pursuant to, and on this form, will be used for purposes described in this form and for no other purpose. Health Quality Ontario (Ontario Health Quality Council) acknowledges that you have provided this personal information freely and voluntarily. If you have any questions about this collection of this personal information, contact:

Amy Lang
Director, Patient, Caregiver and Public Engagement
Tel: (416) 323-6868, Ext. 610, E-mail: amy.lang@hqontario.ca

b) By signing this form as indicated below, you agree to hereby release and forever discharge the Health Quality Ontario (Ontario Health Quality Council), its officers, employees, agents and representatives from any and all claims, demands, expenses, actions, causes of action and for any and all liability howsoever caused, arising out of, or in any way related to the collection, use and disclosure of information, recordings and images authorized to be collected pursuant to, or on this form.

c) By signing this form as indicated below, you agree to forever waive any and all rights that you may have to the use of information and recordings that are authorized to be collected pursuant to, or on this form; and you acknowledge that all information, recordings and images shall hereafter remain the exclusive property of the Health Quality Ontario (Ontario Health Quality Council).

3. Signature is to be affixed in the appropriate space provided below.

I have read this form after it was completed, I understand and agree to be bound by its contents, and I am eighteen (18) years of age or over.

Signature Dr. Amy Lang

Print Name Dr. Amy Lang

Date 11/11/2014

Figure A3: Interview Guide



Interview for TCC, RCW, and Irremovable Cast Walkers

Intro

History of diabetes and wounds

Lived-Experience

What is the day-to-day routine, quality of life?

What is the impact on partner/spouse?

How much self-care is involved?

Mobility?

Other Therapies

What therapies have been used to treat leg/foot wounds? Successes/failures?

Is accessibility to therapies an issue (are you able to take advantage of all potential therapies)?

What are the expectations for these therapies long term?

Are there any side-effects or risks with the therapies that you have experienced?

Was it difficult to weigh up potential benefits and risks when deciding on which therapies to go with?

Are there any other therapies you are considering? How do you go about making a decision?

Off-loading Devices

Which off-loading devices have been used to treat foot ulcers?

Is accessibility to these devices an issue (are you able to take advantage of all potential off-loading devices)?

Do you feel you have enough information to understand risk/benefits and make a decision?

Practicalities of using each off-loading device?

Pros/Cons/Differences

Are there unexpected consequences from the therapy?

REFERENCES

- (1) Brem H, Sheehan P, Rosenberg HJ, Schneider JS, Boulton AJ. Evidence-based protocol for diabetic foot ulcers. *Plast Reconstr Surg.* 2006;117(7 Suppl):193S-209S; discussion 10S-11S.
- (2) Lewis J, Lipp A. Pressure-relieving interventions for treating diabetic foot ulcers. *Cochrane Database of Systematic Reviews* 2013, Issue 1. Art. No.: CD002302. DOI: 10.1002/14651858.CD002302.pub2.
- (3) Cavanagh PR, Lipsky BA, Bradbury AW, Botek G. Treatment for diabetic foot ulcers. *Lancet.* 2005;366(9498):1725-35.
- (4) Wu SC, Crews RT, Armstrong DG. The pivotal role of offloading in the management of neuropathic foot ulceration. *Curr Diab Rep.* 2005;5(6):423-9.
- (5) Canadian Diabetes Association. Diabetes charter backgrounder - Ontario [Internet]. Canada: CDA; 2015 [cited 2015 Nov 23]. Available from: <http://www.diabetes.ca/getmedia/5941b1c2-8b03-45bf-8db0-e18b969d9aa6/diabetes-charter-backgrounder-ontario-english.pdf.aspx>
- (6) Ndip A, Ebah L, Mbako A. Neuropathic diabetic foot ulcers - evidence-to-practice. *Int J Gen Med.* 2012;5:129-34.
- (7) Woo K, Carvill L, Alavi A, Queen D, Rothman A, Woodbury G, et al. An audit of leg and foot ulcer care in an Ontario Community Care Access Centre. *Wound Care Canada.* 2007;5(Suppl 1):S17-S27.
- (8) Canadian Institute for Health Information. Compromised wounds in Canada [Internet]. Canada: Canadian Institute for Health Information; 2013 [cited 2015 Nov 23]. Available from: https://secure.cihi.ca/free_products/AiB_Compromised_Wounds_EN.pdf
- (9) Cross C. Risk of compromised wounds greater among patients with diabetes, CIHI study shows. *CMAJ.* 2013;185(14):E664.
- (10) Wu SC, Armstrong DG. The role of activity, adherence, and off-loading on the healing of diabetic foot wounds. *Plast Reconstr Surg.* 2006;117(7 Suppl.):248S-53S.
- (11) Armstrong DG, Lavery LA, Nixon BP, Boulton AJM. It's not what you put on, but what you take off: techniques for debriding and off-loading the diabetic foot wound. *Clin Infect Dis.* 2004;39(Suppl. 2):S92-S9.
- (12) Braun LR, Fisk WA, Lev-Tov H, Kirsner RS, Isseroff RR. Diabetic foot ulcer: an evidence-based treatment update. *Am J Clin Dermatol.* 2014;15(3):267-81.
- (13) Morona JK, Buckley ES, Jones S, Reddin EA, Merlin TL. Comparison of the clinical effectiveness of different off-loading devices for the treatment of neuropathic foot ulcers in patients with diabetes: a systematic review and meta-analysis. *Diabetes Metab Res Rev.* 2013;29(3):183-93.
- (14) Armstrong DG, Isaac AL, Bevilacqua NJ, Wu SC. Offloading foot wounds in people with diabetes. *Wounds.* 2014;26(1):13-20.
- (15) Miller J, Armstrong DG. Offloading the diabetic and ischemic foot: solutions for the vascular specialist. *Semin Vasc Surg.* 2014;27(1):68-74.
- (16) Lavery LA, Higgins KR, La Fontaine J, Zamorano RG, Constantinides GP, Kim PJ. Randomised clinical trial to compare total contact casts, healing sandals and a shear-reducing removable boot to heal diabetic foot ulcers. *Int Wound J.* 2015;12(6):710-5.
- (17) Greenhagen R. Complications of total contact casting. *Podiatry Manage.* 2012;31(5):153-8.
- (18) Canadian Agency for Drugs and Technologies in Health. Removable off-loading devices for diabetic foot ulcers: a review of clinical and cost-effectiveness. [Internet]. Ottawa: CADTH; 2014 [cited 2015 Nov 23]. Available from:

- <https://www.cadth.ca/sites/default/files/pdf/htis/dec-2014/RC0579-003%20Diabetic%20Foot%20Ulcers%20Final.pdf>
- (19) Botros M, Goettl K, Parsons L, Mendzildzic S, Morin C, Smith T, et al. Best practice recommendations for the prevention, diagnosis, and treatment of diabetic foot ulcers: update 2010. *Wound Care Canada*. 2010;8(4):6-40.
 - (20) McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement. *J Clin Epidemiol*. 2016;75:40-6.
 - (21) O'Neill J, Tabish H, Welch V, Petticrew M, Pottie K, Clarke M, et al. Applying an equity lens to interventions: using PROGRESS ensures consideration of socially stratifying factors to illuminate inequities in health. *J Clin Epidemiol*. 2014;67(1):56-64.
 - (22) Rao SR, Schoenfeld DA. Survival methods. *Circulation*. 2007;115(1):109-13.
 - (23) Review Manager (RevMan) [computer program]. Version 5.3. Copenhagen, Denmark: The Nordic Cochrane Centre, The Cochrane Collaboration; 2014.
 - (24) Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med*. 2002;21(11):1539-58.
 - (25) Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the *Journal of Clinical Epidemiology*. *J Clin Epidemiol*. 2011;64(4):380-2.
 - (26) Higgins JP, Altman DG, Sterne JA. Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 [Internet]. The Cochrane Collaboration, 2011 [updated 2011 Mar; cited 2017 Jan 19]. Available from www.handbook.cochrane.org.
 - (27) Piaggese A, Goretti C, Iacopi E, Clerici G, Romagnoli F, Toscanella F, et al. Comparison of removable and irremovable walking boot to total contact casting in offloading the neuropathic diabetic foot ulceration. *Foot Ankle Int*. 2016;37(8):855-61.
 - (28) Piaggese A, Macchiarini S, Rizzo L, Palumbo F, Tedeschi A, Nobili LA, et al. An off-the-shelf instant contact casting device for the management of diabetic foot ulcers: a randomized prospective trial versus traditional fiberglass cast. *Diabetes Care*. 2007;30(3):586-90.
 - (29) Najafi B, Grewal GS, Bharara M, Menzies R, Talal TK, Armstrong DG. Can't stand the pressure: the association between unprotected standing, walking, and wound healing in people with diabetes. *J Diabetes Sci Technol* [Internet]. Forthcoming 2016.
 - (30) Caravaggi C, Faglia E, De Giglio R, Mantero M, Quarantiello A, Sommariva E, et al. Effectiveness and safety of a nonremovable fiberglass off-bearing cast versus a therapeutic shoe in the treatment of neuropathic foot ulcers. *Diabetes Care*. 2000;23(12):1746-51.
 - (31) Caravaggi C, Sganzeroli A, Fabbi M, Cavaiani P, Pogliaghi I, Ferraresi R, et al. Nonwindowed nonremovable fiberglass off-loading cast versus removable pneumatic cast (AircastXP Diabetic Walker) in the treatment of neuropathic noninfected plantar ulcers: a randomized prospective trial. *Diabetes Care*. 2007;30(10):2577-8.
 - (32) Gutekunst DJ, Hastings MK, Bohnert KL, Strube MJ, Sinacore DR. Removable cast walker boots yield greater forefoot off-loading than total contact casts. *Clin Biomech (Bristol, Avon)*. 2011;26(6):649-54.
 - (33) Faglia E, Caravaggi C, Clerici G, Sganzeroli A, Curci V, Vailati W, et al. Effectiveness of removable walker cast versus nonremovable fiberglass off-bearing cast in the healing of diabetic plantar foot ulcer: a randomized controlled trial. *Diabetes Care*. 2010;33(7):1419-23.
 - (34) Van De Weg FB, Van Der Windt DAWM, Vahl AC. Wound healing: total contact cast vs. custom-made temporary footwear for patients with diabetic foot ulceration. *Prosthet Orthot Int*. 2008;32(1):3-11.

- (35) Katz IA, Harlan A, Miranda-Palma B, Prieto-Sanchez L, Armstrong DG, Bowker JH, et al. A randomized trial of two irremovable off-loading devices in the management of plantar neuropathic diabetic foot ulcers. *Diabetes Care*. 2005;28(3):555-9.
- (36) Armstrong DG, Lavery LA, Wu S, Boulton AJM. Evaluation of removable and irremovable cast walkers in the healing of diabetic foot wounds: a randomized controlled trial. *Diabetes Care*. 2005;28(3):551-4.
- (37) Armstrong DG, Nguyen HC, Lavery LA, van Schie CH, Boulton AJ, Harkless LB. Off-loading the diabetic foot wound: a randomized clinical trial. *Diabetes Care*. 2001;24(6):1019-22.
- (38) Mueller MJ, Diamond JE, Sinacore DR, Delitto A, Blair IVP, Drury DA, et al. Total contact casting in treatment of diabetic plantar ulcers. Controlled clinical trial. *Diabetes Care*. 1989;12(6):384-8.
- (39) Armstrong DG, Lavery LA, Wrobel JS, Vileikyte L. Quality of life in healing diabetic wounds: does the end justify the means? *J Foot Ankle Surg*. 2008;47(4):278-82.
- (40) Moher D, Liberati A, Tetzlaff J, Altman DG, Group tP. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med*. 2009;6(7):e1000097.
- (41) Lavery LA, Armstrong DG, Harkless LB. Classification of diabetic foot wounds. *J Foot Ankle Surg*. 1996;35(6):528-31.
- (42) Craig J, Shenton R, Smith A. Economic analysis of soft-heel casting for diabetic foot ulcer: prevention and treatment. *J Wound Care*. 2013;22(1):44-8.
- (43) Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. *Value Health*. 2013;16(2):231-50.
- (44) Canadian Diabetes Association. Impact of offloading devices on the cost of diabetic foot ulcers in Ontario [Internet]. Toronto (ON): The Association; 2015 [cited 2015 November]. Available from: <http://www.diabetes.ca/getmedia/5109456e-8c0b-458f-b949-a5accd41513a/impact-of-offloading-devices-ontario.pdf.aspx>
- (45) Ragnarson Tennvall G, Apelqvist J. Health-related quality of life in patients with diabetes mellitus and foot ulcers. *J Diabetes Complications*. 2000;14(5):235-41.
- (46) Ministry of Health and Long-Term Care. Schedule of benefits: physician services under the Health Insurance Act [Internet]. Toronto (ON): MOHLTC; 2015 [cited 2016 May 25]. Available from: http://www.health.gov.on.ca/en/pro/programs/ohip/sob/physserv/sob_master11062015.pdf
- (47) Hopkins RB, Burke N, Harlock J, Jegathisawaran J, Goeree R. Economic burden of illness associated with diabetic foot ulcers in Canada. *BMC Health Serv Res*. 2015;15:13.
- (48) Woo KY, Botros M, Kuhnke J, Evans R, Alavi A. Best practices for the management of foot ulcers in people with diabetes. *Adv Skin Wound Care*. 2013;26(11):512-24; quiz 225-6.
- (49) Statistics Canada [Internet]. Ottawa (ON): Government of Canada; 2016 [updated 2016 May 3; cited 2016 May 11]. Available from: <http://www.statcan.gc.ca/start-debut-eng.html>
- (50) Barham L. Public and patient involvement at the UK National Institute for Health and Clinical Excellence. *The patient*. 2011;4(1):1-10.
- (51) Messina J, Grainger DL. A pilot study to identify areas for further improvements in patient and public involvement in health technology assessments for medicines. *The patient*. 2012;5(3):199-211.
- (52) OHTAC Public Engagement Subcommittee. Public engagement for health technology assessment at Health Quality Ontario—final report from the Ontario Health Technology

- Advisory Committee Public Engagement Subcommittee [Internet]. Toronto (ON): Queen's Printer for Ontario; 2015 April [cited 2016]. Available from: <http://www.hqontario.ca/Portals/0/documents/evidence/special-reports/report-subcommittee-20150407-en.pdf>
- (53) Tjornhoj-Thomsen T, Hansen HP. Knowledge in health technology assessment: who, what, how? *Int J Technol Assess Health Care*. 2011;27(4):324-9.
 - (54) Rowe G, Frewer LJ. A typology of public engagement mechanisms. *Sci Technol Hum Val*. 2005;30(2):251-90.
 - (55) Brundisini F, Giacomini M, DeJean D, Vanstone M, Winsor S, Smith A. Chronic disease patients' experiences with accessing health care in rural and remote areas: a systematic review and qualitative meta-synthesis. *Ontario health technology assessment series*. 2013;13(15):1-33.
 - (56) Kvale S. *Interviews: an introduction to qualitative research interviewing*. Thousand Oaks (CA): Sage; 1996.
 - (57) Kuzel AJ. Sampling in qualitative inquiry. In: Miller WL, Crabtree BF, editors. *Doing qualitative research*. Thousand Oaks (CA): Sage Publications; 1999. p. 33–45.
 - (58) Morse J. Emerging from the data: cognitive processes of analysis in qualitative research. In: Morse J, editor. *Critical issues in qualitative research methods*. Thousand Oaks (CA): Sage Publications; 1994. p. 23-41.
 - (59) Patton MQ. *Qualitative research and evaluation methods*. 3rd ed. Thousand Oaks (CA): Sage Publications; 2002.
 - (60) Strauss AL, Corbin JM. *Basics of qualitative research: techniques and procedures of developing a grounded theory*. 2nd ed. Thousand Oaks (CA): Sage Publications; 1998.
 - (61) Health Technology Assessment International Interest Group on Patient and Citizen Involvement in HTA. *Introduction to health technology assessment (HTA)* [Internet]. Edmonton (AB): Health Technology Assessment International; 2015 [cited 2016]. Available from: http://www.htai.org/fileadmin/HTAi_Files/ISG/PatientInvolvement/v2_files/Resource/PCISG-Resource-Intro_to_HTA_KFacey_Jun13.pdf
 - (62) Strauss AL, Corbin JM. Grounded theory research: procedures, canons, and evaluative criteria. *Qual Sociol*. 1990;13(1):3-21.
 - (63) Strauss AL, Corbin JM. Grounded theory methodology: an overview. In: Denzin NK, Lincoln YS, editors. *Handbook of qualitative research*. Thousand Oaks (CA): Sage 1994. p. 273-85.
 - (64) Wagner FW, Jr. The dysvascular foot: a system for diagnosis and treatment. *Foot Ankle*. 1981;2(2):64-122.

About Health Quality Ontario

Health Quality Ontario is the provincial advisor on the quality of health care. We are motivated by a single-minded purpose: **Better health for all Ontarians.**

Who We Are.

We are a scientifically rigorous group with diverse areas of expertise. We strive for complete objectivity, and look at things from a vantage point that allows us to see the forest and the trees. We work in partnership with health care providers and organizations across the system, and engage with patients themselves, to help initiate substantial and sustainable change to the province's complex health system.

What We Do.

We define the meaning of quality as it pertains to health care, and provide strategic advice so all the parts of the system can improve. We also analyze virtually all aspects of Ontario's health care. This includes looking at the overall health of Ontarians, how well different areas of the system are working together, and most importantly, patient experience. We then produce comprehensive, objective reports based on data, facts and the voice of patients, caregivers and those who work each day in the health system. As well, we make recommendations on how to improve care using the best evidence. Finally, we support large scale quality improvements by working with our partners to facilitate ways for health care providers to learn from each other and share innovative approaches.

Why It Matters.

We recognize that, as a system, we have much to be proud of, but also that it often falls short of being the best it can be. Plus certain vulnerable segments of the population are not receiving acceptable levels of attention. Our intent at Health Quality Ontario is to continuously improve the quality of health care in this province regardless of who you are or where you live. We are driven by the desire to make the system better, and by the inarguable fact that better has no limit.

[About the Ontario Health Technology Advisory Committee \(OHTAC\)](#)

[About OHTAS](#)

[How to Obtain OHTAS Reports](#)

[Disclaimer](#)

Health Quality Ontario
130 Bloor Street West, 10th Floor
Toronto, Ontario
M5S 1N5
Tel: 416-323-6868
Toll Free: 1-866-623-6868
Fax: 416-323-9261
Email: EvidenceInfo@hqontario.ca
www.hqontario.ca

ISSN 1915-7398 (online)
ISBN TBA (PDF)

© Queen's Printer for Ontario, 2017